minoxidil has been researched along with Alopecia in 643 studies
Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371)
minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.
Alopecia: Absence of hair from areas where it is normally present.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cetirizine, a widely used agent for allergic disorders, has recently been topically used for treating androgenetic alopecia (AGA)." | 10.60 | Topical cetirizine for treating androgenetic alopecia: A systematic review. ( Chen, X; Xiang, H; Yang, M, 2022) |
| "PRP is effective in the treatment of moderate grades of androgenetic alopecia in men, although perhaps not different from minoxidil." | 9.69 | Efficacy of autologous platelet-rich plasma therapy versus topical Minoxidil in men with moderate androgenetic alopecia: a randomized open-label trial. ( Balasundaram, M; Kumari, R; Ramassamy, S, 2023) |
| "Platelet-rich plasma (PRP) has been increasingly accepted as a potential therapy in the treatment of androgenetic alopecia (AGA), However, there remains a dearth of data on the effectiveness of PRP prepared by automatic blood cell separator with a combination of topical minoxidil for the treatment of AGA." | 9.69 | Injections of platelet-rich plasma prepared by automatic blood cell separator combined with topical 5% minoxidil in the treatment of male androgenetic alopecia. ( Long, B; Wei, W; Zhang, C; Zhang, S; Zhang, Y, 2023) |
| "The goal was to explore the efficacy and side effects of basic fibroblast growth factor (bFGF) combined with minoxidil in the treatment of male patients with early stage of androgenetic alopecia (AGA)." | 9.51 | Clinical observation of basic fibroblast growth factor (bFGF) combined with minoxidil in the treatment of male androgenetic alopecia. ( Liu, C; Wu, W; Zhang, Y; Zhao, H, 2022) |
| "Topical hydroalcoholic solution of flutamide plus minoxidil may be promising treatment for the androgenetic alopecia." | 9.51 | Comparison between "5% minoxidil plus 2% flutamide" solution vs. "5% minoxidil" solution in the treatment of androgenetic alopecia. ( Faghihi, G; Hoseyni, MS; Iraji, F; Jelvan, M; Saber, M; Siadat, AH, 2022) |
| "Based on our findings, the mixed preparation of piperine, capsaicin, and curcumin is effective in treating alopecia areata, but it has not been shown to be superior to minoxidil in short-term therapy." | 9.51 | Efficacy of a mixed preparation containing piperine, capsaicin and curcumin in the treatment of alopecia areata. ( Mao, Y; Mei, X; Shi, W; Song, J; Xie, Y; Xu, Z, 2022) |
| "Treatment of androgenetic alopecia (AGA) with concurrent electrodynamic microneedling and 5% minoxidil may further stimulate hair growth." | 9.51 | Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway. ( Bao, L; Fang, S; Li, Y; Zheng, L; Zong, H, 2022) |
| "Intradermal minoxidil is used as an off-label treatment for patchy non-severe alopecia areata (AA) either alone or in combination with steroids; however, studies estimating its efficacy are still lacking." | 9.51 | Efficacy of intradermal minoxidil 5% injections for treatment of patchy non-severe alopecia areata. ( Abdallah, MAE; Shareef, R; Soltan, MY, 2022) |
| "Topical minoxidil 5% are effective in androgenetic alopecia (AGA)." | 9.41 | A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study. ( Abdel-Aziz, RTA; Abdel-Raouf, H; Ahmed, SS; Aly, UF; Medhat, W, 2021) |
| " In the present study, the efficacy and safety of twice daily application of topical cetirizine 1% versus minoxidil 5% solutions for 16 weeks were compared in male androgenetic alopecia (AGA)." | 9.41 | Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study. ( Firooz, A; Guishard, A; Hossein Mostafa, D; Nasrollahi, SA; Niknam, S; Samadi, A, 2021) |
| " Combining fractional Er:Glass laser therapy with topical minoxidil may yield therapeutic benefits for patients with androgenetic alopecia (AGA)." | 9.30 | A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. ( Khunkhet, S; Rojhirunsakool, S; Suchonwanit, P, 2019) |
| "Compared with topical minoxidil monotherapy, JetPeel-assisted topical minoxidil is more effective during the treatment of androgenetic alopecia." | 9.27 | The clinical effect of JetpPeel-assisted topical minoxidil in the treatment of androgenetic alopecia: A randomized pilot study. ( Bao, L; Gong, L; Li, Y; Tian, T, 2018) |
| "The synergism of combined use between oral finasteride and topical minoxidil has been established in treating androgenetic alopecia among men." | 9.27 | A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. ( Chalermroj, N; Khunkhet, S; Srisuwanwattana, P; Suchonwanit, P, 2018) |
| "A caffeine-based topical liquid should be considered as not inferior to minoxidil 5% solution in men with androgenetic alopecia." | 9.24 | An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia. ( Anandan, S; Chitallia, J; Dhurat, R; Jayaraaman, AM; Klenk, A; Madhukara, J; May, TW; Vaidya, P, 2017) |
| "5% minoxidil solution is approved for the treatment of male androgenetic alopecia (AGA)." | 9.24 | A Comparative Study between the Efficacy and Safety of 5% Minoxidil Solution and 5% Minoxidil Milky Lotion in the Treatment of Male Androgenic Alopecia. ( Suvanasuthi, S; Thanomkitti, K; Thuangtong, R, 2017) |
| "There are knowledge gaps regarding the relative efficacy of 3 commonly used drugs for androgenetic alopecia (AGA), namely, minoxidil and the two 5-α reductase inhibitors dutasteride and finasteride." | 9.22 | Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. ( Bamimore, MA; Gupta, AK; Talukder, M; Venkataraman, M, 2022) |
| "The objective of this article is to discuss various conditions in alopecia where oral minoxidil has found its role." | 9.22 | Comprehensive review of oral minoxidil in alopecia. ( Modha, JD; Pathania, YS, 2022) |
| "Topical minoxidil formulations have been shown to be effective in treating androgenetic alopecia (AGA) for 12 months." | 9.22 | Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104-week open-label clinical trial. ( Blume-Peytavi, U; Canfield, D; Hillmann, K; Kanti, V; Kottner, J; Stroux, A, 2016) |
| "5% minoxidil formulations twice daily are effective in treating vertex male androgenetic alopecia (AGA); however, efficacy and safety data in frontotemporal regions are lacking." | 9.20 | A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men. ( Blume-Peytavi, U; Canfield, D; Garcia Bartels, N; Hillmann, K; Kottner, J; Stroux, A, 2015) |
| "The variable success of topical minoxidil in the treatment of androgenic alopecia has led to the hypothesis that other pathways could mediate this form of hair loss, including infection and/or microinflammation of the hair follicles." | 9.17 | Preparation and evaluation of a multimodal minoxidil microemulsion versus minoxidil alone in the treatment of androgenic alopecia of mixed etiology: a pilot study. ( Adam, AN; Gado, AM; Mohammed, HR; Sakr, FM, 2013) |
| "We sought to compare the efficacy, safety, and acceptability and to show noninferiority of once-daily 5% minoxidil topical foam (MTF) with twice-daily 2% MTS in women with androgenetic alopecia." | 9.15 | A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. ( Blume-Peytavi, U; Canfield, D; Dietz, E; Garcia Bartels, N; Hillmann, K, 2011) |
| "Our study confirms the data of the literature and the evidence coming from years of clinical experience, that twice a day topical application of 5% minoxidil solution, Carexidil ®, is effective in the treatment of male and female androgenetic alopecia, with evident efficacy already after 6 months." | 9.15 | [Efficacy and tolerability of 5% minoxidil solution (Carexidil®) in male and female androgenetic alopecia: a 6-month open multicentric study]. ( Alessandrini, A; Fiorucci, MC; Guarrera, M; Lorenzi, S; Piraccini, B; Starace, M, 2011) |
| "Minoxidil is efficacious in inducing hair growth in patients with androgenetic alopecia by inducing hair follicles to undergo transition from the early to late anagen phase." | 9.14 | Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men. ( Arano, O; Katsuoka, K; Nishikawa, T; Tsuboi, R; Yamada, H, 2009) |
| "To evaluate the efficacy of fulvestrant solution in stimulating hair growth in men and postmenopausal women with androgenetic alopecia in two randomized, phase II, minoxidil- and/or vehicle-controlled studies." | 9.13 | Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies. ( Gassmueller, J; Hoffmann, R; Webster, A, 2008) |
| "To assess the efficacy and safety of a new 5% minoxidil topical formulation in a propylene glycol-free foam vehicle in men with androgenetic alopecia (AGA)." | 9.12 | A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. ( Bergfeld, W; Hordinsky, M; Kohut, B; Miller, J; Olsen, EA; Wanser, R; Whiting, D; Zhang, P, 2007) |
| "Minoxidil solution stimulates hair growth in androgenetic alopecia." | 9.12 | Is topical minoxidil solution effective on androgenetic alopecia in routine daily practice? ( Mapar, MA; Omidian, M, 2007) |
| "Topical minoxidil solution 2% stimulates new hair growth and helps stop the loss of hair in individuals with androgenetic alopecia (AGA)." | 9.10 | A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. ( Dunlap, FE; Funicella, T; Koperski, JA; Olsen, EA; Swinehart, JM; Trancik, RJ; Tschen, EH, 2002) |
| "To compare topical minoxidil 2% and cyproterone acetate in the treatment of female alopecia." | 9.10 | Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. ( Boudou, P; Chaspoux, C; Fiet, J; Hardy, N; Jouanique, C; Reygagne, P; Vexiau, P, 2002) |
| " Topical minoxidil has been shown to be effective for androgenetic alopecia and alopecia areata." | 9.08 | A randomized trial of minoxidil in chemotherapy-induced alopecia. ( Bandstra, BA; Compton, LD; Duvic, M; Farmer, KL; Hortobagyi, GN; Hymes, SR; Lemak, NA; Trancik, RJ; Valero, V, 1996) |
| "The aim of our study was to determine if ketoconazole (KCZ) which is active against the scalp microflora and shows some intrinsic anti-inflammatory activity might improve alopecia." | 9.08 | Ketoconazole shampoo: effect of long-term use in androgenic alopecia. ( Cauwenbergh, G; De Doncker, P; Piérard, GE; Piérard-Franchimont, C, 1998) |
| "Topical diphenylcyclopropenone (DPCP) and minoxidil have been used in the treatment of alopecia areata with variable results." | 9.07 | Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation. ( Abbott, F; Ho, V; Shapiro, J; Tan, J; Tron, V, 1993) |
| " The purpose of this study was to evaluate a 2% topical minoxidil solution (Rogaine/Regaine, The Upjohn Co, Kalamazoo, Mich) for the treatment of female androgenetic alopecia." | 9.07 | Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. ( DeVillez, RL; Jacobs, JP; Szpunar, CA; Warner, ML, 1994) |
| "A 32-week, double-blind, placebo-controlled trial was conducted in 10 European centers to assess the efficacy and safety of 2% topical minoxidil solution for the treatment of androgenetic alopecia in women." | 9.07 | Use of topical minoxidil therapy for androgenetic alopecia in women. ( Jacobs, JP; Szpunar, CA; Warner, ML, 1993) |
| "A 48-week open label trial was conducted in five Middle-Eastern countries (Lebanon, Egypt, Saudi Arabia, Jordan, and the United Arab Emirates) to determine the safety and efficacy of 2% minoxidil in the treatment of early androgenic alopecia and to compare the response with Western countries." | 9.07 | Topical minoxidil therapy for androgenic alopecia in the Middle East. The Middle-Eastern Topical Minoxidil Study Group. ( Karam, P, 1993) |
| "The safety and efficacy of minoxidil 2% for the treatment of female androgenetic alopecia was assessed in a 32-week double-blind placebo-controlled trial." | 9.07 | Treatment of female androgenetic alopecia with minoxidil 2%. ( Jacobson, C; Whiting, DA, 1992) |
| "Thirty-one men with androgenetic alopecia completed 4 1/2 to 5 years of therapy with 2% and 3% topical minoxidil." | 9.06 | Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. ( Amara, IA; DeLong, ER; Olsen, EA; Weiner, MS, 1990) |
| "Seventy-two adult male patients were entered into a double-blind, placebo-controlled investigation using 2% to 3% topical minoxidil solution for androgenetic alopecia." | 9.06 | Topical minoxidil therapy for androgenetic alopecia. A 30-month study. ( Koperski, JA; Orenberg, EK; Wilkinson, DI, 1987) |
| "Of 149 subjects with androgenetic alopecia, 102 completed 1 year of a double-blind, randomized study comparing 2% minoxidil and 3% minoxidil solutions for safety and efficacy." | 9.06 | Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. ( Duncan, SH; Rietschel, RL, 1987) |
| "A double-blind 12-month trial was conducted to evaluate the safety and efficacy of topical minoxidil in patients with androgenetic alopecia." | 9.06 | Androgenetic alopecia: treatment results with topical minoxidil. ( Roberts, JL, 1987) |
| "Topical 5% minoxidil solution was used to treat 47 patients with severe alopecia areata." | 9.06 | Topical minoxidil dose-response effect in alopecia areata. ( Buys, CM; Fiedler-Weiss, VC; Rumsfield, JA; West, DP, 1986) |
| "The combination of finasteride and topical minoxidil has been used for treating patients with androgenetic alopecia (AGA)." | 9.05 | The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis. ( Chen, B; Chen, L; Wang, H; Wang, L; Zhang, J, 2020) |
| "Topical minoxidil has been used for almost 40 years to treat alopecia." | 9.05 | Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. ( Atanaskova Mesinkovska, N; Juhasz, M; Michelle, L; Muller Ramos, P; Sharma, AN, 2020) |
| "Topical minoxidil is a well-known and often-utilized drug in dermatological practice for the treatment of alopecia." | 9.01 | Off-Label Use of Topical Minoxidil in Alopecia: A Review. ( Choi, JN; Colavincenzo, M; Stoehr, JR; Vanderweil, S, 2019) |
| "Introduction: Topical minoxidil is the first-line therapy for treating both male and female androgenetic alopecia." | 9.01 | The Efficacy of Topical Minoxidil for Non-Scarring Alopecia: A Systematic Review ( Choi, FD; Juhasz, ML; Mesinkovska, NA; Sung, CT, 2019) |
| "Hypertrichosis has been reported more frequently in females than in males who use minoxidil topical solution (MTS) for the treatment of androgenetic alopecia (AGA)." | 8.82 | Hypertrichosis in females applying minoxidil topical solution and in normal controls. ( Dawber, RP; Rundegren, J, 2003) |
| "While current studies have supported oral minoxidil as a novel, adjunctive therapy in non-scarring forms of alopecia, there continues to be limited data on oral minoxidil for these conditions." | 8.31 | Oral minoxidil use in androgenetic alopecia and telogen effluvium. ( Cooley, JE; Feaster, B; McMichael, AJ; Onamusi, T, 2023) |
| "To determine the causative gene mutation in a family with monilethrix and observe the therapeutic effect of 5% topical minoxidil." | 8.31 | Gene detection in a family with monilethrix and treatment with 5% topical minoxidil. ( Du, P; Fu, Z; Shen, Q; Wang, J, 2023) |
| "Non-adherence to topical minoxidil in alopecia patients is a barrier to efficacy." | 8.31 | Topical Minoxidil Adherence in Patients With Alopecia. ( De Souza, B; Eginli, A; Harris, T; Larrondo, J; McMichael, A; Senthilnathan, A, 2023) |
| "The strategy in this work was loading Melatonin (MEL), the powerful antioxidant photosensitive molecule, in novel Pickering emulsions (PEs) stabilized by chitosan-dextran sulphate nanoparticles (CS-DS NPs) and enhanced by lecithin, for treatment of androgenic alopecia (AGA)." | 8.31 | Boosting hair growth through follicular delivery of Melatonin through lecithin-enhanced Pickering emulsion stabilized by chitosan-dextran nanoparticles in testosterone induced androgenic alopecia rat model. ( Abd-Elmonsif, NM; Elshall, AA; Ghoneim, AM; Osman, R; Shaker, DS, 2023) |
| "To investigate the mechanism of minoxidil in treating androgenetic alopecia (AGA)." | 8.31 | New Target for Minoxidil in the Treatment of Androgenetic Alopecia. ( Shen, Y; Song, X; Sun, J; Xie, B; Zhang, H; Zhang, L; Zhu, Y, 2023) |
| " Since scalp inflammation was recognized as a potential physiological obstacle to the efficacy of the reference hair regrowth drug Minoxidil in vivo and since perifollicular inflammation is the hallmark of about 50%-70% follicular units in androgenetic alopecia, we decided to investigate whether the anti-inflammatory activity of LLLT/GentleWaves® device were assigned to L'Oréal by Light BioScience L." | 8.02 | Low-Level Light Therapy Downregulates Scalp Inflammatory Biomarkers in Men With Androgenetic Alopecia and Boosts Minoxidil 2% to Bring a Sustainable Hair Regrowth Activity. ( Antonelli, R; Barbarat, P; Buffat, L; Cheniti, A; de Bernard, S; Kanoun-Copy, L; Mahe, YF; Planard-Luong, L; Tacheau, C, 2021) |
| "The efficacy of minoxidil (MXD) ethanolic solutions (1%-5% w/v) in the treatment of androgenetic alopecia is limited by adverse reactions." | 7.96 | The hydroxypropyl-β-cyclodextrin-minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia. ( Cutrignelli, A; Denora, N; Fontana, S; Franco, M; la Forgia, F; Laquintana, V; Lopedota, AA; Maqoud, F; Mele, A; Passantino, G; Scala, R; Tinelli, A; Tricarico, D; Zizzo, N, 2020) |
| "Minoxidil solution has routinely been used for decades for the treatment of androgenic alopecia." | 7.96 | Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report. ( Jain, K; Pereira, A; Venkatesh, R; Yadav, NK, 2020) |
| "We report three cases of severe hypertrichosis in healthy infants, who did not present any type of endocrinological pathology and whose parents used topical minoxidil for the treatment of their baldness." | 7.96 | Severe hypertrichosis in infants due to transdermic exposure to 5% and 7% topical minoxidil. ( Arcangeli, F; Delgado Rubio, A; García Del Monte, J; Lotti, T; Rica Echevarría, I, 2020) |
| "Oral minoxidil (OM) has been reported to be effective for androgenetic alopecia (AGA)." | 7.96 | Efficacy and safety of oral minoxidil in female androgenetic alopecia. ( Annunziata, MC; Cantelli, M; Fabbrocini, G; Nappa, P; Patrì, A; Vastarella, M, 2020) |
| "The combination of nonablative laser and topical minoxidil may be a good alternative therapy for AA patients, including alopecia totalis and alopecia universalis, without systemic and local side effects." | 7.91 | Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil. ( Li, Y; Wang, W, 2019) |
| "Topical minoxidil is the only US FDA approved OTC drug for the treatment of androgenetic alopecia (AGA)." | 7.88 | Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients. ( Dhurat, R; Goldust, M; Goren, A; Kovacevic, M; Lotti, T; Lukinovic Skudar, V; McCoy, J; Shapiro, J; Sharma, A; Sinclair, R; Situm, M, 2018) |
| "Topical use of minoxidil is only one of the very few treatment options for alopecia." | 7.81 | Anti-PDGF receptor β antibody-conjugated squarticles loaded with minoxidil for alopecia treatment by targeting hair follicles and dermal papilla cells. ( Aljuffali, IA; Chang, SH; Fang, JY; Pan, TL; Sung, CT, 2015) |
| "We describe the case of a young man who developed syncope after using a high strength formulation of topical minoxidil as a hair growth restorer." | 7.81 | A hairy fall: syncope resulting from topical application of minoxidil. ( Dubrey, SW; Edwards, CM; VanGriethuysen, J, 2015) |
| "Although minoxidil (MX) is a drug known to stimulate hair growth, the treatment of androgenic alopecia could be improved by delivery strategies that would favor drug accumulation into the hair follicles." | 7.79 | Iontophoresis-targeted, follicular delivery of minoxidil sulfate for the treatment of alopecia. ( Delgado-Charro, MB; Gelfuso, GM; Gratieri, T; Guy, RH; Vianna Lopez, RF, 2013) |
| "To analyze the clinical and histological features of permanent alopecia following a sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel regimen for adjuvant breast cancer treatment." | 7.78 | Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. ( Bessis, D; Dereure, O; Frouin, E; Guillot, B; Jacot, W; Kluger, N; Poujol, S; Rigau, V; Romieu, G, 2012) |
| "Topical 2,4-diamino-6-piperidinopyrimidine-3-oxide (minoxidil) solution has been widely used for the treatment of androgenetic alopecia for over 15 years now and the substance is currently approved for this indication in 2% and 5% formulation." | 7.73 | Positive lymphocyte transformation test in a patient with allergic contact dermatitis of the scalp after short-term use of topical minoxidil solution. ( Allam, JP; Bieber, T; Hagemann, T; Novak, N; Schlütter-Böhmer, B, 2005) |
| "We report a 24-year-old woman with androgenetic alopecia who became sensitized to topical minoxidil following use of an extemporaneous preparation of minoxidil 4% with retinoic acid in a propylene glycol base." | 7.71 | Sensitization to saw palmetto and minoxidil in separate topical extemporaneous treatments for androgenetic alopecia. ( Mallari, RS; Sinclair, RD; Tate, B, 2002) |
| "After more than a decade of use, topical minoxidil solution has proven to be a safe and effective treatment for androgenetic alopecia." | 7.71 | Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. ( Cohen, DE; Friedman, ES; Friedman, PM; Washenik, K, 2002) |
| " Topical minoxidil is a proven therapy for androgenic alopecia and female senile alopecia." | 7.71 | Prevention of temporal alopecia following rhytidectomy: the prophylactic use of minoxidil. A study of 60 patients. ( Eremia, S; Li, CY; Umar, SH, 2002) |
| "As an extension to these observations, we chose to test the efficacy of minoxidil, a drug known to be a hypertrichotic agent, in preventing chemotherapy-induced alopecia in the newborn rat animal model." | 7.69 | Protection against cytosine arabinoside-induced alopecia by minoxidil in a rat animal model. ( Hussein, AM, 1995) |
| "Five women affected by androgenetic alopecia developed severe hypertrichosis of the face and limbs after 2-3 months of treatment with 5% topical minoxidil." | 7.69 | Diffuse hypertrichosis during treatment with 5% topical minoxidil. ( Misciali, C; Peluso, AM; Tosti, A; Vincenzi, C, 1997) |
| "Topical application of minoxidil has been reported to be effective in the treatment of androgenic alopecia." | 7.67 | Topical minoxidil for male pattern alopecia in two sets of twins. ( Kuruvilla, S; Roenigk, HH, 1987) |
| "A 1% minoxidil lotion was used to treat 670 male patients affected by androgenetic alopecia." | 7.67 | Topical minoxidil useful in 18% of patients with androgenetic alopecia: a study of 430 cases. ( Tosti, A, 1986) |
| "A male volunteer with frontal alopecia was treated simultaneously with 20 mg cyproterone acetate and 5 mg minoxidil topically (daily)." | 7.66 | Reversal of androgenic alopecia by minoxidil: lack of effect of simultaneously administered intermediate doses of cyproterone acetate. ( Vermorken, AJ, 1983) |
| "Cetirizine is an antihistamine that may be effective in hair loss treatment." | 7.30 | Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. ( Abbassi, MM; Bassiouny, EA; El-Samanoudy, SI; Farid, SF; Nada, HR, 2023) |
| " However, the efficacy of PRPF combined with minoxidil treatment remains unknown." | 7.30 | Evaluation of platelet-rich plasma plus basic fibroblast growth factor combined with minoxidil in the treatment of androgenetic alopecia: A randomized controlled trial. ( Chen, J; Dai, D; Guan, Q; Hu, Z; Le, D; Liu, S; Liu, W; Miao, Y; Qu, Q; Wu, S, 2023) |
| "Minoxidil is a common therapeutic option for AGA patients because of its availability." | 7.30 | A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia. ( Asim, M; Ouellette, S; Rao, B; Shah, A; Shah, R; Sharif, S, 2023) |
| " Topical latanoprost added to therapeutic efficacy of topical betamethason and minoxidil in treating patchy AA, suggesting it being beneficial and safe adjuvant therapy and add to efficacy of topical treatments without any adverse effects." | 7.11 | Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial. ( Behrangi, E; Ghassemi, M; Goodarzi, A; Jafari, M; Yazdanian, N, 2022) |
| "Female pattern hair loss (FPHL) is a hereditary form of hair loss in women and the most common patterned progressive hair loss in female patients with androgenetic alopecia (AGA)." | 7.01 | A systematic review of clinical trials using single or combination therapy of oral or topical finasteride for women in reproductive age and postmenopausal women with hormonal and nonhormonal androgenetic alopecia. ( Behrangi, E; Ghassemi, M; Goodarzi, A; Nikkhah, F; Nobari, NN; Roohaninasab, M; Sadeghzadeh-Bazargan, A, 2023) |
| " No scarring nor serious adverse events were reported in any of the studies." | 7.01 | Efficacy and safety of combinational therapy using topical minoxidil and microneedling for the treatment of androgenetic alopecia: a systematic review and meta-analysis. ( Abdi, P; Anthony, MR; Awad, C; Farkouh, C; Kenny, B; Maibach, HI; Ogunyemi, B, 2023) |
| "Minoxidil 2% and 5% have been FDA approved for treatment of this condition." | 7.01 | Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. ( Alarawi, A; Bessar, H; Ghonemy, S, 2021) |
| "Female androgenetic alopecia is one cause of alopecia in women, although the ideal treatment for this condition remains far from defined." | 7.01 | Intradermal injections with 0.5% minoxidil for the treatment of female androgenetic alopecia: A randomized, placebo-controlled trial. ( Cesetti, MV; Chartuni, JCN; Costa, IMC; Gavioli, CFB; Lemes, AM; Takano, GHS; Uzel, BPC, 2021) |
| "Androgenetic alopecia (AGA) is a hair loss disorder that frequently affects the male population." | 7.01 | Efficacy of Minoxidil Combined With Photobiomodulation for the Treatment of Male Androgenetic Alopecia. A Double-Blind Half-Head Controlled Trial. ( Contin, LA; de Brito, FF; Donati, A; Ferrara, F; Kakizaki, P; Machado, CJ, 2021) |
| "Androgenic alopecia (AGA) is a common hair loss disorder." | 6.94 | A Randomized, Controlled Pilot Trial Comparing Platelet-Rich Plasma to Topical Minoxidil Foam for Treatment of Androgenic Alopecia in Women. ( Arthurs, JR; Bruce, AJ; Bruce, CJ; Desmond, CM; Diehl, NN; Douglass, EJ; Heckman, MG; Pincelli, TP; Shapiro, SA, 2020) |
| " Although successful encapsulation of MIN has been observed in these nanocarriers, there is still scarce data regarding their loading in a final dosage form." | 6.82 | Exploiting Recent Trends in the Treatment of Androgenic Alopecia through Topical Nanocarriers of Minoxidil. ( Ahmed, N; Saleem, K; Siddiqui, B; Taqi, MM; Ur Rehman, A, 2022) |
| "Treatment with minoxidil can induce an increase in hair density and hair thickness,whereas treatment with alfatradiol results in deceleration or stabilization of hair loss." | 6.73 | Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women. ( Blume-Peytavi, U; Ellwanger, U; Garcia Bartels, N; Hoffmann, R; Krisp, A; Kunte, C, 2007) |
| "Minoxidil (Loxon) was topically applied twice a day massaging the solution into the scalp over 6-12 months." | 6.70 | [Effect of minoxidil on hair growth in androgenic alopecia in women]. ( Brzezińska-Wcisło, L, 2002) |
| "Sixty-four healthy men with early male pattern baldness completed a 6-month, double-blind, placebo-controlled study in which the efficacy of 2% minoxidil gel and solution formulations was compared." | 6.66 | Comparable efficacy of 2% minoxidil gel and solution formulations in the treatment of male pattern alopecia. ( Piepkorn, MW; Weidner, M, 1988) |
| "Fifty-eight men with Hamilton scale type III vertex or type IV male pattern baldness were studied to determine the dose-response activity of low concentrations of topical minoxidil in promoting hair growth." | 6.66 | Dose-response study of topical minoxidil in male pattern alopecia. ( Jondreau, L; Kassimir, JJ; Reed, ML; Shupack, JL; Thirumoorthy, T, 1987) |
| "Frontotemporal hair loss did not respond to treatment and in fact progressed in severity, despite the twice-daily applications of minoxidil." | 6.66 | Topical minoxidil for androgenetic alopecia: optimizing the chance for success by appropriate patient selection. ( DeVillez, RL, 1987) |
| "Minoxidil, 1." | 6.66 | Topical minoxidil therapy in hereditary androgenetic alopecia. ( De Villez, RL, 1985) |
| "Cetirizine, a widely used agent for allergic disorders, has recently been topically used for treating androgenetic alopecia (AGA)." | 6.60 | Topical cetirizine for treating androgenetic alopecia: A systematic review. ( Chen, X; Xiang, H; Yang, M, 2022) |
| "Male pattern hair loss (androgenetic alopecia) is a common problem." | 6.37 | Topical minoxidil in the treatment of male pattern alopecia. ( Baden, HP; Kvedar, JC, 1987) |
| "Topical minoxidil (Rogaine) has recently been approved by the Food and Drug Administration for treatment of androgenetic alopecia." | 6.16 | Topical minoxidil: review of efficacy and safety. ( Katz, HI, 1989) |
| "The most prevalent kind of hair loss is androgenic alopecia (AGA), which is characterized by hair follicle miniaturization and microenvironment dysfunction." | 5.91 | Co-delivery of minoxidil and tocopherol acetate ethosomes to reshape the hair Follicular Microenvironment and promote hair regeneration in androgenetic alopecia. ( Guan, Y; Liu, M; Qiang, W; Ruan, R; Sun, H; Yan, A; Yu, Q; Zhu, H; Zhu, X, 2023) |
| "Alopecia is a condition associated with different etiologies, ranging from hormonal changes to chemotherapy, that affects over 80 million people in the USA." | 5.72 | Nanostructured lipid carriers loaded with an association of minoxidil and latanoprost for targeted topical therapy of alopecia. ( Alencar-Silva, T; Carvalho, JL; Cunha-Filho, M; Gelfuso, GM; Gratieri, T; Oliveira, PM; Pires, FQ, 2022) |
| " Minoxidil (MXD) is commonly used topically to treat alopecia, but its low absorption rate limits widespread use." | 5.72 | Minoxidil-loaded hyaluronic acid dissolving microneedles to alleviate hair loss in an alopecia animal model. ( An, BS; Jeong, JS; Kim, DS; Kim, MJ; Kim, SY; Lee, S; Seong, KY; Yang, SY, 2022) |
| "Both spironolactone as a 5% topical solution and minoxidil as a 5% topical solution might be used safely in a twice-daily dosage to treat AGA in both genders." | 5.72 | Dermoscopic evaluation of the efficacy of combination of topical spironolactone 5% and minoxidil 5% solutions in the treatment of androgenetic alopecia: A cross sectional-comparative study. ( Abdel-Dayem, HA; Ammar, AM; Elsaie, ML; Elshahid, AR; Mohamed, AA, 2022) |
| "PRP is effective in the treatment of moderate grades of androgenetic alopecia in men, although perhaps not different from minoxidil." | 5.69 | Efficacy of autologous platelet-rich plasma therapy versus topical Minoxidil in men with moderate androgenetic alopecia: a randomized open-label trial. ( Balasundaram, M; Kumari, R; Ramassamy, S, 2023) |
| "Platelet-rich plasma (PRP) has been increasingly accepted as a potential therapy in the treatment of androgenetic alopecia (AGA), However, there remains a dearth of data on the effectiveness of PRP prepared by automatic blood cell separator with a combination of topical minoxidil for the treatment of AGA." | 5.69 | Injections of platelet-rich plasma prepared by automatic blood cell separator combined with topical 5% minoxidil in the treatment of male androgenetic alopecia. ( Long, B; Wei, W; Zhang, C; Zhang, S; Zhang, Y, 2023) |
| "The goal was to explore the efficacy and side effects of basic fibroblast growth factor (bFGF) combined with minoxidil in the treatment of male patients with early stage of androgenetic alopecia (AGA)." | 5.51 | Clinical observation of basic fibroblast growth factor (bFGF) combined with minoxidil in the treatment of male androgenetic alopecia. ( Liu, C; Wu, W; Zhang, Y; Zhao, H, 2022) |
| "Topical hydroalcoholic solution of flutamide plus minoxidil may be promising treatment for the androgenetic alopecia." | 5.51 | Comparison between "5% minoxidil plus 2% flutamide" solution vs. "5% minoxidil" solution in the treatment of androgenetic alopecia. ( Faghihi, G; Hoseyni, MS; Iraji, F; Jelvan, M; Saber, M; Siadat, AH, 2022) |
| "Based on our findings, the mixed preparation of piperine, capsaicin, and curcumin is effective in treating alopecia areata, but it has not been shown to be superior to minoxidil in short-term therapy." | 5.51 | Efficacy of a mixed preparation containing piperine, capsaicin and curcumin in the treatment of alopecia areata. ( Mao, Y; Mei, X; Shi, W; Song, J; Xie, Y; Xu, Z, 2022) |
| "To observe the efficacy of unilateral subcutaneous injection of botulinum toxin A combined with finasteride and minoxidil in the treatment of androgenic alopecia." | 5.51 | A study of combination unilateral subcutaneous botulinum toxin a treatment for androgenetic alopecia. ( Gao, S; Jia, Z; Li, K; Tian, K; Wu, L; Xu, W, 2022) |
| "Treatment of androgenetic alopecia (AGA) with concurrent electrodynamic microneedling and 5% minoxidil may further stimulate hair growth." | 5.51 | Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway. ( Bao, L; Fang, S; Li, Y; Zheng, L; Zong, H, 2022) |
| "Intradermal minoxidil is used as an off-label treatment for patchy non-severe alopecia areata (AA) either alone or in combination with steroids; however, studies estimating its efficacy are still lacking." | 5.51 | Efficacy of intradermal minoxidil 5% injections for treatment of patchy non-severe alopecia areata. ( Abdallah, MAE; Shareef, R; Soltan, MY, 2022) |
| "In a small cohort of androgenetic alopecia men, adding the SULT1A1 adjuvant to their daily minoxidil treatment regimen improved hair regrowth." | 5.51 | SULT1A1 (Minoxidil Sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth. ( Daruwalla, S; Dhurat, R; Goren, A; Kovacevic, M; McCoy, J; Pai, S; Shapiro, J; Sinclair, R; Vano-Galvan, S, 2022) |
| "Male androgenetic alopecia (AGA) affects up to 60% of men by the age of 50." | 5.51 | Controversies in the treatment of androgenetic alopecia: The history of finasteride. ( Andy, G; Aseem, S; John, M; Maja, K; Michael, K; Mirna, S; Rachita, D; Zeljana, B, 2019) |
| "Minoxidil has been approved for the treatment of hair loss, however its mechanism of action is still not fully clarified." | 5.46 | An analysis of gene expression data involving examination of signaling pathways activation reveals new insights into the mechanism of action of minoxidil topical foam in men with androgenetic alopecia. ( Aliper, A; Consolo, M; Cooper, KD; McCormick, TS; Mirmirani, P; Ozerov, IV; Pappas, A; Schastnaya, J; Stamatas, GN; Wu, J; Zhavoronkov, A, 2017) |
| "Tofacitinib-treated mice exhibited more hair regrowth than either minoxidil-treated or control mice did between day 7 and 21 (P < 0." | 5.46 | Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction. ( Deenonpoe, R; Meephansan, J; Ponnikorn, S; Suchonwanit, P; Thummakriengkrai, J; Yingmema, W, 2017) |
| "Treatment with dutasteride 0." | 5.46 | Familial frontal fibrosing alopecia treated with dutasteride, minoxidil and artificial hair transplantation. ( Cranwell, WC; Sinclair, R, 2017) |
| " The safety and efficacy of a twice-daily regimen of 2% minoxidil solution used in combination with the botanical hair solution for 12 weeks in 54 subjects was evaluated in a multicenter, single-arm, open-label study." | 5.43 | Efficacy and Safety of Minoxidil 2% Solution in Combination With a Botanical Hair Solution in Women With Female Pattern Hair Loss/Androgenic Alopecia. ( McMichael, A; Meckfessel, MH; Pham, H; von Grote, E, 2016) |
| " The safety and efficacy of a twice-daily regimen of 5% minoxidil foam used in combination with a novel botanical hair solution was evaluated in a 12-week, multicenter, single-arm, open label study in 56 subjects with mild to moderate AGA." | 5.43 | Efficacy and Safety of Minoxidil 5% Foam in Combination With a Botanical Hair Solution in Men With Androgenic Alopecia. ( Keaney, TC; Meckfessel, MH; Pham, H; von Grote, E, 2016) |
| " Currently, there are 3 Food and Drug Administration-approved nonsurgical androgenetic alopecia treatments: minoxidil, finasteride, and low-light laser therapy." | 5.41 | Noninvasive Hair Rejuvenation. ( Sand, J; Walen, S, 2023) |
| "Finasteride and minoxidil are medicaments commonly prescribed for treating benign prostatic hyperplasia (BPA), hypertension, and/or androgenetic alopecia (AGA)." | 5.41 | Comparative effects of finasteride and minoxidil on the male reproductive organs: A systematic review of in vitro and in vivo evidence. ( Da Matta, SLP; Da Silva, J; Gonçalves, RV; Lozi, AA; Santana, FFV, 2023) |
| "Topical minoxidil 5% are effective in androgenetic alopecia (AGA)." | 5.41 | A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study. ( Abdel-Aziz, RTA; Abdel-Raouf, H; Ahmed, SS; Aly, UF; Medhat, W, 2021) |
| " In the present study, the efficacy and safety of twice daily application of topical cetirizine 1% versus minoxidil 5% solutions for 16 weeks were compared in male androgenetic alopecia (AGA)." | 5.41 | Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study. ( Firooz, A; Guishard, A; Hossein Mostafa, D; Nasrollahi, SA; Niknam, S; Samadi, A, 2021) |
| "Tretinoin is a mitogen by itself and also enhances the absorption of minoxidil which acts by enlarging the miniaturized hair follicles." | 5.35 | Alopecia in congenital hidrotic ectodermal dysplasia responding to treatment with a combination of topical minoxidil and tretinoin. ( Dhurat, RS; Jerajani, HR; Melkote, S; Palav, A, 2009) |
| "A 45-year-old Japanese man with paroxysmal atrial fibrillation (AF) developed acute anteroseptal myocardial infarction (MI)." | 5.31 | A case of acute myocardial infarction associated with topical use of minoxidil (RiUP) for treatment of baldness. ( Fujiwara, C; Morikaw, S; Ohno, R; Satoh, H; Terada, H; Uehara, A, 2000) |
| " Combining fractional Er:Glass laser therapy with topical minoxidil may yield therapeutic benefits for patients with androgenetic alopecia (AGA)." | 5.30 | A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. ( Khunkhet, S; Rojhirunsakool, S; Suchonwanit, P, 2019) |
| "One patient had no hair loss in either the treatment or control area." | 5.28 | The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies. ( Baden, H; Frederickson, H; Gajewski, W; Goldstein, A; Goodman, A; Granai, CO, 1991) |
| "Compared with topical minoxidil monotherapy, JetPeel-assisted topical minoxidil is more effective during the treatment of androgenetic alopecia." | 5.27 | The clinical effect of JetpPeel-assisted topical minoxidil in the treatment of androgenetic alopecia: A randomized pilot study. ( Bao, L; Gong, L; Li, Y; Tian, T, 2018) |
| "The synergism of combined use between oral finasteride and topical minoxidil has been established in treating androgenetic alopecia among men." | 5.27 | A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. ( Chalermroj, N; Khunkhet, S; Srisuwanwattana, P; Suchonwanit, P, 2018) |
| "A caffeine-based topical liquid should be considered as not inferior to minoxidil 5% solution in men with androgenetic alopecia." | 5.24 | An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia. ( Anandan, S; Chitallia, J; Dhurat, R; Jayaraaman, AM; Klenk, A; Madhukara, J; May, TW; Vaidya, P, 2017) |
| "5% minoxidil solution is approved for the treatment of male androgenetic alopecia (AGA)." | 5.24 | A Comparative Study between the Efficacy and Safety of 5% Minoxidil Solution and 5% Minoxidil Milky Lotion in the Treatment of Male Androgenic Alopecia. ( Suvanasuthi, S; Thanomkitti, K; Thuangtong, R, 2017) |
| "There are knowledge gaps regarding the relative efficacy of 3 commonly used drugs for androgenetic alopecia (AGA), namely, minoxidil and the two 5-α reductase inhibitors dutasteride and finasteride." | 5.22 | Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. ( Bamimore, MA; Gupta, AK; Talukder, M; Venkataraman, M, 2022) |
| "Oral finasteride is an FDA-approved treatment for androgenetic alopecia (AGA)." | 5.22 | Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative? ( Gupta, AK; Talukder, M, 2022) |
| " Currently, the FDA-approved drugs for the treatment of androgenetic alopecia (AGA) are minoxidil and finasteride and immunosuppressives are therapeutic options for alopecia areata (AA), but the objective adverse effects and high cost of these treatments reduce patient compliance and thus the effectiveness of the drugs." | 5.22 | Exploring the effects of Chinese herbal ingredients on the signaling pathway of alopecia and the screening of effective Chinese herbal compounds. ( Dou, J; Xu, X; Zhang, X; Zhang, Z, 2022) |
| "Minoxidil solution is used for the treatment of androgenetic alopecia (AGA)." | 5.22 | Does topical minoxidil at concentrations higher than 5% provide additional clinical benefit? ( Goldust, M; Kianfar, N; Patil, A; Rudnicka, L; Sinclair, R; Singh, S; Waśkiel-Burnat, A, 2022) |
| " Currently, there are 3 Food and Drug Administration-approved nonsurgical androgenetic alopecia treatments: minoxidil, finasteride, and low-light laser therapy." | 5.22 | Noninvasive Hair Rejuvenation. ( Sand, J; Walen, S, 2022) |
| "The objective of this article is to discuss various conditions in alopecia where oral minoxidil has found its role." | 5.22 | Comprehensive review of oral minoxidil in alopecia. ( Modha, JD; Pathania, YS, 2022) |
| "Topical minoxidil formulations have been shown to be effective in treating androgenetic alopecia (AGA) for 12 months." | 5.22 | Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104-week open-label clinical trial. ( Blume-Peytavi, U; Canfield, D; Hillmann, K; Kanti, V; Kottner, J; Stroux, A, 2016) |
| "5% minoxidil formulations twice daily are effective in treating vertex male androgenetic alopecia (AGA); however, efficacy and safety data in frontotemporal regions are lacking." | 5.20 | A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men. ( Blume-Peytavi, U; Canfield, D; Garcia Bartels, N; Hillmann, K; Kottner, J; Stroux, A, 2015) |
| "The variable success of topical minoxidil in the treatment of androgenic alopecia has led to the hypothesis that other pathways could mediate this form of hair loss, including infection and/or microinflammation of the hair follicles." | 5.17 | Preparation and evaluation of a multimodal minoxidil microemulsion versus minoxidil alone in the treatment of androgenic alopecia of mixed etiology: a pilot study. ( Adam, AN; Gado, AM; Mohammed, HR; Sakr, FM, 2013) |
| "The aim of this study was to evaluate the efficacy of 5% hexane extract of Curcuma aeruginosa, a botanically derived inhibitor of 5α-reductase and 5% minoxidil in the treatment of androgenetic alopecia." | 5.16 | Curcuma aeruginosa, a novel botanically derived 5α-reductase inhibitor in the treatment of male-pattern baldness: a multicenter, randomized, double-blind, placebo-controlled study. ( Asawanonda, P; Ingkaninan, K; Jariyasethavong, V; Leelapornpisit, P; Pumthong, G; Suthipinittharm, P; Triwongwaranat, D; Varothai, S; Waranuch, N, 2012) |
| "Topical minoxidil and oral finasteride have been used to treat men with androgenetic alopecia (AGA)." | 5.16 | Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. ( Tanglertsampan, C, 2012) |
| "We sought to compare the efficacy, safety, and acceptability and to show noninferiority of once-daily 5% minoxidil topical foam (MTF) with twice-daily 2% MTS in women with androgenetic alopecia." | 5.15 | A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. ( Blume-Peytavi, U; Canfield, D; Dietz, E; Garcia Bartels, N; Hillmann, K, 2011) |
| "Our study confirms the data of the literature and the evidence coming from years of clinical experience, that twice a day topical application of 5% minoxidil solution, Carexidil ®, is effective in the treatment of male and female androgenetic alopecia, with evident efficacy already after 6 months." | 5.15 | [Efficacy and tolerability of 5% minoxidil solution (Carexidil®) in male and female androgenetic alopecia: a 6-month open multicentric study]. ( Alessandrini, A; Fiorucci, MC; Guarrera, M; Lorenzi, S; Piraccini, B; Starace, M, 2011) |
| "Minoxidil is efficacious in inducing hair growth in patients with androgenetic alopecia by inducing hair follicles to undergo transition from the early to late anagen phase." | 5.14 | Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men. ( Arano, O; Katsuoka, K; Nishikawa, T; Tsuboi, R; Yamada, H, 2009) |
| "To evaluate the efficacy of fulvestrant solution in stimulating hair growth in men and postmenopausal women with androgenetic alopecia in two randomized, phase II, minoxidil- and/or vehicle-controlled studies." | 5.13 | Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies. ( Gassmueller, J; Hoffmann, R; Webster, A, 2008) |
| "To assess the efficacy and safety of a new 5% minoxidil topical formulation in a propylene glycol-free foam vehicle in men with androgenetic alopecia (AGA)." | 5.12 | A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. ( Bergfeld, W; Hordinsky, M; Kohut, B; Miller, J; Olsen, EA; Wanser, R; Whiting, D; Zhang, P, 2007) |
| "5% topical minoxidil solution has been widely used to stimulate new hair growth and help stop hair loss in men with androgenetic alopecia (AGA)." | 5.12 | Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial. ( Eun, HC; Kim, KH; Kwon, OS; Lee, SH; Shin, HS; Won, CH, 2007) |
| "Minoxidil solution stimulates hair growth in androgenetic alopecia." | 5.12 | Is topical minoxidil solution effective on androgenetic alopecia in routine daily practice? ( Mapar, MA; Omidian, M, 2007) |
| "To pical minoxidil solution 2% stimulates new hair growth and helps stop the loss of hair in men with androgenetic alopecia and women with female pattern hair loss." | 5.11 | A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. ( Ditre, CM; Dunlap, F; Kantor, I; Lucky, AW; Pandya, AG; Piacquadio, DJ; Savin, RC; Tharp, MD, 2004) |
| "Topical minoxidil solution 2% stimulates new hair growth and helps stop the loss of hair in individuals with androgenetic alopecia (AGA)." | 5.10 | A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. ( Dunlap, FE; Funicella, T; Koperski, JA; Olsen, EA; Swinehart, JM; Trancik, RJ; Tschen, EH, 2002) |
| "To compare topical minoxidil 2% and cyproterone acetate in the treatment of female alopecia." | 5.10 | Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. ( Boudou, P; Chaspoux, C; Fiet, J; Hardy, N; Jouanique, C; Reygagne, P; Vexiau, P, 2002) |
| " Topical minoxidil has been shown to be effective for androgenetic alopecia and alopecia areata." | 5.08 | A randomized trial of minoxidil in chemotherapy-induced alopecia. ( Bandstra, BA; Compton, LD; Duvic, M; Farmer, KL; Hortobagyi, GN; Hymes, SR; Lemak, NA; Trancik, RJ; Valero, V, 1996) |
| "The aim of our study was to determine if ketoconazole (KCZ) which is active against the scalp microflora and shows some intrinsic anti-inflammatory activity might improve alopecia." | 5.08 | Ketoconazole shampoo: effect of long-term use in androgenic alopecia. ( Cauwenbergh, G; De Doncker, P; Piérard, GE; Piérard-Franchimont, C, 1998) |
| "Topical diphenylcyclopropenone (DPCP) and minoxidil have been used in the treatment of alopecia areata with variable results." | 5.07 | Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation. ( Abbott, F; Ho, V; Shapiro, J; Tan, J; Tron, V, 1993) |
| " The purpose of this study was to evaluate a 2% topical minoxidil solution (Rogaine/Regaine, The Upjohn Co, Kalamazoo, Mich) for the treatment of female androgenetic alopecia." | 5.07 | Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. ( DeVillez, RL; Jacobs, JP; Szpunar, CA; Warner, ML, 1994) |
| "A 32-week, double-blind, placebo-controlled trial was conducted in 10 European centers to assess the efficacy and safety of 2% topical minoxidil solution for the treatment of androgenetic alopecia in women." | 5.07 | Use of topical minoxidil therapy for androgenetic alopecia in women. ( Jacobs, JP; Szpunar, CA; Warner, ML, 1993) |
| "A 48-week open label trial was conducted in five Middle-Eastern countries (Lebanon, Egypt, Saudi Arabia, Jordan, and the United Arab Emirates) to determine the safety and efficacy of 2% minoxidil in the treatment of early androgenic alopecia and to compare the response with Western countries." | 5.07 | Topical minoxidil therapy for androgenic alopecia in the Middle East. The Middle-Eastern Topical Minoxidil Study Group. ( Karam, P, 1993) |
| "The safety and efficacy of minoxidil 2% for the treatment of female androgenetic alopecia was assessed in a 32-week double-blind placebo-controlled trial." | 5.07 | Treatment of female androgenetic alopecia with minoxidil 2%. ( Jacobson, C; Whiting, DA, 1992) |
| "Psychologic characteristics were studied in a sample of 168 men with alopecia androgenetica who participated in a clinical trial on the efficacy of minoxidil gel." | 5.07 | Psychologic characteristics of men with alopecia androgenetica and their modification. ( Dutree-Meulenberg, RO; Passchier, J; Stolz, E; van der Donk, J; Verhage, F, 1991) |
| "One hundred and sixty nine men with early male pattern baldness (androgenic alopecia) were treated in a random, double-blind fashion with either 2% minoxidil solution or placebo vehicle for 24 weeks, one ml applied twice daily." | 5.06 | Australian trial of topical minoxidil and placebo in early male pattern baldness. ( Connors, TJ; Cooke, DE; De Launey, WE; Downie, M; Eggleston, AS; Knudsen, RG; Shumack, S, 1990) |
| "The paper reports the results of local treatment using minoxidil 2% in a watery solution at a dose of 2 ml/day in 50 patients affected by androgenetic alopecia." | 5.06 | [Efficacy and cardiovascular tolerability of minotricon in the treatment of seborrheic alopecia]. ( Pinelli, S; Rigoni, C; Scarabelli, G; Terenzio, C; Toffolo, P, 1990) |
| "Thirty-one men with androgenetic alopecia completed 4 1/2 to 5 years of therapy with 2% and 3% topical minoxidil." | 5.06 | Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. ( Amara, IA; DeLong, ER; Olsen, EA; Weiner, MS, 1990) |
| "Cutaneous blood flow was measured by Laser Doppler Flowmetry after topical application of minoxidil lotion, in 9 healthy males with androgenetic alopecia, and other volunteers." | 5.06 | Does topical minoxidil increase skin blood flow? A laser Doppler flowmetry study. ( Bezemer, PD; Bruynzeel, DP; de Boer, EM; Nieboer, C, 1988) |
| "Consultations, motives, experience, and attitudes were explored in 201 men with alopecia androgenetica who had two years before shown interest in hair treatment using minoxidil." | 5.06 | Why men with hair loss go to the doctor. ( Dutrée-Meulenberg, RO; Passchier, J; Rijpma, SE; Stolz, E; Verhage, F, 1989) |
| "Seventy-two adult male patients were entered into a double-blind, placebo-controlled investigation using 2% to 3% topical minoxidil solution for androgenetic alopecia." | 5.06 | Topical minoxidil therapy for androgenetic alopecia. A 30-month study. ( Koperski, JA; Orenberg, EK; Wilkinson, DI, 1987) |
| "Of 149 subjects with androgenetic alopecia, 102 completed 1 year of a double-blind, randomized study comparing 2% minoxidil and 3% minoxidil solutions for safety and efficacy." | 5.06 | Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. ( Duncan, SH; Rietschel, RL, 1987) |
| "A double-blind 12-month trial was conducted to evaluate the safety and efficacy of topical minoxidil in patients with androgenetic alopecia." | 5.06 | Androgenetic alopecia: treatment results with topical minoxidil. ( Roberts, JL, 1987) |
| "5% minoxidil has been tested for the promotion of hair growth in 56 subjects with androgenetic alopecia." | 5.06 | Topical tretinoin for hair growth promotion. ( Bazzano, GS; Galen, W; Terezakis, N, 1986) |
| "Topical 5% minoxidil solution was used to treat 47 patients with severe alopecia areata." | 5.06 | Topical minoxidil dose-response effect in alopecia areata. ( Buys, CM; Fiedler-Weiss, VC; Rumsfield, JA; West, DP, 1986) |
| "The combination of finasteride and topical minoxidil has been used for treating patients with androgenetic alopecia (AGA)." | 5.05 | The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis. ( Chen, B; Chen, L; Wang, H; Wang, L; Zhang, J, 2020) |
| "Topical minoxidil has been used for almost 40 years to treat alopecia." | 5.05 | Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. ( Atanaskova Mesinkovska, N; Juhasz, M; Michelle, L; Muller Ramos, P; Sharma, AN, 2020) |
| "low dose oral minoxidil (OM) is an increasingly used treatment for androgenetic alopecia and other types of hair loss." | 5.05 | Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data. ( Fernandez-Nieto, D; Jaen-Olasolo, P; Jimenez-Cauhe, J; Moreno-Arrones, OM; Ortega-Quijano, D; Rodrigues-Barata, R; Saceda-Corralo, D; Vaño-Galvan, S, 2020) |
| "Topical minoxidil is a well-known and often-utilized drug in dermatological practice for the treatment of alopecia." | 5.01 | Off-Label Use of Topical Minoxidil in Alopecia: A Review. ( Choi, JN; Colavincenzo, M; Stoehr, JR; Vanderweil, S, 2019) |
| "Introduction: Topical minoxidil is the first-line therapy for treating both male and female androgenetic alopecia." | 5.01 | The Efficacy of Topical Minoxidil for Non-Scarring Alopecia: A Systematic Review ( Choi, FD; Juhasz, ML; Mesinkovska, NA; Sung, CT, 2019) |
| "This meta-analysis strongly suggests that minoxidil, finasteride, and low-level laser light therapy are effective for promoting hair growth in men with androgenetic alopecia and that minoxidil is effective in women with androgenetic alopecia." | 4.95 | The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. ( Adil, A; Godwin, M, 2017) |
| " However, a recent Cochrane systematic review concludes that the only drug proven to improve alopecia by randomized controlled studies using rigorous criteria is minoxidil." | 4.91 | An update on the treatment of female alopecia and the introduction of a potential novel therapy. ( Check, JH; Cohen, R, 2015) |
| "Topical monoxidil and oral finasteride are commonly in use and have FDA approval for the treatment of male androgenetic alopecia; dutasteride, a type I and II 5-alpha-reductase inhibitor, is on hold in Phase III trials." | 4.86 | Male androgenetic alopecia. ( Rathnayake, D; Sinclair, R, 2010) |
| "Hypertrichosis has been reported more frequently in females than in males who use minoxidil topical solution (MTS) for the treatment of androgenetic alopecia (AGA)." | 4.82 | Hypertrichosis in females applying minoxidil topical solution and in normal controls. ( Dawber, RP; Rundegren, J, 2003) |
| " Minoxidil and Finasteride were recently introduced for the treatment of androgenetic alopecia in Japan, and TGF-beta1 is the next target for innovative treatment." | 4.82 | [Pathomechanism of androgenetic alopecia and new treatment]. ( Itami, S, 2004) |
| "The management of androgenetic alopecia (AGA) has been materially altered by the availability of the 5 alpha-reductase type 2 inhibitor, finasteride." | 4.81 | Management of male pattern hair loss. ( Sinclair, RD, 2001) |
| "While current studies have supported oral minoxidil as a novel, adjunctive therapy in non-scarring forms of alopecia, there continues to be limited data on oral minoxidil for these conditions." | 4.31 | Oral minoxidil use in androgenetic alopecia and telogen effluvium. ( Cooley, JE; Feaster, B; McMichael, AJ; Onamusi, T, 2023) |
| "Topical minoxidil has been used for many years to treat adult alopecia, and there is growing evidence supporting the off-label use of low-dose oral minoxidil (LDOM)." | 4.31 | Systemic minoxidil for hair disorders in pediatric patients: a safety and tolerability review. ( John, JM; Sinclair, RD, 2023) |
| "To determine the causative gene mutation in a family with monilethrix and observe the therapeutic effect of 5% topical minoxidil." | 4.31 | Gene detection in a family with monilethrix and treatment with 5% topical minoxidil. ( Du, P; Fu, Z; Shen, Q; Wang, J, 2023) |
| "Minoxidil has been used as an effective and cost-efficient topical treatment for androgenic alopecia." | 4.31 | Hair regrowth boosting via minoxidil cubosomes: Formulation development, in vivo hair regrowth evaluation, histopathological examination and confocal laser microscopy imaging. ( Elnawawy, T; Makhlouf, A, 2023) |
| "Non-adherence to topical minoxidil in alopecia patients is a barrier to efficacy." | 4.31 | Topical Minoxidil Adherence in Patients With Alopecia. ( De Souza, B; Eginli, A; Harris, T; Larrondo, J; McMichael, A; Senthilnathan, A, 2023) |
| "The strategy in this work was loading Melatonin (MEL), the powerful antioxidant photosensitive molecule, in novel Pickering emulsions (PEs) stabilized by chitosan-dextran sulphate nanoparticles (CS-DS NPs) and enhanced by lecithin, for treatment of androgenic alopecia (AGA)." | 4.31 | Boosting hair growth through follicular delivery of Melatonin through lecithin-enhanced Pickering emulsion stabilized by chitosan-dextran nanoparticles in testosterone induced androgenic alopecia rat model. ( Abd-Elmonsif, NM; Elshall, AA; Ghoneim, AM; Osman, R; Shaker, DS, 2023) |
| "This study evaluated the topical effect of Lepidium sativum lyophilized seed extract (LSLE) towards Sustanon-induced alopecia in male adult Wistar albino rats in vivo, compared to minoxidil topical reference standard drug (MRD)." | 4.31 | The medicinal activity of lyophilized aqueous seed extract of Lepidium sativum L. in an androgenic alopecia model. ( Albalawi, MA; Bakeer, RM; El Hadi, SA; El-Desoky, AH; Elhawary, SS; Hafez, AM; Hassan, OF; Mahgoub, S; Mokhtar, FA; Sedky, NK, 2023) |
| "Recent studies are promising for the intradermal delivery of dutasteride and minoxidil in the treatment of androgenetic alopecia." | 4.31 | Intradermal Delivery of Alopecia Therapeutics: Current State and Future Prospects. ( Alhanshali, L; Buontempo, M; Lo Sicco, K; Majerson, D; Shapiro, J, 2023) |
| "To investigate the mechanism of minoxidil in treating androgenetic alopecia (AGA)." | 4.31 | New Target for Minoxidil in the Treatment of Androgenetic Alopecia. ( Shen, Y; Song, X; Sun, J; Xie, B; Zhang, H; Zhang, L; Zhu, Y, 2023) |
| " Since scalp inflammation was recognized as a potential physiological obstacle to the efficacy of the reference hair regrowth drug Minoxidil in vivo and since perifollicular inflammation is the hallmark of about 50%-70% follicular units in androgenetic alopecia, we decided to investigate whether the anti-inflammatory activity of LLLT/GentleWaves® device were assigned to L'Oréal by Light BioScience L." | 4.02 | Low-Level Light Therapy Downregulates Scalp Inflammatory Biomarkers in Men With Androgenetic Alopecia and Boosts Minoxidil 2% to Bring a Sustainable Hair Regrowth Activity. ( Antonelli, R; Barbarat, P; Buffat, L; Cheniti, A; de Bernard, S; Kanoun-Copy, L; Mahe, YF; Planard-Luong, L; Tacheau, C, 2021) |
| "The efficacy of minoxidil (MXD) ethanolic solutions (1%-5% w/v) in the treatment of androgenetic alopecia is limited by adverse reactions." | 3.96 | The hydroxypropyl-β-cyclodextrin-minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia. ( Cutrignelli, A; Denora, N; Fontana, S; Franco, M; la Forgia, F; Laquintana, V; Lopedota, AA; Maqoud, F; Mele, A; Passantino, G; Scala, R; Tinelli, A; Tricarico, D; Zizzo, N, 2020) |
| "Minoxidil solution has routinely been used for decades for the treatment of androgenic alopecia." | 3.96 | Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report. ( Jain, K; Pereira, A; Venkatesh, R; Yadav, NK, 2020) |
| "We report three cases of severe hypertrichosis in healthy infants, who did not present any type of endocrinological pathology and whose parents used topical minoxidil for the treatment of their baldness." | 3.96 | Severe hypertrichosis in infants due to transdermic exposure to 5% and 7% topical minoxidil. ( Arcangeli, F; Delgado Rubio, A; García Del Monte, J; Lotti, T; Rica Echevarría, I, 2020) |
| "Oral minoxidil (OM) has been reported to be effective for androgenetic alopecia (AGA)." | 3.96 | Efficacy and safety of oral minoxidil in female androgenetic alopecia. ( Annunziata, MC; Cantelli, M; Fabbrocini, G; Nappa, P; Patrì, A; Vastarella, M, 2020) |
| "In spite of several modalities for androgenic alopecia therapy used such as topical minoxidil solution or oral finasteride; it still has a great challenge." | 3.96 | Evaluation of the effect of autologous platelet-rich plasma on androgenic alopecia. ( Makki, M; Salah, I; Younes, AH, 2020) |
| "The combination of nonablative laser and topical minoxidil may be a good alternative therapy for AA patients, including alopecia totalis and alopecia universalis, without systemic and local side effects." | 3.91 | Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil. ( Li, Y; Wang, W, 2019) |
| "The aim of this study was to prepared minoxidil-encapsulated PLLGA nanoparticles and accumulate minoxidil in hair follicles utilizing its drug delivery properties for effective treatment of male and female androgenetic alopecia." | 3.88 | Minoxidil-encapsulated poly(L-lactide-co-glycolide) nanoparticles with hair follicle delivery properties prepared using W/O/W solvent evaporation and sonication. ( Hida, Y; Makino, K; Takeuchi, I, 2018) |
| "The clinical features, alopecia-related quality of life (QoL), and response to minoxidil of EIA in patients with breast cancer were assessed." | 3.88 | Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer. ( Chan, D; Dusza, S; Fornier, M; Freites-Martinez, A; Gajria, D; Goldfarb, S; Lacouture, ME; Modi, S; Shapiro, J, 2018) |
| "Topical minoxidil is the only US FDA approved OTC drug for the treatment of androgenetic alopecia (AGA)." | 3.88 | Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients. ( Dhurat, R; Goldust, M; Goren, A; Kovacevic, M; Lotti, T; Lukinovic Skudar, V; McCoy, J; Shapiro, J; Sharma, A; Sinclair, R; Situm, M, 2018) |
| "Minoxidil is widely used for treatment of androgenic alopecia." | 3.85 | Preparation and in vivo evaluation of lecithin-based microparticles for topical delivery of minoxidil. ( Choi, HC; Han, K; Kim, DW; Lee, HJ; Lee, YB; Na, MJ; Oh, DW; Park, CW; Yuk, DY, 2017) |
| "Minoxidil (Mx) is a conventional drug for treating androgenetic alopecia, preventing hair loss, and promoting hair growth." | 3.83 | Effectiveness of a Layer-by-Layer Microbubbles-Based Delivery System for Applying Minoxidil to Enhance Hair Growth. ( Chen, HK; Liao, AH; Lin, YC; Lu, YJ; Sytwu, HK; Wang, CH, 2016) |
| "Topical use of minoxidil is only one of the very few treatment options for alopecia." | 3.81 | Anti-PDGF receptor β antibody-conjugated squarticles loaded with minoxidil for alopecia treatment by targeting hair follicles and dermal papilla cells. ( Aljuffali, IA; Chang, SH; Fang, JY; Pan, TL; Sung, CT, 2015) |
| "We describe the case of a young man who developed syncope after using a high strength formulation of topical minoxidil as a hair growth restorer." | 3.81 | A hairy fall: syncope resulting from topical application of minoxidil. ( Dubrey, SW; Edwards, CM; VanGriethuysen, J, 2015) |
| "For therapy, the following medications are used: topical minoxidil solution for AGA of men and women; systemic finasteride 1 mg for men with AGA; topical diphencyprone immunotherapy for alopecia areata; systemic antimycotic agents for tinea capitis; antibiotics such as clindamycin and rifampicin for folliculitis decalvans; systemic corticosteroids and isotretinoin for folliculitis et perifolliculitis capitis abscedens et suffodiens; topical corticosteroids for lichen planus and Kossard's frontal fibrosing alopecia." | 3.81 | [Drug treatment of alopecia]. ( Wolff, H, 2015) |
| "Although minoxidil (MX) is a drug known to stimulate hair growth, the treatment of androgenic alopecia could be improved by delivery strategies that would favor drug accumulation into the hair follicles." | 3.79 | Iontophoresis-targeted, follicular delivery of minoxidil sulfate for the treatment of alopecia. ( Delgado-Charro, MB; Gelfuso, GM; Gratieri, T; Guy, RH; Vianna Lopez, RF, 2013) |
| "Minoxidil is one of the drugs approved for the treatment of androgenetic alopecia." | 3.78 | Central chorioretinopathy associated with topical use of minoxidil 2% for treatment of baldness. ( Cacciamani, A; Colletti, M; Mezzana, P; Pasquini, P; Scarinci, F, 2012) |
| " VPA induced ALP in human dermal papilla cells by up-regulating the Wnt/β-catenin pathway, whereas minoxidil (MNX), a drug commonly used to treat alopecia, did not significantly affect the Wnt/β-catenin pathway." | 3.78 | Valproic acid induces hair regeneration in murine model and activates alkaline phosphatase activity in human dermal papilla cells. ( Choi, KY; Kim, HJ; Kim, HY; Lee, SH; Min, do S; Park, PJ; Park, WS; Shin, SH; Yoon, J; Zahoor, M, 2012) |
| "To analyze the clinical and histological features of permanent alopecia following a sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel regimen for adjuvant breast cancer treatment." | 3.78 | Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. ( Bessis, D; Dereure, O; Frouin, E; Guillot, B; Jacot, W; Kluger, N; Poujol, S; Rigau, V; Romieu, G, 2012) |
| " Topical minoxidil treatment promotes hair growth in men with androgenetic alopecia, suggesting that minoxidil may prolong the actively growing phase of the anagen hair cycle." | 3.77 | Minoxidil activates β-catenin pathway in human dermal papilla cells: a possible explanation for its anagen prolongation effect. ( Kang, BM; Kim, JC; Kim, MK; Kwack, MH; Sung, YK, 2011) |
| "Minoxidil (2,4-diamino-6-(piperidin-1'-yl)pyrimidine N(3)-oxide; CASRN 38304-91-5) is a bioactive molecule with several nitrosatable groups widely used as an antihypertensive and antialopecia agent." | 3.77 | Aromatic C-nitrosation of a bioactive molecule. Nitrosation of minoxidil. ( Arenas-Valgañón, J; Calle, E; Casado, J; González-Jiménez, M, 2011) |
| "Minoxidil has generated new interest in hair-loss research." | 3.76 | Topical minoxidil therapy for hair regrowth. ( Fiedler-Weiss, VC; Rumsfield, JA; West, DP, 1987) |
| "Minoxidil enhances hair growth by prolonging the anagen phase and induces new hair growth in androgenetic alopecia (AGA), whereas retinol significantly improves scalp skin condition and promotes hair growth." | 3.74 | The additive effects of minoxidil and retinol on human hair growth in vitro. ( Chang, IY; Cho, KH; Eun, HC; Kang, YJ; Kim, KH; Kwon, OS; Lee, SH; Pyo, HK; Yoo, HG, 2007) |
| "A 53-year-old woman with clinical evidence of female pattern hair loss and histological evidence of androgenetic alopecia was initially treated with the oral antiandrogen spironolactone 200 mg daily." | 3.74 | Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. ( Hoedemaker, C; Sinclair, R; van Egmond, S, 2007) |
| "Topical 2,4-diamino-6-piperidinopyrimidine-3-oxide (minoxidil) solution has been widely used for the treatment of androgenetic alopecia for over 15 years now and the substance is currently approved for this indication in 2% and 5% formulation." | 3.73 | Positive lymphocyte transformation test in a patient with allergic contact dermatitis of the scalp after short-term use of topical minoxidil solution. ( Allam, JP; Bieber, T; Hagemann, T; Novak, N; Schlütter-Böhmer, B, 2005) |
| "Minoxidil has been widely used to treat androgenetic alopecia, but little is known about its pharmacological activity or about the identity of its target cells in hair follicles." | 3.72 | Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle. ( Cho, KH; Chung, JH; Eun, HC; Han, JH; Kim, KH; Kwon, OS, 2004) |
| "We report a 24-year-old woman with androgenetic alopecia who became sensitized to topical minoxidil following use of an extemporaneous preparation of minoxidil 4% with retinoic acid in a propylene glycol base." | 3.71 | Sensitization to saw palmetto and minoxidil in separate topical extemporaneous treatments for androgenetic alopecia. ( Mallari, RS; Sinclair, RD; Tate, B, 2002) |
| "After more than a decade of use, topical minoxidil solution has proven to be a safe and effective treatment for androgenetic alopecia." | 3.71 | Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. ( Cohen, DE; Friedman, ES; Friedman, PM; Washenik, K, 2002) |
| " Topical minoxidil is a proven therapy for androgenic alopecia and female senile alopecia." | 3.71 | Prevention of temporal alopecia following rhytidectomy: the prophylactic use of minoxidil. A study of 60 patients. ( Eremia, S; Li, CY; Umar, SH, 2002) |
| "As an extension to these observations, we chose to test the efficacy of minoxidil, a drug known to be a hypertrichotic agent, in preventing chemotherapy-induced alopecia in the newborn rat animal model." | 3.69 | Protection against cytosine arabinoside-induced alopecia by minoxidil in a rat animal model. ( Hussein, AM, 1995) |
| "Five women affected by androgenetic alopecia developed severe hypertrichosis of the face and limbs after 2-3 months of treatment with 5% topical minoxidil." | 3.69 | Diffuse hypertrichosis during treatment with 5% topical minoxidil. ( Misciali, C; Peluso, AM; Tosti, A; Vincenzi, C, 1997) |
| "A 2% solution of topical minoxidil was applied on the recipient bald scalp of 16 patients aged 25 to 52 years with Hamilton classifications of androgenetic alopecia from III to VI." | 3.67 | Topical minoxidil used before and after hair transplantation. ( Bouhanna, P, 1989) |
| "Twelve patients, aged 21 to 60 years, with varying Hamilton classifications of androgenetic alopecia (male pattern baldness) were treated with a 3% solution of topical minoxidil." | 3.67 | Use of topical minoxidil as a possible adjunct to hair transplant surgery. A pilot study. ( Kassimir, JJ, 1987) |
| "Topical application of minoxidil has been reported to be effective in the treatment of androgenic alopecia." | 3.67 | Topical minoxidil for male pattern alopecia in two sets of twins. ( Kuruvilla, S; Roenigk, HH, 1987) |
| "A 1% minoxidil lotion was used to treat 670 male patients affected by androgenetic alopecia." | 3.67 | Topical minoxidil useful in 18% of patients with androgenetic alopecia: a study of 430 cases. ( Tosti, A, 1986) |
| "A male volunteer with frontal alopecia was treated simultaneously with 20 mg cyproterone acetate and 5 mg minoxidil topically (daily)." | 3.66 | Reversal of androgenic alopecia by minoxidil: lack of effect of simultaneously administered intermediate doses of cyproterone acetate. ( Vermorken, AJ, 1983) |
| "Cetirizine is an antihistamine that may be effective in hair loss treatment." | 3.30 | Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. ( Abbassi, MM; Bassiouny, EA; El-Samanoudy, SI; Farid, SF; Nada, HR, 2023) |
| " However, the efficacy of PRPF combined with minoxidil treatment remains unknown." | 3.30 | Evaluation of platelet-rich plasma plus basic fibroblast growth factor combined with minoxidil in the treatment of androgenetic alopecia: A randomized controlled trial. ( Chen, J; Dai, D; Guan, Q; Hu, Z; Le, D; Liu, S; Liu, W; Miao, Y; Qu, Q; Wu, S, 2023) |
| "Minoxidil is a common therapeutic option for AGA patients because of its availability." | 3.30 | A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia. ( Asim, M; Ouellette, S; Rao, B; Shah, A; Shah, R; Sharif, S, 2023) |
| "To evaluate the efficacy and safety of 2% minoxidil combined with microneedling in the treatment of female pattern hair loss." | 3.11 | Randomized trial of microneedling combined with 2% minoxidil topical solution for the treatment of female pattern hair loss in a Chinese population. ( Hu, R; Sheng, Y; Wang, W; Yang, Q; Zeng, Y; Zhang, Y; Zhao, J, 2022) |
| " Topical latanoprost added to therapeutic efficacy of topical betamethason and minoxidil in treating patchy AA, suggesting it being beneficial and safe adjuvant therapy and add to efficacy of topical treatments without any adverse effects." | 3.11 | Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial. ( Behrangi, E; Ghassemi, M; Goodarzi, A; Jafari, M; Yazdanian, N, 2022) |
| "(2), Minoxidil (5%) treated group (3), Methylsulfonylmethane (10%) treated group (4), Methylsulfonylmethane plus Minoxidil treated group." | 3.11 | EVALUATION OF THE EFFECT OF TOPICALLY APPLIED METHYLSULFONYLMETHANE AND THEIR COMBINATION WITH MINOXIDIL SOLUTION FOR IMPROVEMENT OF HAIR GROWTH IN MALE MICE. ( Gany, SN; Hadi, NR; Hummadi, AA, 2022) |
| " Second-line options include daily oral minoxidil dosed at 1." | 3.01 | Androgenetic alopecia in transgender and gender diverse populations: A review of therapeutics. ( Dommasch, ED; Gao, JL; Peebles, JK; Streed, CG; Thompson, J, 2023) |
| "Alopecia is the most common and difficult-to-treat hair disorder." | 3.01 | Advances in microneedles research based on promoting hair regrowth. ( Chen, G; Fu, Q; Jia, L; Li, N; Zhou, D; Zhou, Y, 2023) |
| "Pediatric androgenetic alopecia is an underrecognized disorder." | 3.01 | Pediatric androgenetic alopecia: an updated review. ( Gomes, TF; Soares, RO, 2023) |
| "Female pattern hair loss (FPHL) is a hereditary form of hair loss in women and the most common patterned progressive hair loss in female patients with androgenetic alopecia (AGA)." | 3.01 | A systematic review of clinical trials using single or combination therapy of oral or topical finasteride for women in reproductive age and postmenopausal women with hormonal and nonhormonal androgenetic alopecia. ( Behrangi, E; Ghassemi, M; Goodarzi, A; Nikkhah, F; Nobari, NN; Roohaninasab, M; Sadeghzadeh-Bazargan, A, 2023) |
| "Hair loss or alopecia is a common dermatological condition affecting up to 2% of the world population." | 3.01 | Natural Compounds Used for Treating Hair Loss. ( Beley, N; Bjørklund, G; Fedorovska, M; Gasmi, A; Komisarenko, A; Lenchyk, L; Lysiuk, R; Muhammad, A; Mujawdiya, PK; Noor, S; Piscopo, S; Shanaida, M; Strus, O, 2023) |
| "Patterned hair loss is a common type of non-scarring alopecia, characterized by miniaturization of hair follicles." | 3.01 | Combination therapy in female pattern hair loss. ( Deoghare, S; Sadick, NS, 2023) |
| "Alopecia is a treatable benign disease, however, approximately 15-30% of women and 50% of men suffer from alopecia, which greatly affects patient's self-esteem and quality of life." | 3.01 | Dissolving microneedles for alopecia treatment. ( Chen, J; Li, Y; Lv, Y; Miao, X; Xiang, H; Xu, S; Xue, X; Zhang, W, 2023) |
| "Novel medical and procedural options for androgenetic alopecia have arrived." | 3.01 | Medical and procedural treatment of androgenetic alopecia - Where are we? ( Arruda, S; Farah, RS; Fruechte, S; Hordinsky, MK; Ly, NY; Sadick, N, 2023) |
| " No scarring nor serious adverse events were reported in any of the studies." | 3.01 | Efficacy and safety of combinational therapy using topical minoxidil and microneedling for the treatment of androgenetic alopecia: a systematic review and meta-analysis. ( Abdi, P; Anthony, MR; Awad, C; Farkouh, C; Kenny, B; Maibach, HI; Ogunyemi, B, 2023) |
| "Minoxidil 2% and 5% have been FDA approved for treatment of this condition." | 3.01 | Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. ( Alarawi, A; Bessar, H; Ghonemy, S, 2021) |
| "Female androgenetic alopecia is one cause of alopecia in women, although the ideal treatment for this condition remains far from defined." | 3.01 | Intradermal injections with 0.5% minoxidil for the treatment of female androgenetic alopecia: A randomized, placebo-controlled trial. ( Cesetti, MV; Chartuni, JCN; Costa, IMC; Gavioli, CFB; Lemes, AM; Takano, GHS; Uzel, BPC, 2021) |
| "Androgenetic alopecia (AGA) is a hair loss disorder that frequently affects the male population." | 3.01 | Efficacy of Minoxidil Combined With Photobiomodulation for the Treatment of Male Androgenetic Alopecia. A Double-Blind Half-Head Controlled Trial. ( Contin, LA; de Brito, FF; Donati, A; Ferrara, F; Kakizaki, P; Machado, CJ, 2021) |
| "Androgenic alopecia (AGA) is a common hair loss disorder." | 2.94 | A Randomized, Controlled Pilot Trial Comparing Platelet-Rich Plasma to Topical Minoxidil Foam for Treatment of Androgenic Alopecia in Women. ( Arthurs, JR; Bruce, AJ; Bruce, CJ; Desmond, CM; Diehl, NN; Douglass, EJ; Heckman, MG; Pincelli, TP; Shapiro, SA, 2020) |
| "Drug trials for male-pattern hair loss (MPHL) did not investigate hair cycling." | 2.94 | Placebo-controlled dose-effect studies with topical minoxidil 2% or 5% in male-patterned hair loss treated with oral finasteride employing an analytical and exhaustive study protocol. ( Van Neste, D, 2020) |
| "The relationship between female pattern hair loss (FPHL) and androgenic hormones is not well established, but some evidence indicates oral finasteride may be efficacious in FPHL." | 2.90 | Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study. ( Iamsumang, W; Rojhirunsakool, S; Suchonwanit, P, 2019) |
| "Female pattern hair loss (FPHL) is the most common form of hair loss in women." | 2.84 | Low level light-minoxidil 5% combination versus either therapeutic modality alone in management of female patterned hair loss: A randomized controlled study. ( Abdel Hay, RM; Allam, RS; El Naggar, R; Esmat, SM; Gawdat, HI; Hegazy, RA; Moneib, H, 2017) |
| "Bicalutamide has no diuretic effect." | 2.82 | Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know. ( Acioly, P; Barcaui, CB; Carvalho, RM; Donda, ALV; Frattini, SC; Machado, CJ; Melo, DF; Ramos, PM; Santos, LDN, 2022) |
| "Individuals with hair loss experience a substantial mental burden, which potentially hinders their social life." | 2.82 | Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management. ( Fujita, T; Matsudo, K; Ohyama, M, 2022) |
| " Although successful encapsulation of MIN has been observed in these nanocarriers, there is still scarce data regarding their loading in a final dosage form." | 2.82 | Exploiting Recent Trends in the Treatment of Androgenic Alopecia through Topical Nanocarriers of Minoxidil. ( Ahmed, N; Saleem, K; Siddiqui, B; Taqi, MM; Ur Rehman, A, 2022) |
| "Various treatments exist for androgenetic alopecia (AGA); we determined the relative efficacies of non-surgical AGA monotherapies separately for men and women." | 2.82 | Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality. ( Bamimore, MA; Foley, KA; Gupta, AK, 2022) |
| "This study confirmed that minoxidil 5% topical foam is a safe and effective treatment for MPHL." | 2.82 | Efficacy and safety of 5% minoxidil topical foam in male pattern hair loss treatment and patient satisfaction. ( Firooz, A; Halavati, N; Hasanzadeh, H; Nasrollahi, SA; Saberi, M, 2016) |
| "Treatment with minoxidil can induce an increase in hair density and hair thickness,whereas treatment with alfatradiol results in deceleration or stabilization of hair loss." | 2.73 | Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women. ( Blume-Peytavi, U; Ellwanger, U; Garcia Bartels, N; Hoffmann, R; Krisp, A; Kunte, C, 2007) |
| "The scheme of hair loss treatment, by means of preparations affecting pathogenetical mechanisms of diffuse hair loss development is offered." | 2.73 | [Effectiveness of the treatment plan for androgenetic alopecia]. ( Tsiskarishvili, NV; Tsiskarishvili, TsI, 2007) |
| "To highlight treatment options for androgenetic alopecia taking into consideration the efficacy, side effect profiles, practicality of treatment (compliance), and costs to help clinicians offer ethically appropriate treatment regimens to their patients." | 2.72 | Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. ( Ablon, G; Fischer, DL; Gade, A; Han, H; Nestor, MS, 2021) |
| "We identified 7 articles discussing androgenetic alopecia in patients aged younger than 18." | 2.72 | Pediatric androgenetic alopecia: A review. ( Burroway, B; Griggs, J; Tosti, A, 2021) |
| "Oral minoxidil was found to be an effective and well-tolerated treatment alternative for healthy patients having difficulty with topical formulations." | 2.72 | Oral minoxidil treatment for hair loss: A review of efficacy and safety. ( Randolph, M; Tosti, A, 2021) |
| " The main side effect was pain due to PRP injection, which disappeared after ending the treatment and only one article reported more serious side effects." | 2.72 | Systematic review of platelet-rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability. ( Behrangi, E; Ghassemi, M; Goodarzi, A; Najar Nobari, N; Roohaninasab, M; Sadeghzadeh-Bazargan, A, 2021) |
| "Alopecia areata is the third most common cause of dermatology consultations in children but the treatment of paediatric alopecia areata remains challenging." | 2.72 | Therapeutic management in paediatric alopecia areata: A systematic review. ( Kołodziejak, M; Olszewska, M; Rakowska, A; Rudnicka, L; Sikora, M; Stochmal, A; Waśkiel-Burnat, A, 2021) |
| "Oral minoxidil has proven to be a successful and well-tolerated alternative for patients with hair loss, including those with poor adherence to other therapies." | 2.72 | Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose. ( Fabbrocini, G; Ocampo-Candiani, J; Ocampo-Garza, SS; Ruggiero, A; Villani, A, 2021) |
| "Significant androgenetic hair loss occurs in men older than 50 years, and in women it occurs in many who are perimenopausal, menopausal, and postmenopausal." | 2.72 | Combination Approaches for Combatting Hair Loss. ( Rose, PT, 2021) |
| "Thus, in patients with cancer, alopecia can be iatrogenic (chemotherapies, endocrine therapies, targeted therapies, immunotherapies, radiotherapy, surgery) or directly the consequence of the disease itself (malnutrition, scalp metastases, paraneoplastic syndromes)." | 2.72 | [Alopecia and cancers: From basics to clinical practice]. ( Baussard, L; Fiteni, F; Guichard, A; Le Vigouroux, S; Quesada, S, 2021) |
| " The conventional topical dosage forms available in the market falls short in effectively managing alopecia." | 2.72 | Potential of nanoparticulate based delivery systems for effective management of alopecia. ( Handa, M; Kesharwani, P; Mishra, P; Shukla, R; Singh, V; Ujjwal, RR, 2021) |
| "Our understanding of the aetiology of androgenetic alopecia (AGA) has substantially increased in recent years." | 2.70 | Comparative efficacy of various treatment regimens for androgenetic alopecia in men. ( Khandpur, S; Reddy, BS; Suman, M, 2002) |
| "Minoxidil (Loxon) was topically applied twice a day massaging the solution into the scalp over 6-12 months." | 2.70 | [Effect of minoxidil on hair growth in androgenic alopecia in women]. ( Brzezińska-Wcisło, L, 2002) |
| " Cumulative urinary excretion profiles within steady-state, 12-h dosing intervals were well described by straight lines for all treatments, indicating that systemic minoxidil elimination was rate controlled by constant, zero-order percutaneous drug absorption." | 2.67 | Relationship between contact time of applied dose and percutaneous absorption of minoxidil from a topical solution. ( Ferry, JJ; Shepard, JH; Szpunar, GJ, 1990) |
| "Female androgenetic alopecia (FAGA) is a common cause of non-scarring alopecia in women." | 2.66 | Female Androgenetic Alopecia: An Update on Diagnosis and Management. ( Alessandrini, A; Orlando, G; Piraccini, BM; Starace, M, 2020) |
| "Minoxidil is a strong arterial vasodilator, first introduced as an antihypertensive medication." | 2.66 | Topical and oral minoxidil for hair disorders in pediatric patients: What do we know so far? ( de La-Rocque, M; de Oliveira, DS; Lemes, LR; Melo, DF; Ramos, PM; Zompero, C, 2020) |
| "Androgenic alopecia is a common and unpleasant problem that directly influences the self-confidence and individual life quality." | 2.66 | Herbal Medicines For Treatment of Androgenic Alopecia. ( Asnaashari, S; Javadzadeh, Y, 2020) |
| "Forty-seven men with male pattern baldness were treated in a double-blind clinical trial with topical 2% minoxidil or placebo." | 2.66 | Quantitative assessment of 2% topical minoxidil in the treatment of male pattern baldness. ( Cotterill, PC; James, KC; Kingsley, P; Rushton, DH; Unger, WP, 1989) |
| "Nine healthy men with type IVa or Va male pattern baldness completed a 4-month single-blinded controlled pilot study designed to assess the effect of ultraviolet light (UVL) on topical minoxidil-induced hair growth." | 2.66 | Effect of ultraviolet light on topical minoxidil-induced hair growth in advanced male pattern baldness. ( Delong, ER; Murray, JC; Olsen, EA; Pestana, A, 1987) |
| "Ten men with male pattern baldness who had been treated with 2% or 3% minoxidil for at least 4 months were evaluated for any changes in scalp hair growth on and off drug." | 2.66 | Topical minoxidil in male pattern baldness: effects of discontinuation of treatment. ( Olsen, EA; Weiner, MS, 1987) |
| "Sixty-four healthy men with early male pattern baldness completed a 6-month, double-blind, placebo-controlled study in which the efficacy of 2% minoxidil gel and solution formulations was compared." | 2.66 | Comparable efficacy of 2% minoxidil gel and solution formulations in the treatment of male pattern alopecia. ( Piepkorn, MW; Weidner, M, 1988) |
| "Fifty-eight men with Hamilton scale type III vertex or type IV male pattern baldness were studied to determine the dose-response activity of low concentrations of topical minoxidil in promoting hair growth." | 2.66 | Dose-response study of topical minoxidil in male pattern alopecia. ( Jondreau, L; Kassimir, JJ; Reed, ML; Shupack, JL; Thirumoorthy, T, 1987) |
| "Forty-one men with male pattern baldness completed 132 study weeks (2 years 9 months) with topical minoxidil and had follow-up 1-inch target-area vertex scalp hair counts." | 2.66 | Long-term follow-up of men with male pattern baldness treated with topical minoxidil. ( DeLong, ER; Olsen, EA; Weiner, MS, 1987) |
| "Frontotemporal hair loss did not respond to treatment and in fact progressed in severity, despite the twice-daily applications of minoxidil." | 2.66 | Topical minoxidil for androgenetic alopecia: optimizing the chance for success by appropriate patient selection. ( DeVillez, RL, 1987) |
| "Eighty-nine healthy men with male pattern baldness completed a 6-month double-blind, placebo-controlled study of 0." | 2.66 | Dose-response study of topical minoxidil in male pattern baldness. ( DeLong, ER; Olsen, EA; Weiner, MS, 1986) |
| "Minoxidil, 1." | 2.66 | Topical minoxidil therapy in hereditary androgenetic alopecia. ( De Villez, RL, 1985) |
| "No subject had a net hair loss in the target area during the study." | 2.66 | Topical minoxidil in early male pattern baldness. ( Delong, ER; Olsen, EA; Pinnell, SR; Weiner, MS, 1985) |
| "Three of five patients with androgenic alopecia using 5% minoxidil for 12 months noted hair regrowth, ranging from minimally observable hair to an appreciable restoration of larger, pigmented, terminal hair in one patient." | 2.65 | Topical minoxidil for hair regrowth. ( Case, P; Ellis, CN; Headington, JT; Kang, S; Swanson, NA; Vanderveen, EE; Voorhees, JJ, 1984) |
| "Its physiopathology comprises a genetic predisposition affording an exacerbated response of the hair follicles cells to androgens aggravated by scalp inflammation and extrinsic factors." | 2.61 | Physiopathology and current treatments of androgenetic alopecia: Going beyond androgens and anti-androgens. ( Beck, R; da Silva, C; Katzer, T; Leite Junior, A, 2019) |
| "Alopecia is mostly reversible, but permanent damage can occur depending on the type, overall length, and dose of oncological treatment and other factors." | 2.61 | Alopecia and Hair Damage Induced by Oncological Therapy. ( Jedličková, H; Malečková, A; Vojtíšek, R; Vokurka, S, 2019) |
| "(i) The term "female pattern hair loss" should be used, avoiding the previous terms of alopecia or androgenetic alopecia." | 2.61 | Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. ( Azziz, R; Bergfeld, W; Carmina, E; Escobar-Morreale, HF; Futterweit, W; Huddleston, H; Lobo, R; Olsen, E, 2019) |
| "minoxidil 5% was high; minoxidil 5% vs." | 2.58 | Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis. ( Dotzert, MS; Gupta, AK; Mays, RR; Piguet, V; Shear, NH; Versteeg, SG, 2018) |
| " INTRODUCTION: Hair loss is a common complaint seen in dermatology clinics." | 2.55 | Hair Loss Myths. ( DiMarco, G; McMichael, A, 2017) |
| "Female pattern hair loss (FPHL), or androgenic alopecia, is the most common type of hair loss affecting women." | 2.53 | Interventions for female pattern hair loss. ( Fedorowicz, Z; Schoones, J; van Zuuren, EJ, 2016) |
| "The use of the medical term androgenetic alopecia reflects current knowledge about the important role of androgens and genetic factors in its etiology." | 2.53 | Multi-therapies in androgenetic alopecia: review and clinical experiences. ( Anzalone, A; Carlesimo, M; Caro, G; Fortuna, MC; Garelli, V; Pranteda, G; Rossi, A, 2016) |
| "Excessive daily hair loss (effluvium) may be physiological, as in the postpartum state, or pathological, due for example to thyroid disturbances, drug effects, iron deficiency, or syphilis." | 2.53 | The Diagnosis and Treatment of Hair and Scalp Diseases. ( Blume-Peytavi, U; Fischer, TW; Wolff, H, 2016) |
| "Finasteride and minoxidil for male androgenetic alopecia and minoxidil for female androgenetic alopecia still are the therapeutic options with the highest level evidence." | 2.53 | Androgenetic Alopecia: An Update of Treatment Options. ( Blanco, A; Kelly, Y; Tosti, A, 2016) |
| "Common types of nonscarring hair loss, including female pattern hair loss and telogen effluvium, may be diagnosed and managed by the obstetrician/gynecologist." | 2.52 | Hair loss in women. ( Bechtel, MA; Harfmann, KL, 2015) |
| "Male baldness is the most common diagnosis in men that present with hair loss." | 2.52 | Androgenetic, diffuse and senescent alopecia in men: practical evaluation and management. ( Torres, F, 2015) |
| "Female pattern hair loss, or female pattern androgenetic alopecia, is a nonscarring alopecia with a multi-factorial etiology that mostly affects postmenopausal women and is characterized by a reduction in hair density over the crown and frontal scalp." | 2.52 | Female pattern hair loss. ( Ioannides, D; Lazaridou, E, 2015) |
| "To fully understand hair loss during childhood, a basic comprehension of normal hair growth is necessary." | 2.52 | Hair loss in children. ( Alves, R; Grimalt, R, 2015) |
| "It is characterized by progressive hair loss, especially of scalp hair, and has distinctive patterns of loss in women versus men, but in both genders the central scalp is most severely affected." | 2.50 | Androgenetic alopecia: an evidence-based treatment update. ( Bergfeld, WF; Varothai, S, 2014) |
| "Some degree of hair loss is accepted as a normal part of the aging process, in line with the observation that more than 50% of men will develop androgenetic alopecia by the age of 50 years." | 2.49 | Hair restoration approaches for early onset male androgenetic alopecia. ( Basra, MK; Bhatti, HA; Patel, GK, 2013) |
| "Because androgenetic alopecia is progressive in nature, stabilization of the process using medical therapy is an important adjunct to any surgical hair-restoration plan." | 2.49 | Nonsurgical therapy for hair loss. ( Nusbaum, AG; Nusbaum, BP; Rose, PT, 2013) |
| "Female pattern hair loss (FPHL) is the most common cause of alopecia in women." | 2.49 | Hair: what is new in diagnosis and management? Female pattern hair loss update: diagnosis and treatment. ( Atanaskova Mesinkovska, N; Bergfeld, WF, 2013) |
| "The exact pathogenesis of androgenetic alopecia is not well understood." | 2.49 | Pattern hair loss in men: diagnosis and medical treatment. ( Banka, N; Bunagan, MJ; Shapiro, J, 2013) |
| "Minoxidil is a potassium channel opener, causing hyperpolarization of cell membranes and it is also a vasodilator, it is speculated that, by widening blood vessels and opening potassium channels, it allows more oxygen, blood and nutrients to the follicle." | 2.48 | Minoxidil use in dermatology, side effects and recent patents. ( Calvieri, S; Cantisani, C; Iorio, A; Melis, L; Rossi, A; Scali, E, 2012) |
| "Female pattern hair loss, or androgenic alopecia, is the most common type of hair loss affecting women." | 2.48 | Interventions for female pattern hair loss. ( Andriolo, RB; Carter, B; Fedorowicz, Z; Schoones, J; van Zuuren, EJ, 2012) |
| "Female pattern hair loss (FPHL) or androgenic alopecia is the most common type of hair loss affecting women with reduced hair density and can have a serious psychological impact." | 2.48 | Evidence-based treatments for female pattern hair loss: a summary of a Cochrane systematic review. ( Carter, B; Fedorowicz, Z; van Zuuren, EJ, 2012) |
| "In men it produces male pattern hair loss with bitemporal recession and vertex baldness." | 2.47 | Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. ( Dawson, TL; Patel, M; Perez, A; Rufaut, NW; Sinclair, R; Yazdabadi, A; Yip, L, 2011) |
| "Traditional methods of treating hair loss have included minoxidil, finasteride, and surgical transplantation." | 2.46 | Types of hair loss and treatment options, including the novel low-level light therapy and its proposed mechanism. ( Ghanaat, M, 2010) |
| "Fortunately, chemotherapy-induced hair loss is mostly reversible, and appropriate hair and scalp care and temporarily wearing a wig may be the most effective coping strategy." | 2.46 | Chemotherapy-induced alopecia. ( Trüeb, RM, 2010) |
| "Dutasteride has been shown to be more effective than finasteride in the treatment of AGA but is not yet a recommended therapy." | 2.45 | Androgens and hair loss. ( Alsantali, A; Shapiro, J, 2009) |
| "Focal hair loss can be further broken down into scarring and nonscarring." | 2.45 | Diagnosing and treating hair loss. ( Mounsey, AL; Reed, SW, 2009) |
| "Flutamide was found to be more effective than spironolactone or cyproterone in one study." | 2.44 | A review of hormonal therapy for female pattern (androgenic) alopecia. ( Scheinfeld, N, 2008) |
| "Male and female pattern hair loss affects a large percentage of the population, and patients frequently present for treatment of this to their dermatologist." | 2.44 | Medical treatments for male and female pattern hair loss. ( Avram, MR; Rogers, NE, 2008) |
| "Female pattern hair loss is the commonest cause of hair loss in women and prevalence increases with advancing age." | 2.44 | Female pattern hair loss: current treatment concepts. ( Dinh, QQ; Sinclair, R, 2007) |
| "Frontal scalp DPCs from androgenetic alopecia (AGA) are the target cells of androgen action." | 2.44 | [Hair follicle regeneration]. ( Itami, S, 2008) |
| "Androgenetic alopecia In men, or male pattern baldness, is recognized increasingly as a physically and psychologically harmful medical condition that can be managed effectively by generalist clinicians." | 2.43 | Psychological effect, pathophysiology, and management of androgenetic alopecia in men. ( Haber, R; Parsley, WM; Stenn, K; Stough, D; Vogel, JE; Washenik, K; Whiting, DA, 2005) |
| "In advanced cases, men may develop baldness with remaining hair exclusively in the temporal and occipital regions." | 2.42 | [Androgenetic alopecia. Current aspects of a common phenotype]. ( Hanneken, S; Kruse, R; Nöthen, MM; Ritzmann, S, 2003) |
| "Minoxidil may also cause prolongation of anagen and increases hair follicle size." | 2.42 | Minoxidil: mechanisms of action on hair growth. ( Messenger, AG; Rundegren, J, 2004) |
| "Hair loss is a common complaint in the outpatient setting." | 2.42 | Hair loss remedies--separating fact from fiction. ( Bandaranayake, I; Mirmirani, P, 2004) |
| "Pharmacologic management of pattern hair loss is an active area of research, and clinicians should be aware of new data and treatment modalities." | 2.42 | Pharmacologic management of pattern hair loss. ( Haber, RS, 2004) |
| "Female pattern hair loss is a common condition characterized by a diffuse reduction in hair density over the crown and frontal scalp with retention of the frontal hairline." | 2.41 | Female pattern hair loss. ( Birch, MP; Lalla, SC; Messenger, AG, 2002) |
| "Knowledge of the pathogenesis of androgenetic alopecia has increased markedly in recent years." | 2.41 | Androgenetic alopecia: pathogenesis and potential for therapy. ( Ellis, JA; Harrap, SB; Sinclair, R, 2002) |
| "Male pattern baldness, or androgenetic alopecia (AGA) in men, occurs with varying severity and age of onset." | 2.41 | Male pattern baldness. ( Chamberlain, M; Hogan, DJ, 2000) |
| "Androgenetic alopecia is caused by the heightened sensitivity of scalp follicles to dihydro- testosterone whereas alopecia areata is induced by an autoimmune reaction." | 2.41 | Treatments for androgenetic alopecia and alopecia areata: current options and future prospects. ( Meidan, VM; Touitou, E, 2001) |
| "Common baldness or androgenetic alopecia is a normal physiological process of hair loss in genetically predisposed individuals." | 2.40 | Understanding and managing common baldness. ( Sinclair, RD; Tran, D, 1999) |
| " Oral finasteride at the dosage of 1 mg/day produced clinical improvement in up to 66% of patients treated for 2 years." | 2.40 | Management of androgenetic alopecia. ( Camacho-Martinez, F; Dawber, R; Tosti, A, 1999) |
| "More importantly, androgenetic alopecia is typically experienced as a moderately stressful condition that diminishes body image satisfaction." | 2.40 | The psychosocial consequences of androgenetic alopecia: a review of the research literature. ( Cash, TF, 1999) |
| "The pattern of hair loss in women differs from that of classical male pattern alopecia, being more diffuse and with retention of the frontal hair line in most cases." | 2.39 | Female androgenetic alopecia: an update. ( Callan, AW; Montalto, J, 1995) |
| "Minoxidil has been studied extensively and has been shown to improve balding at the vertex of the scalp, particularly in young men who have only begun to lose hair." | 2.38 | Hair loss. What causes it and what can be done about it. ( Burke, KE, 1989) |
| "Male pattern hair loss (androgenetic alopecia) is a common problem." | 2.37 | Topical minoxidil in the treatment of male pattern alopecia. ( Baden, HP; Kvedar, JC, 1987) |
| "Male androgenetic alopecia is a common condition and represents a major concern for patients who experience this condition." | 1.91 | What's New in Therapy for Male Androgenetic Alopecia? ( Domínguez-Santas, M; Grimalt, R; Saceda-Corralo, D; Vañó-Galván, S, 2023) |
| "Minoxidil was radiolabeled with technetium (99mTc) with an efficiency of 99." | 1.91 | In Vitro and In Vivo Scalp Retention and Penetration of 99mTc-Minoxidil Solution. ( Arora, G; Chandra, N; Jain, GK; Kesharwani, P; Mishra, A, 2023) |
| " The few and widely used monotherapies approved by the US Food and Drug Administration, such as minoxidil or finasteride, are not efficacious in all people and cause adverse events that prevent patient compliance." | 1.91 | Real-World, Open-Label Study of the Efficacy and Safety of a Novel Serum in Androgenetic Alopecia. ( Abidi, Z; Arruda, S; Rapaport, J; Sadgrove, NJ; Sadick, N; Swearingen, A, 2023) |
| "The most common causes of hair loss are androgenetic alopecia (AGA) and telogen effluvium (TE)." | 1.91 | Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic alopecia. ( Bruni, F; Caro, G; Cedirian, S; Fortuna, M; Piraccini, BM; Quadrelli, F; Rossi, A; Starace, M, 2023) |
| "Many people suffer from hair loss and abnormal skin pigmentation, highlighting the need for simple assays to support drug discovery research." | 1.91 | Sensitive Quantitative In Vivo Assay for Evaluating the Effects of Biomolecules on Hair Growth and Coloring Using Direct Microinjections into Mouse Whisker Follicles. ( Gao, L; Liao, XH; Song, H; Tan, XY; Wang, YG; Yuan, VL; Zhang, HL, 2023) |
| "The most prevalent kind of hair loss is androgenic alopecia (AGA), which is characterized by hair follicle miniaturization and microenvironment dysfunction." | 1.91 | Co-delivery of minoxidil and tocopherol acetate ethosomes to reshape the hair Follicular Microenvironment and promote hair regeneration in androgenetic alopecia. ( Guan, Y; Liu, M; Qiang, W; Ruan, R; Sun, H; Yan, A; Yu, Q; Zhu, H; Zhu, X, 2023) |
| "Alopecia is a common cutaneous adverse event reported with CK4/6i therapy." | 1.91 | Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients. ( Cathcart-Rake, E; Cherian, M; Dulmage, B; Gatti-Mays, M; Loprinzi, CL; Lustberg, M; Minta, A; Park, C; Ramaswamy, B; Rose, L; Ruddy, KJ; Sardesai, S; Stover, D; Sudheendra, P; Trovato, S; Wesolowski, R; Williams, N, 2023) |
| "Alopecia is a condition associated with different etiologies, ranging from hormonal changes to chemotherapy, that affects over 80 million people in the USA." | 1.72 | Nanostructured lipid carriers loaded with an association of minoxidil and latanoprost for targeted topical therapy of alopecia. ( Alencar-Silva, T; Carvalho, JL; Cunha-Filho, M; Gelfuso, GM; Gratieri, T; Oliveira, PM; Pires, FQ, 2022) |
| " Minoxidil (MXD) is commonly used topically to treat alopecia, but its low absorption rate limits widespread use." | 1.72 | Minoxidil-loaded hyaluronic acid dissolving microneedles to alleviate hair loss in an alopecia animal model. ( An, BS; Jeong, JS; Kim, DS; Kim, MJ; Kim, SY; Lee, S; Seong, KY; Yang, SY, 2022) |
| " In animal tests, compared with topical administration of minoxidil, the drug-free microneedle patches can more significantly promote hair regeneration within 7 days with lower dosing frequency." | 1.72 | A Drug-Free, Hair Follicle Cycling Regulatable, Separable, Antibacterial Microneedle Patch for Hair Regeneration Therapy. ( Chen, X; Kong, M; Li, H; Qin, D; Qiu, K; Shi, Y; Yu, M; Zhang, W; Zhao, J, 2022) |
| "Both spironolactone as a 5% topical solution and minoxidil as a 5% topical solution might be used safely in a twice-daily dosage to treat AGA in both genders." | 1.72 | Dermoscopic evaluation of the efficacy of combination of topical spironolactone 5% and minoxidil 5% solutions in the treatment of androgenetic alopecia: A cross sectional-comparative study. ( Abdel-Dayem, HA; Ammar, AM; Elsaie, ML; Elshahid, AR; Mohamed, AA, 2022) |
| "Hair loss, specifically androgenetic alopecia (AGA), is a common outpatient dermatology complaint." | 1.72 | A Survey of Patient Attitudes Towards Topical Minoxidil in the Treatment of Hair Loss. ( Friedman, A; Gonzalez-Lopez, A; Murphy, E; Nelson, K; Nussbaum, D; Qureshi, A; Schwartz, J, 2022) |
| "Androgenic alopecia is a genetically determined and leads to a progressive hair loss of the vertex, affecting both men and women." | 1.62 | [A new treatment for androgenetic alopecia : platelet-rich plasma injections]. ( Castronovo, C; Kaux, JF; Moreau, T; Nikkels, AF; Paquet, P, 2021) |
| "The major concern regarding the use of low-dose oral minoxidil (LDOM) for the treatment of hair loss is the potential risk of systemic adverse effects." | 1.62 | Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. ( Bhoyrul, B; Hermosa-Gelbard, A; Jaén-Olasolo, P; Jerjen, R; Jimenez-Cauhe, J; John, JM; Koh, WL; Lo-Sicco, K; Moreno-Arrones, ÓM; Piraccini, BM; Pirmez, R; Poa, JE; Rodrigues-Barata, R; Rudnicka, L; Saceda-Corralo, D; Salas-Callo, CI; Shapiro, J; Sinclair, R; Starace, M; Tosti, A; Trindade de Carvalho, L; Vañó-Galván, S; Vincenzi, C; Waskiel-Burnat, A; Yin, L; Zamorano, JL, 2021) |
| "The clinical and trichoscopic features, scalp radiation dose-response relationship, and response to topical minoxidil were assessed using standardized clinical photographs of the scalp, trichoscopic images, and radiotherapy treatment plans." | 1.56 | Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer. ( Beal, K; Disa, JJ; Dusza, SW; Freites-Martinez, A; Freret, ME; Friedman, DN; Kukoyi, O; Lacouture, ME; Mechalakos, JG; Phillips, GS; Tinkle, CL; Trelles, S; Unger, RH; Wexler, LH; Wolden, SL, 2020) |
| "Male androgenetic alopecia (AGA) affects up to 60% of men by the age of 50." | 1.51 | Controversies in the treatment of androgenetic alopecia: The history of finasteride. ( Andy, G; Aseem, S; John, M; Maja, K; Michael, K; Mirna, S; Rachita, D; Zeljana, B, 2019) |
| "Diffuse alopecia was predominant in patients with pCIA compared with patients with EIAC (31 of 75 [41%] vs 23 of 92 [25%]; P = ." | 1.51 | Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia. ( Chan, D; Cho, J; Cigler, T; Fabbrocini, G; Freites-Martinez, A; Gajria, D; Goldfarb, S; Lacouture, ME; Modi, S; Norton, L; Paus, R; Shapiro, J; Sibaud, V; Tosti, A, 2019) |
| "Androgenetic alopecia is the most common hair loss disorder, affecting both men and women." | 1.48 | Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. ( Blume-Peytavi, U; Blumeyer, A; Del Marmol, V; Dobos, G; Finner, A; Kanti, V; Messenger, A; Nast, A; Piraccini, BM; Reygagne, P; Tosti, A; Trakatelli, M, 2018) |
| "Mean hair loss severity at baseline was Sinclair 2." | 1.48 | Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. ( Sinclair, RD, 2018) |
| "Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty." | 1.48 | Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version. ( Amoh, Y; Inui, S; Itami, S; Ito, T; Kono, T; Kurata, S; Manabe, M; Nakamura, M; Narusawa, H; Ohyama, M; Osada, SI; Saito, N; Sato, A; Shimomura, Y; Tsuboi, R; Ueki, R; Yamazaki, M, 2018) |
| "Female pattern hair loss (FPHL) is a commonly encountered clinical presentation in primary care." | 1.48 | Female pattern hair loss. ( Chan, L; Cook, DK, 2018) |
| "Overall, 40." | 1.48 | Characterization of follicular minoxidil sulfotransferase activity in a cohort of pattern hair loss patients from the Indian Subcontinent. ( Chitalia, J; Dhurat, R; Goren, A; Kovacevic, M; Lotti, T; McCoy, J; Naccarato, T; Situm, M, 2018) |
| "Minoxidil has been approved for the treatment of hair loss, however its mechanism of action is still not fully clarified." | 1.46 | An analysis of gene expression data involving examination of signaling pathways activation reveals new insights into the mechanism of action of minoxidil topical foam in men with androgenetic alopecia. ( Aliper, A; Consolo, M; Cooper, KD; McCormick, TS; Mirmirani, P; Ozerov, IV; Pappas, A; Schastnaya, J; Stamatas, GN; Wu, J; Zhavoronkov, A, 2017) |
| "Tofacitinib-treated mice exhibited more hair regrowth than either minoxidil-treated or control mice did between day 7 and 21 (P < 0." | 1.46 | Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction. ( Deenonpoe, R; Meephansan, J; Ponnikorn, S; Suchonwanit, P; Thummakriengkrai, J; Yingmema, W, 2017) |
| "Treatment with dutasteride 0." | 1.46 | Familial frontal fibrosing alopecia treated with dutasteride, minoxidil and artificial hair transplantation. ( Cranwell, WC; Sinclair, R, 2017) |
| "Traction alopecia is characterized by localized hair loss related to persistent excessive traction." | 1.43 | Bitemporal hair loss related to traction alopecia. ( Muñoz Moreno-Arrones, O; Vañó-Galván, S, 2016) |
| " The safety and efficacy of a twice-daily regimen of 2% minoxidil solution used in combination with the botanical hair solution for 12 weeks in 54 subjects was evaluated in a multicenter, single-arm, open-label study." | 1.43 | Efficacy and Safety of Minoxidil 2% Solution in Combination With a Botanical Hair Solution in Women With Female Pattern Hair Loss/Androgenic Alopecia. ( McMichael, A; Meckfessel, MH; Pham, H; von Grote, E, 2016) |
| " The safety and efficacy of a twice-daily regimen of 5% minoxidil foam used in combination with a novel botanical hair solution was evaluated in a 12-week, multicenter, single-arm, open label study in 56 subjects with mild to moderate AGA." | 1.43 | Efficacy and Safety of Minoxidil 5% Foam in Combination With a Botanical Hair Solution in Men With Androgenic Alopecia. ( Keaney, TC; Meckfessel, MH; Pham, H; von Grote, E, 2016) |
| " However, little is known about the differences in adverse effects between these two drugs." | 1.43 | Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. ( Li, Q; Wu, M; Yu, Q, 2016) |
| "Female pattern hair loss is a common but difficult to manage condition." | 1.37 | Treatment of female pattern hair loss with the androgen receptor antagonist flutamide. ( Sinclair, R; Yazdabadi, A, 2011) |
| "Adolescent androgenic alopecia is pattern hair loss occurring in boys and girls younger than 18 years, whereas early-onset androgenic alopecia refers to pattern hair loss before 35 years of age." | 1.37 | Adolescent androgenic alopecia. ( McDonough, PH; Schwartz, RA, 2011) |
| "While androgenetic alopecia (AGA) is the most common form of hair loss in adults, little is known about its prevalence, clinical features and response to treatments in the paediatric population." | 1.36 | Androgenetic alopecia in the paediatric population: a retrospective review of 57 patients. ( Cantatore-Francis, J; Gonzalez, ME; Orlow, SJ, 2010) |
| "Spironolactone is a synthetic steroid structurally related to aldosterone." | 1.36 | Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. ( Rathnayake, D; Sinclair, R, 2010) |
| "Tretinoin is a mitogen by itself and also enhances the absorption of minoxidil which acts by enlarging the miniaturized hair follicles." | 1.35 | Alopecia in congenital hidrotic ectodermal dysplasia responding to treatment with a combination of topical minoxidil and tretinoin. ( Dhurat, RS; Jerajani, HR; Melkote, S; Palav, A, 2009) |
| "Three of these women were premenopausal." | 1.33 | Frontal fibrosing alopecia: a survey in 16 patients. ( Camacho Martínez, F; Moreno-Ramírez, D, 2005) |
| "Regression of male androgenetic alopecia from Hamilton type V to type III can be achieved by combining drugs with hair grafts." | 1.32 | Androgenetic alopecia: combining medical and surgical treatments. ( Bouhanna, P, 2003) |
| "Patients seeking advice for hair loss are not necessarily bald." | 1.31 | [TrichoScan. A new instrument for digital hair analysis]. ( Hoffmann, R, 2002) |
| "A 45-year-old Japanese man with paroxysmal atrial fibrillation (AF) developed acute anteroseptal myocardial infarction (MI)." | 1.31 | A case of acute myocardial infarction associated with topical use of minoxidil (RiUP) for treatment of baldness. ( Fujiwara, C; Morikaw, S; Ohno, R; Satoh, H; Terada, H; Uehara, A, 2000) |
| "Respondents rated their hair loss on a 5-point, textual scale that ranged from 'no hair loss' to 'bald areas'." | 1.31 | [Status of scalp hair and therapy of alopecia in men in Switzerland]. ( de Viragh, PA; Trüeb, RM, 2001) |
| "Especially for young men progressive hair loss can be distressing." | 1.31 | [Androgenetic alopecia in the man]. ( Bader, U; Trüeb, RM, 2002) |
| "Diffuse hair loss in women was formerly classified as an entity of its own." | 1.31 | [Diffuse hair loss in women]. ( Trüeb, RM, 2002) |
| "Although androgenetic alopecia (common baldness) is the most frequently occurring type of hair loss, hair loss can result from a variety of local and systemic conditions." | 1.29 | Alopecia: diagnosis and management. ( Nielson, TA; Reichel, M, 1995) |
| "Male pattern baldness is a common affliction affecting up to half the adult male population." | 1.29 | Male pattern baldness. ( Duplechain, G; White, JA, 1994) |
| "Both minoxidil-SEPA treatments produced significantly greater cumulative hair weight over the entire 16-week study compared to either of the Rogaine TS treatments." | 1.29 | The penetration enhancer SEPA augments stimulation of scalp hair growth by topical minoxidil in the balding stumptail macaque. ( Brunden, MN; Diani, AR; Shull, KL; Zaya, MJ, 1995) |
| "Minoxidil is a potent vasodilator useful in treating severe hypertension." | 1.28 | Topical treatment with minoxidil 2% and smoking intolerance. ( Ingber, A; Trattner, A, 1992) |
| "One patient had no hair loss in either the treatment or control area." | 1.28 | The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies. ( Baden, H; Frederickson, H; Gajewski, W; Goldstein, A; Goodman, A; Granai, CO, 1991) |
| " However, the safety of no systemic adverse effect and the potential of inhibiting progressive shedding of hair were valuable as a topical drug." | 1.28 | Safety and efficacy of 2% topical minoxidil in the management of male pattern baldness in Chinese. ( Chan, HL; Chen, MJ; Chen, SY; Kuan, YZ; Wang, CN, 1990) |
| "The data demonstrate that hair loss in the AGA mouse is androgen dependent and that this mutant strain can serve as a suitable model for the screening of compounds, such as antiandrogens and vasodilators, which may influence the balding process." | 1.28 | Animal models of androgen-dependent disorders of the pilosebaceous apparatus. 1. The androchronogenetic alopecia (AGA) mouse as a model for male-pattern baldness. ( Malloy, V; Matias, JR; Orentreich, N, 1989) |
| "The cause of male pattern baldness remains unknown." | 1.27 | Unravelling the pathophysiology of male pattern baldness. ( Herring, BD, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 103 (16.02) | 18.7374 |
| 1990's | 80 (12.44) | 18.2507 |
| 2000's | 97 (15.09) | 29.6817 |
| 2010's | 147 (22.86) | 24.3611 |
| 2020's | 216 (33.59) | 2.80 |
| Authors | Studies |
|---|---|
| Li, JJ | 1 |
| Mitchell, LH | 1 |
| Dow, RL | 1 |
| Vahabi-Amlashi, S | 1 |
| Layegh, P | 1 |
| Kiafar, B | 1 |
| Hoseininezhad, M | 1 |
| Abbaspour, M | 1 |
| Khaniki, SH | 1 |
| Forouzanfar, M | 1 |
| Sabeti, V | 1 |
| Yin, L | 2 |
| Svigos, K | 1 |
| Gutierrez, D | 1 |
| Peterson, E | 1 |
| Lo Sicco, K | 2 |
| Shapiro, J | 18 |
| Trüeb, RM | 10 |
| Caballero-Uribe, N | 1 |
| Gupta, AK | 8 |
| Quinlan, EM | 1 |
| Venkataraman, M | 2 |
| Bamimore, MA | 4 |
| Moussa, A | 3 |
| Kazmi, A | 2 |
| Bokhari, L | 4 |
| Sinclair, RD | 13 |
| Nestor, MS | 1 |
| Ablon, G | 1 |
| Gade, A | 1 |
| Han, H | 1 |
| Fischer, DL | 1 |
| Gao, JL | 1 |
| Streed, CG | 1 |
| Thompson, J | 1 |
| Dommasch, ED | 1 |
| Peebles, JK | 1 |
| Melo, DF | 4 |
| Saceda-Corralo, D | 13 |
| Tosti, A | 20 |
| Weffort, F | 1 |
| Carla Jorge, M | 1 |
| de Barros, CC | 1 |
| de Melo Carvalho, R | 1 |
| Starace, M | 8 |
| Gilhar, A | 2 |
| Keren, A | 2 |
| Ullmann, Y | 1 |
| Wu, J | 2 |
| Paus, R | 4 |
| Hassan, GFR | 1 |
| Sadoma, MET | 1 |
| Elbatsh, MM | 1 |
| Ibrahim, ZA | 1 |
| Elsebay, SAG | 1 |
| Nada, HF | 1 |
| Sultan, NSS | 1 |
| El-Waseef, DAEA | 1 |
| Carvalho, RM | 1 |
| Santos, LDN | 1 |
| Ramos, PM | 8 |
| Machado, CJ | 2 |
| Acioly, P | 1 |
| Frattini, SC | 1 |
| Barcaui, CB | 1 |
| Donda, ALV | 1 |
| Liu, C | 1 |
| Zhao, H | 2 |
| Zhang, Y | 4 |
| Wu, W | 2 |
| Subedi, L | 1 |
| Pandey, P | 1 |
| Shim, JH | 1 |
| Kim, KT | 1 |
| Cho, SS | 1 |
| Koo, KT | 1 |
| Kim, BJ | 3 |
| Park, JW | 1 |
| Talukder, M | 5 |
| Korbi, M | 1 |
| Said El Mabrouk, R | 1 |
| Abdelaali, M | 1 |
| Youssef, M | 1 |
| Belhadjali, H | 1 |
| Zili, J | 1 |
| Nascimento E Silva, M | 1 |
| Silva, MR | 1 |
| Nascimento E Silva, R | 1 |
| Barbosa Raposo, NR | 1 |
| Huang, KP | 1 |
| Senna, MM | 2 |
| Oliveira, PM | 1 |
| Alencar-Silva, T | 1 |
| Pires, FQ | 1 |
| Cunha-Filho, M | 1 |
| Gratieri, T | 2 |
| Carvalho, JL | 1 |
| Gelfuso, GM | 2 |
| Faghihi, G | 3 |
| Iraji, F | 4 |
| Siadat, AH | 1 |
| Saber, M | 1 |
| Jelvan, M | 1 |
| Hoseyni, MS | 1 |
| Kim, MJ | 2 |
| Seong, KY | 1 |
| Kim, DS | 1 |
| Jeong, JS | 1 |
| Kim, SY | 1 |
| Lee, S | 1 |
| Yang, SY | 1 |
| An, BS | 1 |
| Feaster, B | 1 |
| Onamusi, T | 1 |
| Cooley, JE | 1 |
| McMichael, AJ | 2 |
| Villarreal-Villarreal, CD | 1 |
| Boland-Rodriguez, E | 1 |
| Rodríguez-León, S | 1 |
| Le Voti, F | 1 |
| Vano-Galvan, S | 19 |
| Luu, NC | 1 |
| Rezende, HD | 1 |
| Mao, Y | 1 |
| Xu, Z | 1 |
| Song, J | 1 |
| Xie, Y | 1 |
| Mei, X | 1 |
| Shi, W | 1 |
| Feryel, A | 1 |
| Mouna, K | 1 |
| Nesrine, BS | 1 |
| Hichem, B | 1 |
| Jameleddine, Z | 1 |
| de Nicolas-Ruanes, B | 1 |
| Moreno-Arrones, OM | 8 |
| Hermosa-Gelbard, A | 6 |
| Rodrigues-Barata, R | 6 |
| Gil-Redondo, R | 2 |
| Garcia-Mouronte, E | 1 |
| Dou, J | 1 |
| Zhang, Z | 1 |
| Xu, X | 1 |
| Zhang, X | 2 |
| Mir-Bonafé, JF | 1 |
| Mir-Bonafé, M | 1 |
| Rozas-Muñoz, E | 1 |
| Mir-Bonafé, JM | 1 |
| Nilforoushzadeh, MA | 2 |
| Heidari-Kharaji, M | 2 |
| Torkamaniha, E | 1 |
| Sadeghi, S | 1 |
| Seirafianpour, F | 1 |
| Yekaninejad, MS | 1 |
| Behrangi, E | 4 |
| Roohaninasab, M | 3 |
| Amini, Z | 1 |
| Goodarzi, A | 4 |
| Sanabria, BD | 1 |
| Palmegiani, E | 1 |
| Seron, AF | 1 |
| Perdomo, YC | 1 |
| Miot, HA | 5 |
| Müller Ramos, P | 3 |
| Ohyama, M | 2 |
| Matsudo, K | 1 |
| Fujita, T | 1 |
| Klein, EJ | 1 |
| Karim, M | 1 |
| Sicco, KL | 1 |
| Sánchez-Meza, E | 1 |
| Ocampo-Candiani, J | 3 |
| Gómez-Flores, M | 1 |
| Herz-Ruelas, ME | 1 |
| Ocampo-Garza, J | 1 |
| Orizaga-Y-Quiroga, TL | 1 |
| Martínez-Moreno, A | 1 |
| Ocampo-Garza, SS | 4 |
| Tian, K | 1 |
| Gao, S | 1 |
| Jia, Z | 1 |
| Xu, W | 1 |
| Li, K | 2 |
| Wu, L | 1 |
| Vastarella, M | 3 |
| Martora, F | 1 |
| Ocampo-Garza, S | 1 |
| Patri, A | 2 |
| Battista, T | 1 |
| Nappa, P | 2 |
| Fabbrocini, G | 6 |
| Cantelli, M | 3 |
| Toma, DM | 1 |
| Atallah, RB | 1 |
| Eldahshan, RM | 1 |
| John, JM | 3 |
| Sinclair, R | 23 |
| Shi, Y | 1 |
| Zhao, J | 2 |
| Li, H | 1 |
| Yu, M | 1 |
| Zhang, W | 3 |
| Qin, D | 1 |
| Qiu, K | 1 |
| Chen, X | 2 |
| Kong, M | 1 |
| Jia, L | 2 |
| Xiong, J | 1 |
| Guo, R | 1 |
| Li, Y | 5 |
| Jiang, H | 1 |
| Singh, S | 1 |
| Patil, A | 1 |
| Kianfar, N | 1 |
| Waśkiel-Burnat, A | 3 |
| Rudnicka, L | 3 |
| Goldust, M | 5 |
| Williams, G | 1 |
| Sand, J | 2 |
| Walen, S | 2 |
| Yuan, A | 3 |
| Gu, Y | 3 |
| Bian, Q | 3 |
| Wang, R | 3 |
| Xu, Y | 2 |
| Ma, X | 3 |
| Zhou, Y | 3 |
| Gao, J | 3 |
| Jimenez-Cauhe, J | 8 |
| Pindado-Ortega, C | 2 |
| de Dios Berna-Rico, E | 1 |
| Ortega-Quijano, D | 5 |
| Fernandez-Nieto, D | 6 |
| Gallo, G | 1 |
| Burzi, L | 1 |
| Torrelli, F | 1 |
| Quaglino, P | 1 |
| Ribero, S | 1 |
| Xiang, H | 2 |
| Yang, M | 1 |
| Abdurrahman, S | 1 |
| Ruslin, R | 1 |
| Hasanah, AN | 1 |
| Mustarichie, R | 1 |
| Ifaya, M | 1 |
| Ammar, AM | 1 |
| Elshahid, AR | 1 |
| Abdel-Dayem, HA | 1 |
| Mohamed, AA | 1 |
| Elsaie, ML | 3 |
| Modha, JD | 1 |
| Pathania, YS | 2 |
| Hu, D | 1 |
| Yang, S | 1 |
| Shome, D | 2 |
| Tandel, H | 1 |
| Kumar, V | 2 |
| Kapoor, R | 2 |
| Domínguez-Santas, M | 1 |
| Grimalt, R | 5 |
| Arora, G | 1 |
| Mishra, A | 1 |
| Chandra, N | 1 |
| Kesharwani, P | 2 |
| Jain, GK | 1 |
| Sheng, Y | 1 |
| Zeng, Y | 2 |
| Hu, R | 1 |
| Wang, W | 2 |
| Yang, Q | 2 |
| Nussbaum, D | 1 |
| Murphy, E | 1 |
| Nelson, K | 1 |
| Gonzalez-Lopez, A | 1 |
| Qureshi, A | 1 |
| Schwartz, J | 1 |
| Friedman, A | 1 |
| Young, PC | 1 |
| Mahajan, C | 1 |
| Ghassemi, M | 3 |
| Yazdanian, N | 1 |
| Jafari, M | 1 |
| Zhang, C | 3 |
| Yu, Y | 1 |
| Shi, S | 1 |
| Liang, M | 1 |
| Yang, D | 1 |
| Sui, N | 1 |
| Yu, WW | 1 |
| Wang, L | 2 |
| Zhu, Z | 1 |
| Saleem, K | 1 |
| Siddiqui, B | 1 |
| Ur Rehman, A | 1 |
| Taqi, MM | 1 |
| Ahmed, N | 1 |
| Haddad, N | 1 |
| Arruda, S | 3 |
| Sadick, N | 3 |
| Shen, Q | 3 |
| Fu, Z | 3 |
| Du, P | 3 |
| Wang, J | 4 |
| Kang, J | 2 |
| Lee, JW | 4 |
| Kwon, O | 2 |
| Zhong, T | 1 |
| Zhang, S | 2 |
| Li, L | 1 |
| Hu, W | 1 |
| Qin, C | 1 |
| Navarro-Triviño, FJ | 1 |
| Pegalajar-García, MD | 2 |
| Gil-Villalba, A | 2 |
| Ruiz-Villaverde, R | 1 |
| Zhou, D | 1 |
| Chen, G | 3 |
| Fu, Q | 1 |
| Li, N | 1 |
| Bassiouny, EA | 1 |
| El-Samanoudy, SI | 1 |
| Abbassi, MM | 1 |
| Nada, HR | 1 |
| Farid, SF | 1 |
| Hummadi, AA | 1 |
| Gany, SN | 1 |
| Hadi, NR | 1 |
| Clarysse, KLJ | 1 |
| Gomes, TF | 1 |
| Soares, RO | 1 |
| Alsalhi, W | 2 |
| Nguyen, B | 1 |
| Morrison, BW | 1 |
| Gwillim, EC | 1 |
| Makhlouf, A | 1 |
| Elnawawy, T | 1 |
| Balasundaram, M | 1 |
| Kumari, R | 1 |
| Ramassamy, S | 1 |
| Awad, A | 1 |
| Chim, I | 1 |
| Sharma, P | 1 |
| Bhoyrul, B | 5 |
| Senthilnathan, A | 1 |
| Larrondo, J | 1 |
| De Souza, B | 1 |
| Harris, T | 1 |
| Eginli, A | 2 |
| McMichael, A | 3 |
| Nobari, NN | 1 |
| Sadeghzadeh-Bazargan, A | 2 |
| Nikkhah, F | 1 |
| Lee, YY | 1 |
| Sung, YK | 2 |
| Hong, D | 1 |
| Jung, KE | 1 |
| Seo, YJ | 2 |
| Lee, Y | 2 |
| Yin, M | 1 |
| Liu, HQ | 1 |
| Wang, C | 1 |
| Chen, C | 2 |
| Li, W | 1 |
| Elshall, AA | 1 |
| Ghoneim, AM | 1 |
| Abd-Elmonsif, NM | 1 |
| Osman, R | 1 |
| Shaker, DS | 1 |
| Gasmi, A | 1 |
| Mujawdiya, PK | 1 |
| Beley, N | 1 |
| Shanaida, M | 1 |
| Lysiuk, R | 1 |
| Lenchyk, L | 1 |
| Noor, S | 1 |
| Muhammad, A | 1 |
| Strus, O | 1 |
| Piscopo, S | 1 |
| Komisarenko, A | 1 |
| Fedorovska, M | 1 |
| Bjørklund, G | 1 |
| Goodwin Cartwright, BM | 1 |
| Wang, M | 1 |
| Rodriguez, P | 1 |
| Stewart, S | 1 |
| Worsham, CM | 1 |
| Stucky, N | 1 |
| Jena, AB | 1 |
| Devjani, S | 1 |
| Ezemma, O | 1 |
| Kelley, KJ | 1 |
| Stratton, E | 1 |
| Senna, M | 1 |
| Albalawi, MA | 1 |
| Hafez, AM | 1 |
| Elhawary, SS | 1 |
| Sedky, NK | 1 |
| Hassan, OF | 1 |
| Bakeer, RM | 1 |
| El Hadi, SA | 1 |
| El-Desoky, AH | 1 |
| Mahgoub, S | 1 |
| Mokhtar, FA | 1 |
| Milan, E | 1 |
| Alessandrini, A | 4 |
| Bruni, F | 2 |
| Piraccini, BM | 10 |
| Wu, S | 1 |
| Liu, S | 1 |
| Chen, J | 2 |
| Dai, D | 1 |
| Liu, W | 1 |
| Le, D | 1 |
| Guan, Q | 1 |
| Miao, Y | 4 |
| Hu, Z | 3 |
| Qu, Q | 3 |
| Rapaport, J | 1 |
| Sadgrove, NJ | 1 |
| Swearingen, A | 1 |
| Abidi, Z | 1 |
| Deoghare, S | 1 |
| Sadick, NS | 1 |
| de la Torre-Gomar, FJ | 1 |
| Alhanshali, L | 1 |
| Buontempo, M | 1 |
| Majerson, D | 1 |
| Cedirian, S | 1 |
| Quadrelli, F | 1 |
| Caro, G | 2 |
| Fortuna, M | 1 |
| Rossi, A | 4 |
| Minta, A | 2 |
| Park, C | 2 |
| Rose, L | 2 |
| Trovato, S | 2 |
| Dulmage, B | 2 |
| Gao, L | 1 |
| Zhang, HL | 1 |
| Tan, XY | 1 |
| Wang, YG | 1 |
| Song, H | 1 |
| Yuan, VL | 1 |
| Liao, XH | 1 |
| Li, P | 1 |
| Sun, Y | 1 |
| Nie, L | 1 |
| Shavandi, A | 1 |
| Yunusov, KE | 1 |
| Hua, Y | 1 |
| Jiang, G | 1 |
| Wei, W | 1 |
| Long, B | 1 |
| Xu, S | 1 |
| Xue, X | 1 |
| Lv, Y | 1 |
| Miao, X | 1 |
| Polla Ravi, S | 1 |
| Wang, T | 2 |
| Mokhtari, F | 2 |
| Zavare, Z | 1 |
| Ly, NY | 1 |
| Fruechte, S | 1 |
| Hordinsky, MK | 2 |
| Farah, RS | 1 |
| Wang, Q | 1 |
| Yang, K | 1 |
| Lin, J | 2 |
| Liu, Q | 1 |
| Zhu, Y | 2 |
| Li, Z | 1 |
| Ni, C | 1 |
| Legiawati, L | 1 |
| Suseno, LS | 1 |
| Sitohang, IBS | 1 |
| Yusharyahya, SN | 1 |
| Pawitan, JA | 1 |
| Liem, IK | 1 |
| Kurniawati, T | 1 |
| Ardelia, A | 1 |
| Paramastri, K | 1 |
| Shen, Y | 1 |
| Zhang, L | 1 |
| Sun, J | 1 |
| Xie, B | 1 |
| Zhang, H | 2 |
| Song, X | 1 |
| Abdi, P | 1 |
| Awad, C | 1 |
| Anthony, MR | 1 |
| Farkouh, C | 1 |
| Kenny, B | 1 |
| Maibach, HI | 2 |
| Ogunyemi, B | 1 |
| Asim, M | 1 |
| Shah, R | 1 |
| Sharif, S | 1 |
| Ouellette, S | 1 |
| Shah, A | 1 |
| Rao, B | 1 |
| Santana, FFV | 1 |
| Lozi, AA | 1 |
| Gonçalves, RV | 1 |
| Da Silva, J | 1 |
| Da Matta, SLP | 1 |
| Yan, A | 1 |
| Ruan, R | 1 |
| Zhu, X | 1 |
| Qiang, W | 1 |
| Guan, Y | 1 |
| Yu, Q | 2 |
| Sun, H | 1 |
| Liu, M | 1 |
| Zhu, H | 1 |
| Hu, L | 1 |
| Luo, F | 1 |
| Ibraheim, MK | 1 |
| Elsensohn, A | 1 |
| Hauschild, C | 1 |
| Hilliard, A | 1 |
| Dao, H | 1 |
| Mirmirani, P | 5 |
| Young, PA | 1 |
| Vanderweil, SG | 1 |
| Vanchinathan, V | 1 |
| Click, JW | 1 |
| McCleskey, PE | 1 |
| Ramaswamy, B | 1 |
| Stover, D | 1 |
| Gatti-Mays, M | 1 |
| Cherian, M | 1 |
| Williams, N | 1 |
| Sudheendra, P | 1 |
| Wesolowski, R | 1 |
| Sardesai, S | 1 |
| Lustberg, M | 1 |
| Loprinzi, CL | 1 |
| Ruddy, KJ | 1 |
| Cathcart-Rake, E | 1 |
| Katzer, T | 1 |
| Leite Junior, A | 1 |
| Beck, R | 1 |
| da Silva, C | 1 |
| Ghonemy, S | 1 |
| Alarawi, A | 1 |
| Bessar, H | 1 |
| Dowd, M | 1 |
| Antonov, N | 1 |
| Garzon, M | 1 |
| Lauren, C | 1 |
| Griggs, J | 1 |
| Burroway, B | 1 |
| Goren, A | 12 |
| Kasprzak, M | 1 |
| Wambier, CG | 1 |
| Craiglow, BG | 2 |
| King, BA | 1 |
| Pirmez, R | 2 |
| Salas-Callo, CI | 2 |
| Bruce, AJ | 1 |
| Pincelli, TP | 1 |
| Heckman, MG | 1 |
| Desmond, CM | 1 |
| Arthurs, JR | 1 |
| Diehl, NN | 1 |
| Douglass, EJ | 1 |
| Bruce, CJ | 1 |
| Shapiro, SA | 1 |
| Jedličková, H | 1 |
| Vokurka, S | 1 |
| Vojtíšek, R | 1 |
| Malečková, A | 1 |
| Orlando, G | 1 |
| Ismail, FF | 1 |
| Kochar, P | 1 |
| Nayak, K | 1 |
| Thakkar, S | 1 |
| Polaka, S | 1 |
| Khunt, D | 1 |
| Misra, M | 1 |
| Li, A | 1 |
| Meng, X | 1 |
| Xing, X | 1 |
| Tan, H | 1 |
| Liu, J | 1 |
| Li, C | 1 |
| Lyakhovitsky, A | 1 |
| Warshavsky, K | 1 |
| Ben Mordechai, Y | 1 |
| Pavlotsky, F | 1 |
| Barzilai, A | 1 |
| Van Neste, D | 3 |
| Alalola, A | 1 |
| Randolph, M | 2 |
| Gwillim, E | 1 |
| Yi, Y | 1 |
| Qiu, J | 1 |
| Jia, J | 1 |
| Djakaya, GDN | 1 |
| Li, X | 1 |
| Fu, J | 2 |
| Chen, Y | 1 |
| Chen, Q | 1 |
| York, K | 1 |
| Meah, N | 2 |
| Marks, DH | 1 |
| Sfouq Aleanizy, F | 1 |
| Yahya Alqahtani, F | 1 |
| Alkahtani, HM | 1 |
| Alquadeib, B | 1 |
| Eltayeb, EK | 1 |
| Aldarwesh, A | 1 |
| Abdelhady, HG | 1 |
| Alsarra, IA | 1 |
| Galadari, H | 1 |
| Shivakumar, S | 1 |
| Lotti, T | 5 |
| Wollina, U | 1 |
| Rokni, GR | 1 |
| Grabbe, S | 1 |
| Nilforooshzadeh, MA | 1 |
| Lotfi, E | 1 |
| Zolghadr, S | 1 |
| Mansouri, P | 1 |
| Chen, L | 1 |
| Zhang, J | 1 |
| Wang, H | 1 |
| Chen, B | 1 |
| Foley, KA | 1 |
| Therianou, A | 1 |
| Vincenzi, C | 4 |
| Trindade de Carvalho, L | 3 |
| Kerkemeyer, KL | 1 |
| Gentile, P | 1 |
| Garcovich, S | 1 |
| Tai, T | 1 |
| Kochhar, A | 1 |
| Maqoud, F | 2 |
| Zizzo, N | 1 |
| Mele, A | 1 |
| Denora, N | 3 |
| Passantino, G | 1 |
| Scala, R | 1 |
| Cutrignelli, A | 3 |
| Tinelli, A | 1 |
| Laquintana, V | 3 |
| la Forgia, F | 2 |
| Fontana, S | 2 |
| Franco, M | 3 |
| Lopedota, AA | 1 |
| Tricarico, D | 2 |
| Ferial Ismail, F | 1 |
| Bao, L | 2 |
| Zong, H | 1 |
| Fang, S | 1 |
| Zheng, L | 1 |
| McCoy, J | 7 |
| Wambier, C | 2 |
| Yang, G | 1 |
| Gu, Z | 1 |
| Chrétien, B | 1 |
| Sassier, M | 1 |
| Alexandre, J | 1 |
| Lelong-Boulouard, V | 1 |
| Dolladille, C | 1 |
| Fedrizzi, S | 1 |
| Fan, Z | 1 |
| Jha, AK | 1 |
| Sonthalia, S | 1 |
| Zeeshan, MD | 1 |
| Vinay, K | 1 |
| Behbahani, S | 1 |
| Ward, B | 1 |
| Montovano, M | 1 |
| Wilson, BN | 1 |
| Ravikumar, V | 1 |
| Karanfilian, K | 1 |
| Paskhover, B | 1 |
| Fujita, J | 1 |
| Venkatesh, R | 1 |
| Pereira, A | 1 |
| Jain, K | 1 |
| Yadav, NK | 1 |
| Sharma, AN | 1 |
| Michelle, L | 1 |
| Juhasz, M | 2 |
| Atanaskova Mesinkovska, N | 2 |
| Sohng, C | 1 |
| Lee, EH | 1 |
| Woo, SK | 1 |
| Kim, JY | 1 |
| Park, KD | 1 |
| Lee, SJ | 1 |
| Lee, WJ | 1 |
| Gohad, P | 1 |
| Lemes, LR | 1 |
| de Oliveira, DS | 1 |
| de La-Rocque, M | 1 |
| Zompero, C | 1 |
| Barbareschi, M | 2 |
| Vescovi, V | 1 |
| Milani, M | 1 |
| Abdallah, MAE | 1 |
| Shareef, R | 1 |
| Soltan, MY | 1 |
| Nagarajan, H | 1 |
| Rai, R | 1 |
| Huerth, K | 1 |
| Kindred, C | 1 |
| Phillips, GS | 1 |
| Freret, ME | 1 |
| Friedman, DN | 1 |
| Trelles, S | 1 |
| Kukoyi, O | 1 |
| Freites-Martinez, A | 3 |
| Unger, RH | 1 |
| Disa, JJ | 1 |
| Wexler, LH | 1 |
| Tinkle, CL | 1 |
| Mechalakos, JG | 1 |
| Dusza, SW | 1 |
| Beal, K | 1 |
| Wolden, SL | 1 |
| Lacouture, ME | 3 |
| Jaen-Olasolo, P | 4 |
| Gozali, MM | 1 |
| Kurniawati, Y | 1 |
| Zulkarnain, SD | 1 |
| Rica Echevarría, I | 1 |
| García Del Monte, J | 1 |
| Delgado Rubio, A | 1 |
| Arcangeli, F | 1 |
| Kovacevic, M | 5 |
| Situm, M | 4 |
| Annunziata, MC | 1 |
| Cinelli, E | 1 |
| Villani, A | 2 |
| Nabavinejad, S | 1 |
| Fatemi Naeini, F | 1 |
| Pakhomova, EE | 1 |
| Smirnova, IO | 1 |
| Makki, M | 1 |
| Younes, AH | 1 |
| Salah, I | 1 |
| Liu, Y | 1 |
| Jiang, LL | 1 |
| Liu, F | 1 |
| Fan, ZX | 1 |
| Guo, Z | 1 |
| Hu, ZQ | 1 |
| Guillon-Rolf, R | 1 |
| Boutboul, S | 1 |
| Borderie, V | 1 |
| Dincer, D | 1 |
| Tanacan, E | 1 |
| Kose Ozkan, C | 1 |
| Beach, RA | 3 |
| McDonald, KA | 2 |
| Muylaert Barrett, B | 1 |
| Masoud, F | 1 |
| Alamdari, HA | 1 |
| Asnaashari, S | 2 |
| Shokri, J | 1 |
| Javadzadeh, Y | 2 |
| Martínez-Pizarro, S | 1 |
| Yu, CQ | 1 |
| Guo, ME | 1 |
| Li, XK | 1 |
| Chen, HD | 1 |
| Li, YH | 2 |
| Xu, XG | 2 |
| Sanabria, B | 1 |
| Vanzela, TN | 1 |
| Uzel, BPC | 1 |
| Takano, GHS | 1 |
| Chartuni, JCN | 1 |
| Cesetti, MV | 1 |
| Gavioli, CFB | 1 |
| Lemes, AM | 1 |
| Costa, IMC | 1 |
| Abdel-Raouf, H | 1 |
| Aly, UF | 1 |
| Medhat, W | 1 |
| Ahmed, SS | 1 |
| Abdel-Aziz, RTA | 1 |
| Bukowiecki, J | 1 |
| Pförringer, D | 1 |
| Thor, D | 1 |
| Duscher, D | 1 |
| Brett, E | 1 |
| Olamiju, B | 1 |
| Barrett, BM | 1 |
| Abdel-Qadir, H | 1 |
| Zaky, MS | 1 |
| Abo Khodeir, H | 1 |
| Ahmed, HA | 1 |
| Najar Nobari, N | 1 |
| Heymann, WR | 1 |
| Moreau, T | 1 |
| Castronovo, C | 1 |
| Kaux, JF | 1 |
| Nikkels, AF | 1 |
| Paquet, P | 1 |
| Ibrahim, IM | 1 |
| Hasan, MS | 1 |
| Elsabaa, KI | 1 |
| Kołodziejak, M | 1 |
| Sikora, M | 1 |
| Stochmal, A | 1 |
| Rakowska, A | 1 |
| Olszewska, M | 1 |
| Koh, WL | 1 |
| Poa, JE | 1 |
| Jerjen, R | 1 |
| Lo-Sicco, K | 1 |
| Zamorano, JL | 1 |
| Ruggiero, A | 1 |
| Mercuri, SR | 1 |
| Paolino, G | 1 |
| Di Nicola, MR | 1 |
| Vollono, L | 1 |
| Dong, X | 1 |
| Jin, X | 1 |
| Doshi, K | 1 |
| Patel, G | 1 |
| Vadera, S | 1 |
| Hossein Mostafa, D | 1 |
| Samadi, A | 1 |
| Niknam, S | 1 |
| Nasrollahi, SA | 2 |
| Guishard, A | 1 |
| Firooz, A | 2 |
| Mahe, YF | 1 |
| Cheniti, A | 1 |
| Tacheau, C | 1 |
| Antonelli, R | 1 |
| Planard-Luong, L | 1 |
| de Bernard, S | 1 |
| Buffat, L | 1 |
| Barbarat, P | 1 |
| Kanoun-Copy, L | 1 |
| Ferrara, F | 1 |
| Kakizaki, P | 1 |
| de Brito, FF | 1 |
| Contin, LA | 1 |
| Donati, A | 1 |
| Rose, PT | 3 |
| Dhurat, R | 5 |
| Daruwalla, S | 1 |
| Pai, S | 1 |
| Lobon, K | 1 |
| Pinczewski, J | 1 |
| Xia, F | 1 |
| Wu, H | 1 |
| Huang, L | 1 |
| Huang, Q | 1 |
| Rao, Y | 1 |
| Ling, D | 1 |
| Li, F | 1 |
| Quesada, S | 1 |
| Guichard, A | 1 |
| Le Vigouroux, S | 1 |
| Baussard, L | 1 |
| Fiteni, F | 1 |
| Mishra, P | 1 |
| Handa, M | 1 |
| Ujjwal, RR | 1 |
| Singh, V | 1 |
| Shukla, R | 1 |
| Jones, LN | 1 |
| Muñoz Moreno-Arrones, O | 1 |
| Qiu, L | 1 |
| Yi, C | 1 |
| Xue, P | 1 |
| Yu, Z | 1 |
| Su, Y | 1 |
| Guo, S | 1 |
| Chen, YF | 2 |
| Chen, LH | 1 |
| Yeh, YM | 1 |
| Wu, PY | 1 |
| Chang, LY | 1 |
| Chang, JY | 1 |
| Shen, MR | 1 |
| Adil, A | 1 |
| Godwin, M | 1 |
| Dothard, E | 1 |
| Bagayoko, CW | 1 |
| Huang, K | 1 |
| Daniel, A | 1 |
| Esmat, SM | 1 |
| Hegazy, RA | 1 |
| Gawdat, HI | 1 |
| Abdel Hay, RM | 1 |
| Allam, RS | 1 |
| El Naggar, R | 1 |
| Moneib, H | 1 |
| Alves, R | 2 |
| Wehner, MR | 1 |
| Nead, KT | 1 |
| Lipoff, JB | 1 |
| Stamatas, GN | 1 |
| Pappas, A | 1 |
| McCormick, TS | 1 |
| Cooper, KD | 1 |
| Consolo, M | 2 |
| Schastnaya, J | 1 |
| Ozerov, IV | 1 |
| Aliper, A | 1 |
| Zhavoronkov, A | 1 |
| DiMarco, G | 1 |
| Rodrigues, M | 1 |
| Antunes, I | 1 |
| Magalhães, S | 1 |
| Pereira, N | 1 |
| Lee, HJ | 1 |
| Oh, DW | 1 |
| Na, MJ | 1 |
| Kim, DW | 1 |
| Yuk, DY | 1 |
| Choi, HC | 1 |
| Lee, YB | 1 |
| Han, K | 1 |
| Park, CW | 1 |
| Abdelmaksoud, A | 1 |
| Meephansan, J | 1 |
| Thummakriengkrai, J | 1 |
| Ponnikorn, S | 1 |
| Yingmema, W | 1 |
| Deenonpoe, R | 1 |
| Suchonwanit, P | 4 |
| Chitallia, J | 1 |
| May, TW | 1 |
| Jayaraaman, AM | 1 |
| Madhukara, J | 1 |
| Anandan, S | 1 |
| Vaidya, P | 1 |
| Klenk, A | 1 |
| Gong, L | 1 |
| Tian, T | 2 |
| Kanti, V | 2 |
| Messenger, A | 1 |
| Dobos, G | 1 |
| Reygagne, P | 3 |
| Finner, A | 1 |
| Blumeyer, A | 1 |
| Trakatelli, M | 1 |
| Del Marmol, V | 1 |
| Nast, A | 1 |
| Blume-Peytavi, U | 6 |
| Lopedota, A | 2 |
| Lopalco, A | 2 |
| Curci, A | 1 |
| Mastrodonato, M | 1 |
| Rubio-Gonzalez, B | 1 |
| Fortman, J | 1 |
| Mesinkovska, NA | 2 |
| Takeuchi, I | 1 |
| Hida, Y | 1 |
| Makino, K | 1 |
| Chan, D | 2 |
| Fornier, M | 1 |
| Modi, S | 2 |
| Gajria, D | 2 |
| Dusza, S | 1 |
| Goldfarb, S | 2 |
| Zimmerman, B | 1 |
| Ivars, M | 1 |
| Cordoro, KM | 1 |
| Mays, RR | 1 |
| Dotzert, MS | 1 |
| Versteeg, SG | 1 |
| Shear, NH | 2 |
| Piguet, V | 1 |
| Manabe, M | 2 |
| Tsuboi, R | 3 |
| Itami, S | 5 |
| Osada, SI | 1 |
| Amoh, Y | 1 |
| Ito, T | 1 |
| Inui, S | 2 |
| Ueki, R | 2 |
| Kurata, S | 2 |
| Kono, T | 2 |
| Saito, N | 2 |
| Sato, A | 1 |
| Shimomura, Y | 1 |
| Nakamura, M | 1 |
| Narusawa, H | 1 |
| Yamazaki, M | 2 |
| Miguel-Gómez, L | 1 |
| Rodrigues-Barata, AR | 1 |
| Molina-Ruiz, A | 1 |
| Martorell-Calatayud, A | 2 |
| Fernández-Crehuet, P | 2 |
| Barco, D | 1 |
| Arias-Santiago, S | 2 |
| Serrano-Falcón, C | 1 |
| Camacho, FM | 1 |
| Anitua, E | 1 |
| Pino, A | 1 |
| Jaén, P | 1 |
| Navarro, MR | 1 |
| Thuangtong, R | 1 |
| Thanomkitti, K | 1 |
| Suvanasuthi, S | 1 |
| Yu, AJ | 1 |
| Luo, YJ | 1 |
| Bao, LL | 1 |
| Li, ZX | 1 |
| Dong, YX | 1 |
| Srisuwanwattana, P | 1 |
| Chalermroj, N | 1 |
| Khunkhet, S | 2 |
| Chan, L | 1 |
| Cook, DK | 1 |
| Naccarato, T | 2 |
| Iamsumang, W | 1 |
| Rojhirunsakool, S | 2 |
| Sharma, A | 2 |
| Lukinovic Skudar, V | 1 |
| Andy, G | 1 |
| John, M | 1 |
| Mirna, S | 1 |
| Rachita, D | 1 |
| Michael, K | 1 |
| Maja, K | 1 |
| Aseem, S | 1 |
| Zeljana, B | 1 |
| Rahmatpour Rokni, G | 1 |
| Sadr, S | 1 |
| Mirabi, A | 1 |
| Rezaee, E | 1 |
| Chitalia, J | 1 |
| Bater, K | 1 |
| Rieder, E | 1 |
| Stoehr, JR | 1 |
| Choi, JN | 1 |
| Colavincenzo, M | 1 |
| Vanderweil, S | 1 |
| Kinoshita-Ise, M | 1 |
| Foster, FS | 1 |
| Paik, SH | 1 |
| Kim, HT | 1 |
| Chang, SE | 1 |
| Iorizzo, M | 2 |
| Carmina, E | 1 |
| Azziz, R | 1 |
| Bergfeld, W | 3 |
| Escobar-Morreale, HF | 1 |
| Futterweit, W | 1 |
| Huddleston, H | 1 |
| Lobo, R | 1 |
| Olsen, E | 1 |
| Sung, CT | 2 |
| Juhasz, ML | 1 |
| Choi, FD | 1 |
| Kozicka, K | 1 |
| Łukasik, A | 1 |
| Pastuszczak, M | 1 |
| Wojas-Pelc, A | 1 |
| Sibaud, V | 1 |
| Cho, J | 1 |
| Norton, L | 1 |
| Cigler, T | 1 |
| Cohen, PR | 1 |
| Agrawal, S | 1 |
| Tan, Y | 1 |
| Hunter, N | 1 |
| Sayed, K | 1 |
| Hay, RA | 1 |
| Allam, R | 1 |
| Hussein, N | 1 |
| de Mattos Barreto, T | 1 |
| Plata, GT | 1 |
| Araujo, LR | 1 |
| Tortelly, VD | 1 |
| Park, GH | 1 |
| Kim, WI | 1 |
| Yang, MY | 1 |
| Lee, WK | 1 |
| Kim, GW | 1 |
| Kim, HS | 1 |
| Ko, HC | 1 |
| Kim, BS | 1 |
| Kim, MB | 1 |
| Delgado-Charro, MB | 1 |
| Guy, RH | 2 |
| Vianna Lopez, RF | 1 |
| Lee, HE | 1 |
| Chang, IK | 1 |
| Im, M | 1 |
| Lee, JH | 1 |
| Sakr, FM | 1 |
| Gado, AM | 1 |
| Mohammed, HR | 1 |
| Adam, AN | 1 |
| Bhatti, HA | 1 |
| Basra, MK | 1 |
| Patel, GK | 1 |
| Nusbaum, AG | 1 |
| Nusbaum, BP | 1 |
| Rajaee Harandi, M | 1 |
| Askari, G | 1 |
| Ryu, HJ | 1 |
| Yoo, MG | 1 |
| Son, SW | 1 |
| Calvieri, S | 2 |
| Gomes, MJ | 1 |
| Martins, S | 1 |
| Ferreira, D | 1 |
| Segundo, MA | 1 |
| Reis, S | 1 |
| Selva, S | 1 |
| Ragni, L | 1 |
| Tongiani, S | 1 |
| Chen, W | 1 |
| Kigitsidou, E | 1 |
| Prucha, H | 1 |
| Ring, J | 1 |
| Andres, C | 1 |
| Gupta, R | 1 |
| High, WA | 1 |
| Butler, D | 1 |
| Murase, JE | 2 |
| Varothai, S | 2 |
| Bergfeld, WF | 5 |
| Oyetakin-White, P | 1 |
| Baron, E | 1 |
| Leahy, P | 1 |
| Karnik, P | 1 |
| Guerouaz, N | 1 |
| Mohamed, AO | 1 |
| Choi, JC | 1 |
| Uyama, H | 1 |
| Lee, CH | 1 |
| Sung, MH | 1 |
| Harfmann, KL | 1 |
| Bechtel, MA | 1 |
| Gargallo, V | 1 |
| Gutierrez, C | 1 |
| Vanaclocha, F | 1 |
| Guerra-Tapia, A | 1 |
| Hillmann, K | 3 |
| Garcia Bartels, N | 3 |
| Kottner, J | 2 |
| Stroux, A | 2 |
| Canfield, D | 3 |
| Kwon, TR | 1 |
| Oh, CT | 1 |
| Park, HM | 1 |
| Han, HJ | 1 |
| Ji, HJ | 1 |
| Rossi, AM | 1 |
| Aljuffali, IA | 1 |
| Pan, TL | 1 |
| Chang, SH | 1 |
| Fang, JY | 1 |
| Danesh, M | 1 |
| Dubrey, SW | 1 |
| VanGriethuysen, J | 1 |
| Edwards, CM | 1 |
| Goodier, M | 1 |
| Hordinsky, M | 2 |
| Torres, F | 1 |
| Ioannides, D | 1 |
| Lazaridou, E | 1 |
| Wolff, H | 5 |
| Check, JH | 1 |
| Cohen, R | 1 |
| Vary, JC | 1 |
| Hugh Rushton, D | 1 |
| Norris, MJ | 1 |
| Pham, H | 2 |
| von Grote, E | 2 |
| Meckfessel, MH | 2 |
| Keaney, TC | 1 |
| Liao, AH | 1 |
| Lu, YJ | 1 |
| Lin, YC | 1 |
| Chen, HK | 1 |
| Sytwu, HK | 1 |
| Wang, CH | 1 |
| van Zuuren, EJ | 4 |
| Fedorowicz, Z | 4 |
| Schoones, J | 2 |
| Cranwell, WC | 1 |
| Anzalone, A | 1 |
| Fortuna, MC | 1 |
| Garelli, V | 1 |
| Pranteda, G | 1 |
| Carlesimo, M | 1 |
| Fischer, TW | 1 |
| Camacho-Martínez, FM | 1 |
| Kelly, Y | 1 |
| Blanco, A | 1 |
| Hasanzadeh, H | 1 |
| Halavati, N | 1 |
| Saberi, M | 1 |
| Wu, M | 1 |
| Li, Q | 1 |
| Avram, MR | 3 |
| Rogers, NE | 2 |
| Scheinfeld, N | 1 |
| Melkote, S | 1 |
| Dhurat, RS | 1 |
| Palav, A | 1 |
| Jerajani, HR | 1 |
| Alsantali, A | 1 |
| Mounsey, AL | 1 |
| Reed, SW | 1 |
| Arano, O | 1 |
| Nishikawa, T | 1 |
| Yamada, H | 1 |
| Katsuoka, K | 2 |
| Sisti, A | 1 |
| Duque-Estrada, B | 1 |
| Lam, SM | 1 |
| Karamanovski, E | 1 |
| Gonzalez, ME | 1 |
| Cantatore-Francis, J | 1 |
| Orlow, SJ | 1 |
| Rastmanesh, R | 1 |
| Rathnayake, D | 2 |
| Ghanaat, M | 1 |
| Jandali, S | 1 |
| Low, DW | 1 |
| Torgerson, R | 1 |
| Kwack, MH | 1 |
| Kang, BM | 1 |
| Kim, MK | 1 |
| Kim, JC | 1 |
| Yazdabadi, A | 2 |
| Dietz, E | 1 |
| Pumthong, G | 1 |
| Asawanonda, P | 1 |
| Jariyasethavong, V | 1 |
| Triwongwaranat, D | 1 |
| Suthipinittharm, P | 1 |
| Ingkaninan, K | 1 |
| Leelapornpisit, P | 1 |
| Waranuch, N | 1 |
| González-Jiménez, M | 1 |
| Arenas-Valgañón, J | 1 |
| Calle, E | 1 |
| Casado, J | 1 |
| Mireles-Rocha, H | 1 |
| Sánchez-Dueñas, LE | 1 |
| Hernández-Torres, M | 1 |
| Scarinci, F | 1 |
| Mezzana, P | 1 |
| Pasquini, P | 1 |
| Colletti, M | 1 |
| Cacciamani, A | 1 |
| Guarneri, C | 1 |
| Cannavò, SP | 1 |
| McDonough, PH | 1 |
| Schwartz, RA | 1 |
| Patel, M | 1 |
| Dawson, TL | 1 |
| Yip, L | 1 |
| Perez, A | 1 |
| Rufaut, NW | 1 |
| Choi, JW | 1 |
| Na, SY | 1 |
| Park, KC | 1 |
| Youn, SW | 1 |
| Huh, CH | 1 |
| Park, MK | 1 |
| Kim, MN | 1 |
| Piraccini, B | 1 |
| Guarrera, M | 1 |
| Fiorucci, MC | 1 |
| Lorenzi, S | 1 |
| Bergstrom, KG | 1 |
| Cantisani, C | 1 |
| Melis, L | 1 |
| Iorio, A | 1 |
| Scali, E | 1 |
| Lee, SH | 3 |
| Yoon, J | 1 |
| Shin, SH | 1 |
| Zahoor, M | 1 |
| Kim, HJ | 1 |
| Park, PJ | 1 |
| Park, WS | 1 |
| Min, do S | 1 |
| Kim, HY | 1 |
| Choi, KY | 1 |
| Kluger, N | 1 |
| Jacot, W | 1 |
| Frouin, E | 1 |
| Rigau, V | 1 |
| Poujol, S | 1 |
| Dereure, O | 1 |
| Guillot, B | 1 |
| Romieu, G | 1 |
| Bessis, D | 1 |
| Carter, B | 2 |
| Andriolo, RB | 1 |
| McElwee, KJ | 1 |
| Shapiro, JS | 1 |
| Jang, WS | 1 |
| Yoo, KH | 1 |
| Han, TY | 1 |
| Seo, SJ | 1 |
| Hong, CK | 1 |
| Adenuga, P | 1 |
| Summers, P | 1 |
| Banka, N | 1 |
| Bunagan, MJ | 1 |
| Lim, C | 1 |
| Lee, JY | 1 |
| Im, KR | 1 |
| Yoon, KS | 1 |
| Song, JM | 1 |
| Tanglertsampan, C | 1 |
| Birch, MP | 1 |
| Lalla, SC | 1 |
| Messenger, AG | 4 |
| Olsen, EA | 11 |
| Dunlap, FE | 1 |
| Funicella, T | 1 |
| Koperski, JA | 2 |
| Swinehart, JM | 1 |
| Tschen, EH | 1 |
| Trancik, RJ | 2 |
| Khandpur, S | 1 |
| Suman, M | 1 |
| Reddy, BS | 1 |
| Foote, SI | 1 |
| Cole, JP | 1 |
| Gandelman, M | 1 |
| Haber, R | 2 |
| Knudsen, R | 2 |
| Leavitt, MT | 1 |
| Leonard, RT | 1 |
| Puig, CJ | 1 |
| Vogel, JE | 2 |
| Ziering, CL | 1 |
| Mallari, RS | 1 |
| Tate, B | 1 |
| Hoffmann, R | 4 |
| Brzezińska-Wcisło, L | 1 |
| Price, VH | 7 |
| Dawber, RP | 1 |
| Rundegren, J | 2 |
| Springer, K | 1 |
| Brown, M | 1 |
| Stulberg, DL | 1 |
| Robb-Nicholson, C | 1 |
| Berger, RS | 1 |
| Fu, JL | 1 |
| Smiles, KA | 1 |
| Turner, CB | 1 |
| Schnell, BM | 1 |
| Werchowski, KM | 1 |
| Lammers, KM | 1 |
| Hanneken, S | 1 |
| Ritzmann, S | 1 |
| Nöthen, MM | 1 |
| Kruse, R | 1 |
| Saraswat, A | 1 |
| Kumar, B | 1 |
| Ellis, JA | 1 |
| Harrap, SB | 1 |
| Bouhanna, P | 4 |
| Arck, PC | 1 |
| Handjiski, B | 1 |
| Peters, EM | 1 |
| Hagen, E | 1 |
| Klapp, BF | 1 |
| Bandaranayake, I | 1 |
| Han, JH | 1 |
| Kwon, OS | 3 |
| Chung, JH | 1 |
| Cho, KH | 2 |
| Eun, HC | 3 |
| Kim, KH | 3 |
| Lucky, AW | 1 |
| Piacquadio, DJ | 1 |
| Ditre, CM | 1 |
| Dunlap, F | 1 |
| Kantor, I | 1 |
| Pandya, AG | 1 |
| Savin, RC | 3 |
| Tharp, MD | 1 |
| Haber, RS | 1 |
| Arca, E | 1 |
| Açikgöz, G | 1 |
| Taştan, HB | 1 |
| Köse, O | 1 |
| Kurumlu, Z | 1 |
| Roberts, JL | 2 |
| Stough, D | 2 |
| Washenik, K | 3 |
| Whiting, DA | 4 |
| Bienová, M | 1 |
| Kucerová, R | 1 |
| Fiurásková, M | 1 |
| Hajdúch, M | 1 |
| Koláŕ, Z | 1 |
| Hagemann, T | 1 |
| Schlütter-Böhmer, B | 1 |
| Allam, JP | 1 |
| Bieber, T | 1 |
| Novak, N | 1 |
| Simon, HB | 1 |
| Stenn, K | 1 |
| Parsley, WM | 1 |
| Luggen, AS | 1 |
| Chen, CH | 1 |
| Sheu, MT | 1 |
| Wu, AB | 1 |
| Lin, KP | 1 |
| Ho, HO | 1 |
| Moreno-Ramírez, D | 1 |
| Camacho Martínez, F | 1 |
| Kwong, RA | 1 |
| Kossard, S | 1 |
| Hannuksela, M | 2 |
| Yoo, HG | 1 |
| Chang, IY | 1 |
| Pyo, HK | 1 |
| Kang, YJ | 1 |
| Hoedemaker, C | 1 |
| van Egmond, S | 1 |
| Epstein, JS | 1 |
| Kunte, C | 3 |
| Krisp, A | 1 |
| Ellwanger, U | 1 |
| Tsiskarishvili, NV | 1 |
| Tsiskarishvili, TsI | 1 |
| Otberg, N | 1 |
| Finner, AM | 1 |
| Whiting, D | 1 |
| Miller, J | 1 |
| Wanser, R | 1 |
| Zhang, P | 1 |
| Kohut, B | 1 |
| Shin, HS | 1 |
| Won, CH | 1 |
| Mapar, MA | 1 |
| Omidian, M | 1 |
| Gassmueller, J | 1 |
| Webster, A | 1 |
| Dinh, QQ | 1 |
| Vermorken, AJ | 1 |
| Wester, RC | 2 |
| Novak, E | 2 |
| Vanderveen, EE | 1 |
| Ellis, CN | 1 |
| Kang, S | 1 |
| Case, P | 1 |
| Headington, JT | 3 |
| Voorhees, JJ | 2 |
| Swanson, NA | 1 |
| King, CM | 1 |
| Harrop, B | 1 |
| Dave, VK | 1 |
| Ingles, RM | 1 |
| Kahn, T | 1 |
| Seidman, M | 1 |
| Westfried, M | 1 |
| Maxey, R | 1 |
| Rao, TK | 1 |
| Friedman, EA | 1 |
| Zappacosta, AR | 1 |
| Walsh, DS | 1 |
| Dunn, CL | 1 |
| James, WD | 1 |
| Vickers, MA | 1 |
| Barton, CJ | 1 |
| Hussein, AM | 1 |
| Ebner, H | 1 |
| Müller, E | 1 |
| Callan, AW | 1 |
| Montalto, J | 1 |
| Shrank, AB | 1 |
| Nielson, TA | 1 |
| Reichel, M | 1 |
| Roblin, X | 1 |
| Blais, J | 1 |
| Boisson, C | 1 |
| Kalmouni, M | 1 |
| André, F | 1 |
| Rodriguez, R | 1 |
| Machiavelli, M | 1 |
| Leone, B | 1 |
| Romero, A | 1 |
| Cuevas, MA | 1 |
| Langhi, M | 1 |
| Romero Acuña, L | 1 |
| Romero Acuña, J | 1 |
| Amato, S | 1 |
| Barbieri, M | 1 |
| Tan, J | 1 |
| Ho, V | 1 |
| Abbott, F | 1 |
| Tron, V | 1 |
| Baral, J | 2 |
| DeVillez, RL | 2 |
| Jacobs, JP | 2 |
| Szpunar, CA | 2 |
| Warner, ML | 2 |
| Duplechain, G | 1 |
| White, JA | 1 |
| Sasson, M | 1 |
| Shupack, JL | 2 |
| Stiller, MJ | 1 |
| Karam, P | 1 |
| Duvic, M | 2 |
| Atton, AV | 1 |
| Kohl, PK | 1 |
| Bammel, A | 1 |
| Stern, R | 1 |
| Sterry, W | 1 |
| Diani, AR | 1 |
| Shull, KL | 1 |
| Zaya, MJ | 1 |
| Brunden, MN | 1 |
| Rand, S | 2 |
| Lemak, NA | 1 |
| Valero, V | 1 |
| Hymes, SR | 1 |
| Farmer, KL | 1 |
| Hortobagyi, GN | 1 |
| Bandstra, BA | 1 |
| Compton, LD | 1 |
| Peluso, AM | 1 |
| Misciali, C | 1 |
| Piérard-Franchimont, C | 2 |
| Piérard, GE | 2 |
| Davies, K | 1 |
| Zhong, WZ | 1 |
| Sánchez-Motilla, JM | 1 |
| Pont, V | 1 |
| Nagore, E | 1 |
| Rodríguez-Serna, M | 1 |
| Sánchez, JL | 1 |
| Aliaga, A | 1 |
| De Doncker, P | 1 |
| Cauwenbergh, G | 1 |
| Esteve, E | 1 |
| Aubin, F | 1 |
| Dubertret, L | 1 |
| Molitor, L | 1 |
| Tran, D | 2 |
| Sato, T | 1 |
| Tadokoro, T | 1 |
| Sonoda, T | 1 |
| Asada, Y | 1 |
| Takayasu, S | 1 |
| Scow, DT | 1 |
| Nolte, RS | 1 |
| Shaughnessy, AF | 1 |
| Camacho-Martinez, F | 1 |
| Dawber, R | 3 |
| Menefee, E | 2 |
| Strauss, PC | 1 |
| Sawaya, M | 1 |
| Cash, TF | 1 |
| Kurbel, S | 1 |
| Kurbel, B | 1 |
| Zanić-Matanić, D | 1 |
| Tschöp, M | 1 |
| Pflaum, CD | 1 |
| Strasburger, CJ | 1 |
| Gärtner, R | 1 |
| Schopohl, J | 1 |
| Barth, JH | 1 |
| Dey, R | 1 |
| Donald, TG | 1 |
| Scheman, AJ | 1 |
| West, DP | 4 |
| Hordinksy, MK | 1 |
| Osburn, AH | 1 |
| West, LE | 1 |
| Schwarer, AP | 1 |
| Chow, CW | 1 |
| Wasielewski, S | 1 |
| Hogan, DJ | 1 |
| Chamberlain, M | 1 |
| Saiag, P | 1 |
| Granel, F | 1 |
| Satoh, H | 1 |
| Morikaw, S | 1 |
| Fujiwara, C | 1 |
| Terada, H | 1 |
| Uehara, A | 1 |
| Ohno, R | 1 |
| Meidan, VM | 1 |
| Touitou, E | 1 |
| Bierl, H | 1 |
| Patel, JC | 1 |
| Shirai, A | 2 |
| Ikeda, J | 1 |
| Kawashima, S | 1 |
| Tamaoki, T | 2 |
| Kamiya, T | 2 |
| de Viragh, PA | 1 |
| Tsunoda, H | 1 |
| Paukstadt, W | 1 |
| Sawaya, ME | 1 |
| Friedman, ES | 1 |
| Friedman, PM | 1 |
| Cohen, DE | 1 |
| Eremia, S | 1 |
| Umar, SH | 1 |
| Li, CY | 1 |
| Vexiau, P | 1 |
| Chaspoux, C | 1 |
| Boudou, P | 1 |
| Fiet, J | 1 |
| Jouanique, C | 1 |
| Hardy, N | 1 |
| Trattner, A | 2 |
| David, M | 1 |
| Bader, U | 1 |
| Kidwai, BJ | 1 |
| George, M | 1 |
| Jacobson, C | 1 |
| Ingber, A | 1 |
| Gandy, W | 1 |
| Brenner, S | 1 |
| Tamir, A | 1 |
| Uno, H | 3 |
| Takeshita, K | 1 |
| Yamagishi, I | 1 |
| Sugimoto, T | 1 |
| Otomo, S | 1 |
| Moriwaki, K | 1 |
| Wilson, C | 1 |
| Walkden, V | 1 |
| Powell, S | 1 |
| Shaw, S | 1 |
| Wilkinson, J | 1 |
| van der Donk, J | 1 |
| Passchier, J | 2 |
| Dutree-Meulenberg, RO | 3 |
| Stolz, E | 4 |
| Verhage, F | 2 |
| Kiesewetter, F | 1 |
| Langer, P | 1 |
| Schell, H | 1 |
| Lavrijsen, AP | 1 |
| Vermeer, BJ | 1 |
| O'Loughlin, S | 1 |
| Granai, CO | 1 |
| Frederickson, H | 1 |
| Gajewski, W | 1 |
| Goodman, A | 1 |
| Goldstein, A | 1 |
| Baden, H | 1 |
| Connors, TJ | 1 |
| Cooke, DE | 1 |
| De Launey, WE | 1 |
| Downie, M | 1 |
| Knudsen, RG | 1 |
| Shumack, S | 1 |
| Eggleston, AS | 1 |
| Rigoni, C | 2 |
| Pinelli, S | 2 |
| Toffolo, P | 1 |
| Scarabelli, G | 1 |
| Terenzio, C | 1 |
| Weiner, MS | 5 |
| Amara, IA | 1 |
| DeLong, ER | 5 |
| Fenske, NA | 1 |
| Albers, SE | 1 |
| Shiell, R | 1 |
| Kuan, YZ | 1 |
| Chen, SY | 1 |
| Chen, MJ | 1 |
| Wang, CN | 1 |
| Chan, HL | 1 |
| D'Ovidio, R | 1 |
| Di Prima, T | 1 |
| De Pasquale, R | 1 |
| D'Ovidio, F | 1 |
| London-Wong, DM | 1 |
| Hart, LL | 1 |
| Burnett, JW | 1 |
| Jordan, WP | 1 |
| Farmer, ER | 1 |
| Uitto, JJ | 1 |
| Ferry, JJ | 1 |
| Shepard, JH | 1 |
| Szpunar, GJ | 1 |
| Anderson, C | 1 |
| Berne, B | 1 |
| Juhlin, L | 1 |
| Skogh, M | 1 |
| Strand, A | 1 |
| Vahlquist, A | 1 |
| de Boer, EM | 1 |
| Bezemer, PD | 1 |
| Bruynzeel, DP | 1 |
| Nieboer, C | 2 |
| Burton, JL | 1 |
| Bardelli, A | 1 |
| Rebora, A | 1 |
| Katz, HI | 2 |
| Burke, KE | 1 |
| Grimalt, F | 1 |
| Rijpma, SE | 1 |
| Rushton, DH | 2 |
| Unger, WP | 2 |
| Cotterill, PC | 1 |
| Kingsley, P | 1 |
| James, KC | 2 |
| Bardazzi, F | 2 |
| Montagnani, A | 1 |
| Dover, JS | 1 |
| Arndt, KA | 2 |
| de Groot, AC | 4 |
| Nater, JP | 4 |
| Blanchard, G | 1 |
| Blanchard, B | 1 |
| Matias, JR | 1 |
| Malloy, V | 1 |
| Orentreich, N | 1 |
| Baran, R | 1 |
| Stålhammar, J | 1 |
| Neher, JO | 1 |
| Herxheimer, A | 2 |
| Mitchell, AD | 2 |
| De Villez, R | 1 |
| Jorizzo, JL | 1 |
| Feldman, SR | 1 |
| Degreef, H | 1 |
| Hendrickx, I | 1 |
| Dooms-Goossens, A | 1 |
| van der Willigen, AH | 1 |
| Geursen-Reitsma, AM | 1 |
| van Joost, T | 2 |
| Valsecchi, R | 1 |
| Cainelli, T | 1 |
| Zaun, H | 1 |
| Mørk, C | 1 |
| Braathen, LR | 1 |
| Zlotogorski, A | 1 |
| Seidenbaum, M | 1 |
| Heyman, A | 1 |
| Birnbaum, PS | 1 |
| Leenen, FH | 1 |
| Smith, DL | 1 |
| Menni, S | 1 |
| Pestana, A | 1 |
| Murray, JC | 1 |
| Rumsfield, JA | 2 |
| Fiedler-Weiss, VC | 2 |
| Orenberg, EK | 1 |
| Wilkinson, DI | 1 |
| Civatte, J | 1 |
| Laux, B | 1 |
| Simpson, NB | 1 |
| Vickers, CF | 1 |
| Kvedar, JC | 1 |
| Baden, HP | 1 |
| Epstein, E | 2 |
| Alomar, A | 1 |
| Smandia, JA | 1 |
| Piepkorn, MW | 1 |
| Weidner, M | 1 |
| Rietschel, RL | 2 |
| Robertson, DB | 1 |
| Storer, JS | 1 |
| Brzuskiewicz, J | 1 |
| Floyd, H | 1 |
| Rice, JC | 1 |
| De Villez, RL | 2 |
| Kassimir, JJ | 2 |
| Thirumoorthy, T | 1 |
| Reed, ML | 1 |
| Jondreau, L | 1 |
| Duncan, SH | 1 |
| Hien, NT | 1 |
| Prawer, SE | 1 |
| Goldman, SJ | 1 |
| Kreindler, TG | 1 |
| Spindler, JR | 1 |
| Clissold, SP | 1 |
| Heel, RC | 1 |
| Roenigk, HH | 2 |
| Pepper, E | 1 |
| Kuruvilla, S | 2 |
| Cappas, A | 2 |
| Brigham, P | 1 |
| De Prost, Y | 1 |
| van der Sluis, I | 1 |
| de Koning Gans, HJ | 1 |
| Devillez, R | 1 |
| Morgan, JP | 1 |
| Zappa, M | 1 |
| Bunker, CB | 1 |
| Dowd, PM | 1 |
| Shi, YP | 1 |
| Bazzano, GS | 1 |
| Terezakis, N | 1 |
| Galen, W | 1 |
| Natow, AJ | 1 |
| Stern, RS | 1 |
| Bamford, JT | 1 |
| Franz, TJ | 1 |
| Pinnell, SR | 1 |
| Feinstein, RP | 1 |
| Buys, CM | 1 |
| Weiss, VC | 1 |
| Herring, BD | 1 |
| Schlagel, C | 1 |
| De Padova, MP | 1 |
| Caponeri, GM | 1 |
| Melino, M | 1 |
| Veronesi, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia: A Randomized, Double-blind Clinical Trial[NCT05296863] | Phase 3 | 37 participants (Actual) | Interventional | 2021-10-11 | Completed | ||
| A Randomized Controlled Trial Comparing Platelet Rich Plasma (PRP) to Minoxidil Foam for Treatment of Androgenic Alopecia in Women[NCT03488108] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2017-01-23 | Completed | ||
| Use of Botulinum Toxin in the Treatment of Androgenic Alopecia[NCT05456087] | Phase 2 | 20 participants (Anticipated) | Interventional | 2022-08-12 | Recruiting | ||
| International Phase III, Multi Center, Randomized, Double Blind, Placebo and Active Controlled and Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of Oral Minoxidil 1 mg in Female Patients With Androgenetic Alopecia[NCT05888922] | Phase 3 | 520 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| The Efficacy of Combining 308 Nm-Excimer Light and Topical Steroid in the Treatment of Alopecia Areata[NCT04793945] | Phase 4 | 30 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| Evaluating the Efficacy of Topical Herbal Solution on the Treatment of Androgenetic Alopecia and Comparison With Minoxidil 5%: A Double-Blind, Randomized, Clinical Trial Study[NCT03753113] | Phase 3 | 24 participants (Actual) | Interventional | 2018-11-28 | Completed | ||
| Randomised, Crossover Bioavailability Clinical Trial of Oral Minoxidil 1 MG, After Single and Multiple Dose Administration to Healthy Volunteers Under Fasting Conditions.[NCT06015516] | Phase 1 | 14 participants (Anticipated) | Interventional | 2024-02-29 | Not yet recruiting | ||
| the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial[NCT03388840] | Phase 4 | 40 participants (Anticipated) | Interventional | 2018-01-15 | Recruiting | ||
| Efficacy of Platelet-rich Plasma Versus Mesotherapy With Recombinant Growth Factors and Stem Cell Conditioned Media in Androgenetic Alopecia: A Retrospective Study.[NCT05129800] | 100 participants (Anticipated) | Observational | 2021-12-31 | Not yet recruiting | |||
| Efficacy of Combined CO2 Fractional Laser With Bimatoprost 0.03% in Treatment of Alopecia Areata[NCT05600673] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2019-01-01 | Completed | ||
| Efficacy of Platelet-Rich Plasma Therapy for Androgenetic Alopecia: A Systematic Review and Meta-analysis[NCT04191005] | 15 participants (Anticipated) | Observational | 2020-01-07 | Recruiting | |||
| Role of Vitamin D in Androgenetic Alopecia[NCT03154528] | 90 participants (Anticipated) | Observational | 2019-03-30 | Not yet recruiting | |||
| Evaluating PAI-1 Expression in the Hair Follicles of Patients With Non-scarring Hair Loss.[NCT02548689] | 10 participants (Actual) | Observational | 2015-07-31 | Terminated (stopped due to Original lead investigator left Northwestern University) | |||
| A Randomized Controlled Trial to Evaluate Effectiveness of Cooling Cap to Prevent Permanent Chemotherapy-induced Alopecia Among Breast Cancer Patients[NCT04678544] | 170 participants (Actual) | Interventional | 2020-12-23 | Completed | |||
| Efficacy and Safety of 3% Minoxidil Lotion for Beard Enhancement : A Randomized, Double-blind, Placebo-controlled Study[NCT02275832] | Phase 4 | 48 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| Efficacy and Safety of 3% Minoxidil Lotion for Chest Hair Enhancement : A Randomized, Double-blind, Placebo-controlled Study[NCT02283645] | Phase 4 | 64 participants (Anticipated) | Interventional | 2015-01-31 | Not yet recruiting | ||
| Assessment of the Role of the JAK-STAT Pathway in the Pathogenesis of Male Androgenetic Alopecia[NCT03694067] | 25 participants (Actual) | Observational | 2018-10-15 | Completed | |||
| Minoxidil Response Testing in Males With Androgenetic Alopecia[NCT02198261] | 300 participants (Anticipated) | Observational | 2014-07-31 | Completed | |||
| Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil[NCT02486848] | 0 participants (Actual) | Interventional | 2016-06-30 | Withdrawn | |||
| Minoxidil Response Testing in Females With Female Pattern Hair Loss[NCT02206802] | 300 participants (Anticipated) | Observational | 2014-07-31 | Completed | |||
| Polymorphism of Janus Kinase 1 and 2 (JAK 1&2) in Patients With Alopecia Areata[NCT05861401] | 100 participants (Anticipated) | Interventional | 2023-04-30 | Recruiting | |||
| Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial[NCT02999737] | Phase 4 | 40 participants (Actual) | Interventional | 2016-11-30 | Active, not recruiting | ||
| Microarray Analysis of Scalp Biopsies in Subjects With Androgenetic Alopecia Before and After the Use of Topical Minoxidil[NCT01309191] | 14 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total number of participants experiencing Redness on Scalp was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: after 12 weeks of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Platelet Rich Plasma | 0 |
| Minoxidil Foam | 0 |
Total number of participants experiencing swelling on scalp was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: after 12 weeks of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Platelet Rich Plasma | 0 |
| Minoxidil Foam | 0 |
Phototrichograms of all scalps performed using FotoFinder video-epiluminescence microscopy (FotoFinder Systems GmbH) in combination with TrichoScan digital image analysis (TRICHOLOG GmbH and DatInf mbH). The percent change in the total sum of thickness of each hair was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: baseline, after 12 weeks of treatment
| Intervention | percent change (Median) |
|---|---|
| Platelet Rich Plasma | -3.5 |
| Minoxidil Foam | 20.6 |
Phototrichograms of all scalps performed using FotoFinder video-epiluminescence microscopy (FotoFinder Systems GmbH) in combination with TrichoScan digital image analysis (TRICHOLOG GmbH and DatInf mbH). The percent change in the total number of hairs per 0.65 cm2 was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: baseline, after 12 weeks of treatment
| Intervention | percent change (Median) |
|---|---|
| Platelet Rich Plasma | 7.7 |
| Minoxidil Foam | 22.7 |
Phototrichograms of all scalps performed using FotoFinder video-epiluminescence microscopy (FotoFinder Systems GmbH) in combination with TrichoScan digital image analysis (TRICHOLOG GmbH and DatInf mbH). The percent change in the total number of Terminal hairs per cm2 was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: baseline, after 12 weeks of treatment
| Intervention | percent change (Median) |
|---|---|
| Platelet Rich Plasma | -0.7 |
| Minoxidil Foam | 12.8 |
Phototrichograms of all scalps performed using FotoFinder video-epiluminescence microscopy (FotoFinder Systems GmbH) in combination with TrichoScan digital image analysis (TRICHOLOG GmbH and DatInf mbH). The percent change in the total number of vellus hairs per cm2 was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: baseline, after 12 weeks of treatment
| Intervention | percent change (Median) |
|---|---|
| Platelet Rich Plasma | 25.7 |
| Minoxidil Foam | 18.6 |
Self-administered hair growth questionnaire, consisting of 4 questions in the patient's language on treatment efficacy and three questions on satisfaction with appearance. For differences between self-assessment questionnaires. This questionnaire following 5-point scale: 1 = very satisfied, 2 = satisfied, 3 = neutral (neither satisfied nor dissatisfied), 4 = dissatisfied, 5 = very dissatisfied. Higher scores indicated a worse outcome. (NCT03753113)
Timeframe: through study completion
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Group | 1.25 |
| Control Group | 2.58 |
Incidence of adverse events such as itching, redness, inflammation etc (NCT03753113)
Timeframe: baseline, 12, 24, and 36 weeks
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| scalp itching | scalp dryness | headache | |
| Control Group | 4 | 2 | 2 |
| Treatment Group | 1 | 0 | 0 |
Change in hair diameter over time as compared to Baseline. Hair diameter measured via a digital micrometer. (NCT03753113)
Timeframe: baseline, 12, 24, and 36 weeks
| Intervention | micrometer (Mean) | ||
|---|---|---|---|
| Week 12 | Week 24 | Week 36 | |
| Control Group | 51.58 | 51.17 | 50.58 |
| Treatment Group | 57.42 | 60.92 | 62.67 |
164 reviews available for minoxidil and Alopecia
| Article | Year |
|---|---|
Microneedling for Hair Loss.
Topics: Alopecia; Hair; Humans; Minoxidil; Needles; Platelet-Rich Plasma; Treatment Outcome | 2022 |
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
Topics: Alopecia; Alopecia Areata; Female; Finasteride; Hair Follicle; Humans; Male; Minoxidil; Quality of L | 2021 |
Androgenetic alopecia in transgender and gender diverse populations: A review of therapeutics.
Topics: Alopecia; Dutasteride; Finasteride; Humans; Minoxidil; Transgender Persons; Treatment Outcome | 2023 |
Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know.
Topics: Alopecia; Dermatologists; Female; Humans; Minoxidil; Quality of Life | 2022 |
Natural products for male androgenetic alopecia.
Topics: Alopecia; Biological Products; Finasteride; Humans; Male; Minoxidil; Treatment Outcome | 2022 |
Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis.
Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Bayes Theorem; Dutasteride; Finasteride; Humans; Male | 2022 |
Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative?
Topics: Administration, Topical; Alopecia; Clinical Trials, Phase III as Topic; Female; Finasteride; Hair; H | 2022 |
Exploring the effects of Chinese herbal ingredients on the signaling pathway of alopecia and the screening of effective Chinese herbal compounds.
Topics: Alopecia; Alopecia Areata; China; Drugs, Chinese Herbal; Humans; Minoxidil; Plants, Medicinal; Signa | 2022 |
The first study on combined carboxytherapy and minoxidil 20% in the treatment of Lichen planopilaris: A case series and literature review.
Topics: Alopecia; Humans; Lichen Planus; Minoxidil | 2022 |
Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management.
Topics: Alopecia; Alopecia Areata; COVID-19; COVID-19 Drug Treatment; Humans; Minoxidil; SARS-CoV-2 | 2022 |
Does topical minoxidil at concentrations higher than 5% provide additional clinical benefit?
Topics: Administration, Topical; Alopecia; Humans; Minoxidil; Treatment Outcome | 2022 |
Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Dutasteride; Finasteride; Hair; Humans; Male; Minoxidil | 2022 |
Noninvasive Hair Rejuvenation.
Topics: Alopecia; Female; Finasteride; Hair; Humans; Male; Minoxidil; Rejuvenation; Treatment Outcome | 2022 |
Topical cetirizine for treating androgenetic alopecia: A systematic review.
Topics: Administration, Topical; Alopecia; Cetirizine; Hair; Humans; Minoxidil; Treatment Outcome | 2022 |
Comprehensive review of oral minoxidil in alopecia.
Topics: Administration, Topical; Alopecia; Female; Humans; Minoxidil; Treatment Outcome | 2022 |
Exploiting Recent Trends in the Treatment of Androgenic Alopecia through Topical Nanocarriers of Minoxidil.
Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Male; Minoxidil; Nanoparticles; Particle Si | 2022 |
Advances in microneedles research based on promoting hair regrowth.
Topics: Alopecia; Drug Delivery Systems; Finasteride; Hair; Humans; Minoxidil | 2023 |
Pediatric androgenetic alopecia: an updated review.
Topics: Adolescent; Alopecia; Child; Female; Finasteride; Hair; Humans; Minoxidil; Treatment Outcome | 2023 |
A systematic review of clinical trials using single or combination therapy of oral or topical finasteride for women in reproductive age and postmenopausal women with hormonal and nonhormonal androgenetic alopecia.
Topics: Alopecia; Combined Modality Therapy; Female; Finasteride; Humans; Minoxidil; Postmenopause; Treatmen | 2023 |
Natural Compounds Used for Treating Hair Loss.
Topics: Alopecia; Animals; Bees; Finasteride; Hair; Minoxidil; Plants, Medicinal; Quality of Life; United St | 2023 |
Androgenetic Alopecia: Therapy Update.
Topics: Administration, Oral; Administration, Topical; Alopecia; Female; Finasteride; Humans; Male; Minoxidi | 2023 |
Noninvasive Hair Rejuvenation.
Topics: Alopecia; Female; Finasteride; Hair; Humans; Male; Minoxidil; Rejuvenation; Treatment Outcome | 2023 |
Combination therapy in female pattern hair loss.
Topics: Alopecia; Combined Modality Therapy; Female; Finasteride; Humans; Minoxidil; Spironolactone; Treatme | 2023 |
Dissolving microneedles for alopecia treatment.
Topics: Alopecia; Female; Finasteride; Hair Follicle; Humans; Male; Minoxidil; Quality of Life; Treatment Ou | 2023 |
Systematic review of mesotherapy: a novel avenue for the treatment of hair loss.
Topics: Alopecia; Humans; Injections, Intradermal; Mesotherapy; Minoxidil; Treatment Outcome | 2023 |
Medical and procedural treatment of androgenetic alopecia - Where are we?
Topics: Alopecia; Behavior Therapy; Dietary Supplements; Finasteride; Humans; Minoxidil | 2023 |
Efficacy and safety of combinational therapy using topical minoxidil and microneedling for the treatment of androgenetic alopecia: a systematic review and meta-analysis.
Topics: Alopecia; Female; Hair; Humans; Male; Meta-Analysis as Topic; Minoxidil; Systematic Reviews as Topic | 2023 |
Comparative effects of finasteride and minoxidil on the male reproductive organs: A systematic review of in vitro and in vivo evidence.
Topics: Administration, Oral; Adult; Alopecia; Animals; Finasteride; Humans; Male; Mice; Minoxidil; Prostati | 2023 |
Physiopathology and current treatments of androgenetic alopecia: Going beyond androgens and anti-androgens.
Topics: Adult; Alopecia; Androgen Antagonists; Finasteride; Genetic Predisposition to Disease; Hair; Humans; | 2019 |
Pediatric androgenetic alopecia: A review.
Topics: Adolescent; Alopecia; Child; Finasteride; Humans; Incidence; Minoxidil; Retrospective Studies | 2021 |
Alopecia and Hair Damage Induced by Oncological Therapy.
Topics: Alopecia; Antineoplastic Agents; Humans; Minoxidil; Neoplasms; Radiotherapy | 2019 |
Female Androgenetic Alopecia: An Update on Diagnosis and Management.
Topics: Alopecia; Androgen Antagonists; Disease Progression; Female; Hair; Humans; Hyperandrogenism; Minoxid | 2020 |
Female Androgenetic Alopecia: An Update on Diagnosis and Management.
Topics: Alopecia; Androgen Antagonists; Disease Progression; Female; Hair; Humans; Hyperandrogenism; Minoxid | 2020 |
Female Androgenetic Alopecia: An Update on Diagnosis and Management.
Topics: Alopecia; Androgen Antagonists; Disease Progression; Female; Hair; Humans; Hyperandrogenism; Minoxid | 2020 |
Female Androgenetic Alopecia: An Update on Diagnosis and Management.
Topics: Alopecia; Androgen Antagonists; Disease Progression; Female; Hair; Humans; Hyperandrogenism; Minoxid | 2020 |
Novel drug delivery approaches for the management of hair loss.
Topics: Alopecia; Drug Delivery Systems; Humans; Minoxidil; Nanoparticles; Pharmaceutical Preparations | 2020 |
A review of the treatment of male pattern hair loss
Topics: Administration, Oral; Administration, Topical; Alopecia; Dry Needling; Finasteride; Hair; Humans; Lo | 2020 |
Androgenetic Alopecia in Gender Minority Patients.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgens; Dermatologic Agents; Estrogens; Finasteride; Hair | 2020 |
Low-level laser therapy and narrative review of other treatment modalities in androgenetic alopecia.
Topics: Alopecia; Androgen Antagonists; Hair; Humans; Low-Level Light Therapy; Minoxidil; Platelet-Rich Plas | 2020 |
The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis.
Topics: Alopecia; Finasteride; Hair; Humans; Minoxidil; Photography; Treatment Outcome | 2020 |
Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality.
Topics: Alopecia; Female; Finasteride; Humans; Male; Minoxidil; Network Meta-Analysis; Treatment Outcome | 2022 |
Systematic Review of Platelet-Rich Plasma Use in Androgenetic Alopecia Compared with Minoxidil
Topics: Adult Stem Cells; Alopecia; Combined Modality Therapy; Finasteride; Humans; Minoxidil; Platelet-Rich | 2020 |
Physiology and Medical Treatments for Alopecia.
Topics: Alopecia; Dihydrotestosterone; Dutasteride; Finasteride; Hair Preparations; Humans; Low-Level Light | 2020 |
Transdermal Drug Delivery for Hair Regrowth.
Topics: Acrylates; Administration, Cutaneous; Alopecia; Drug Carriers; Finasteride; Hair Follicle; Humans; J | 2021 |
The effectiveness of combination therapies for androgenetic alopecia: A systematic review and meta-analysis.
Topics: Alopecia; Female; Finasteride; Hair; Humans; Male; Minoxidil; Treatment Outcome | 2020 |
Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Female; Humans; Hypertrichosis; Male; Minoxidil; | 2020 |
Topical and oral minoxidil for hair disorders in pediatric patients: What do we know so far?
Topics: Administration, Topical; Adolescent; Adult; Alopecia; Child; Hair; Humans; Minoxidil; Vasodilator Ag | 2020 |
Oral minoxidil treatment for hair loss: A review of efficacy and safety.
Topics: Administration, Oral; Alopecia; Drug Administration Schedule; Humans; Medication Adherence; Minoxidi | 2021 |
Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data.
Topics: Alopecia; Humans; Hypertrichosis; Minoxidil; Treatment Outcome | 2020 |
Micro needling: A novel therapeutic approach for androgenetic alopecia, A Review of Literature.
Topics: Alopecia; Finasteride; Hair; Humans; Low-Level Light Therapy; Minoxidil | 2020 |
Systematic review of platelet-rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability.
Topics: Alopecia; Alopecia Areata; Hair; Humans; Injections; Minoxidil; Platelet-Rich Plasma; Treatment Outc | 2021 |
Therapeutic management in paediatric alopecia areata: A systematic review.
Topics: Adolescent; Alopecia; Alopecia Areata; Child; Humans; Janus Kinase Inhibitors; Leflunomide; Minoxidi | 2021 |
Diagnosis and Treatment of Nonscarring Hair Loss in Primary Care in 2021.
Topics: Alopecia; Alopecia Areata; Diagnosis, Differential; Female; Humans; Male; Minoxidil; Primary Health | 2021 |
Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose.
Topics: Alopecia; Alopecia Areata; Female; Humans; Male; Minoxidil; Monilethrix | 2021 |
Investigating the Safety and Efficacy of Platelet-Rich Plasma (PRP) Treatment for Female Androgenetic Alopecia: Review of the Literature.
Topics: Adult; Alopecia; Female; Humans; Male; Middle Aged; Minoxidil; Platelet-Rich Plasma; Quality of Life | 2021 |
Combination Approaches for Combatting Hair Loss.
Topics: Alopecia; Child; Female; Finasteride; Humans; Male; Middle Aged; Minoxidil | 2021 |
[Alopecia and cancers: From basics to clinical practice].
Topics: Alopecia; Antihypertensive Agents; Antineoplastic Agents; Bimatoprost; Hair; Hair Follicle; Humans; | 2021 |
Potential of nanoparticulate based delivery systems for effective management of alopecia.
Topics: Administration, Topical; Adult; Alopecia; Drug Delivery Systems; Hair; Humans; Minoxidil; Pharmaceut | 2021 |
The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.
Topics: Alopecia; Finasteride; Humans; Low-Level Light Therapy; Minoxidil; Randomized Controlled Trials as T | 2017 |
Hair Loss Myths.
Topics: Administration, Topical; Alopecia; Biological Products; Dermatologists; Dietary Supplements; Humans; | 2017 |
The use of minoxidil in the treatment of male and female androgenetic alopecia: a story of more than 30 years.
Topics: Administration, Topical; Alopecia; Chemistry, Pharmaceutical; Female; Hair; Hair Follicle; Humans; M | 2018 |
Pathogenesis and treatment options for chemotherapy-induced alopecia: a systematic review.
Topics: Alopecia; Animals; Antihypertensive Agents; Antineoplastic Agents; Bimatoprost; Cryotherapy; Hair Fo | 2018 |
Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Dutasteride; Finasteride; Humans; Low-Level Light Therapy; M | 2018 |
Minoxidil in the treatment of androgenetic alopecia.
Topics: Alopecia; Humans; Minoxidil; Vasodilator Agents | 2018 |
Off-Label Use of Topical Minoxidil in Alopecia: A Review.
Topics: Administration, Topical; Adult; Alopecia; Animals; Humans; Minoxidil; Off-Label Use; Treatment Outco | 2019 |
Frontal Fibrosing Alopecia: An Update on Pathogenesis, Diagnosis, and Treatment.
Topics: 5-alpha Reductase Inhibitors; Administration, Topical; Alopecia; Calcineurin Inhibitors; Chronic Dis | 2019 |
Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgen Antagonists; Female; Humans; Hyperandrogenism; Low- | 2019 |
The Efficacy of Topical Minoxidil for Non-Scarring Alopecia: A Systematic Review
Topics: Administration, Topical; Alopecia; Female; Humans; Male; Minoxidil; Treatment Outcome; Vasodilator A | 2019 |
Herbal Medicines For Treatment of Androgenic Alopecia.
Topics: Alopecia; Finasteride; Herbal Medicine; Humans; Minoxidil; Phytotherapy; Plants, Medicinal; Scalp | 2020 |
Hair restoration approaches for early onset male androgenetic alopecia.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Azasteroids; Cosmetic Techniques; Drug Therapy, Combination; | 2013 |
Nonsurgical therapy for hair loss.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Azasteroids; Combined Modality Therapy; Dutasteride; Female; | 2013 |
Androgenetic alopecia.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgen Antagonists; Biopsy; Comorbidity; Contraindications | 2014 |
Treatment for alopecia.
Topics: 5-alpha Reductase Inhibitors; Adrenal Cortex Hormones; Alopecia; Androgen Antagonists; Anti-Infectiv | 2014 |
Androgenetic alopecia: an evidence-based treatment update.
Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid | 2014 |
Androgenetic alopecia: an evidence-based treatment update.
Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid | 2014 |
Androgenetic alopecia: an evidence-based treatment update.
Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid | 2014 |
Androgenetic alopecia: an evidence-based treatment update.
Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid | 2014 |
Androgenetic alopecia: an evidence-based treatment update.
Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid | 2014 |
Androgenetic alopecia: an evidence-based treatment update.
Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid | 2014 |
Androgenetic alopecia: an evidence-based treatment update.
Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid | 2014 |
Androgenetic alopecia: an evidence-based treatment update.
Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid | 2014 |
Androgenetic alopecia: an evidence-based treatment update.
Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid | 2014 |
Hair loss in women.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgen Antagonists; Female; Finasteride; Flutamide; Hair; | 2015 |
Men's aesthetic dermatology.
Topics: Alopecia; Botulinum Toxins; Cosmetic Techniques; Dermal Fillers; Face; Female; Humans; Lipectomy; Ma | 2014 |
Normal and aging hair biology and structure 'aging and hair'.
Topics: 5-alpha Reductase Inhibitors; Aging; Alopecia; Finasteride; Hair; Hair Follicle; Humans; Melanocytes | 2015 |
Androgenetic, diffuse and senescent alopecia in men: practical evaluation and management.
Topics: 5-alpha Reductase Inhibitors; Administration, Cutaneous; Alopecia; Dutasteride; Finasteride; Hair; H | 2015 |
Female pattern hair loss.
Topics: 5-alpha Reductase Inhibitors; Administration, Cutaneous; Alopecia; Androgen Antagonists; Androgen Re | 2015 |
Hair loss in children.
Topics: Adrenal Cortex Hormones; Alopecia; Alopecia Areata; Child; Child, Preschool; Diagnosis, Differential | 2015 |
An update on the treatment of female alopecia and the introduction of a potential novel therapy.
Topics: Alopecia; Central Nervous System Stimulants; Dextroamphetamine; Female; Humans; Minoxidil; Randomize | 2015 |
Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis.
Topics: Acetylcholine Release Inhibitors; Acne Vulgaris; Algorithms; Alopecia; Anti-Bacterial Agents; Antipe | 2015 |
Interventions for female pattern hair loss.
Topics: Alopecia; Drug Administration Schedule; Female; Finasteride; Hair; Humans; Low-Level Light Therapy; | 2016 |
Multi-therapies in androgenetic alopecia: review and clinical experiences.
Topics: 5-alpha Reductase Inhibitors; Administration, Cutaneous; Administration, Oral; Alopecia; Finasteride | 2016 |
The Diagnosis and Treatment of Hair and Scalp Diseases.
Topics: Alopecia; Combined Modality Therapy; Dermatologic Agents; Diagnosis, Differential; Evidence-Based Me | 2016 |
Androgenetic Alopecia: An Update of Treatment Options.
Topics: Alopecia; Androgen Antagonists; Animals; Female; Finasteride; Humans; Male; Minoxidil | 2016 |
[Androgenetic alopecia: What's new in the last two years ?]
Topics: Alopecia; Early Diagnosis; Finasteride; France; Gene Expression Regulation; Genetic Association Stud | 2016 |
Hair transplantation for men.
Topics: Alopecia; Cicatrix; Cosmetic Techniques; Finasteride; Hair; Hair Follicle; Humans; Low-Level Light T | 2008 |
A review of hormonal therapy for female pattern (androgenic) alopecia.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgen Antagonists; Androgens; Cyproterone Acetate; Dermat | 2008 |
Medical treatments for male and female pattern hair loss.
Topics: Adult; Alopecia; Androgen Antagonists; Azasteroids; Drug Therapy, Combination; Dutasteride; Female; | 2008 |
Chemotherapy-induced alopecia.
Topics: Alopecia; Antineoplastic Agents; Cryotherapy; Hair Follicle; Humans; Minoxidil; Vasodilator Agents | 2009 |
Androgens and hair loss.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Administration, Cutaneous; Alop | 2009 |
Diagnosing and treating hair loss.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Diagnosis, Differential; Female; Hair; Humans; M | 2009 |
Hair loss in women.
Topics: Alopecia; Biotin; Contraceptives, Oral, Hormonal; Female; Finasteride; Gonadal Steroid Hormones; Hai | 2009 |
Hair restoration in the ethnic patient and review of hair transplant fundamentals.
Topics: Alopecia; Enzyme Inhibitors; Esthetics; Ethnicity; Finasteride; Hair; Hair Follicle; Humans; Minoxid | 2010 |
Male androgenetic alopecia.
Topics: Administration, Oral; Administration, Topical; Alopecia; Androgen Receptor Antagonists; Azasteroids; | 2010 |
Types of hair loss and treatment options, including the novel low-level light therapy and its proposed mechanism.
Topics: Alopecia; Androgens; Dermatologic Agents; Drugs, Investigational; Female; Finasteride; Humans; Male; | 2010 |
From surgery to pharmacology to gene therapy: the past, present, and future of hair restoration.
Topics: Alopecia; Female; Finasteride; Forecasting; Genetic Therapy; Hair; Hair Follicle; Humans; Male; Mino | 2010 |
Chemotherapy-induced alopecia.
Topics: Alopecia; Antineoplastic Agents; Female; Hair Follicle; Humans; Male; Minoxidil; Neoplasms; Scalp; V | 2010 |
Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgen Antagonists; Cosmetic Techniques; Female; Finasteri | 2011 |
Minoxidil use in dermatology, side effects and recent patents.
Topics: Administration, Topical; Alopecia; Animals; Antihypertensive Agents; Female; Hair; Humans; Male; Min | 2012 |
Interventions for female pattern hair loss.
Topics: Alopecia; Drug Administration Schedule; Female; Hair; Humans; Minoxidil; Randomized Controlled Trial | 2012 |
Promising therapies for treating and/or preventing androgenic alopecia.
Topics: Alopecia; Female; Finasteride; Hair; Humans; Laser Therapy; Male; Minoxidil; Sex Factors | 2012 |
Evidence-based treatments for female pattern hair loss: a summary of a Cochrane systematic review.
Topics: Alopecia; Databases, Factual; Evidence-Based Medicine; Female; Hair; Humans; Laser Therapy; Minoxidi | 2012 |
Hair: what is new in diagnosis and management? Female pattern hair loss update: diagnosis and treatment.
Topics: 14-alpha Demethylase Inhibitors; Alopecia; Androgen Antagonists; Female; Hair; Humans; Ketoconazole; | 2013 |
Pattern hair loss in men: diagnosis and medical treatment.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgens; Azasteroids; Dutasteride; Female; Finasteride; Ge | 2013 |
Female pattern hair loss.
Topics: Alopecia; Androgens; Female; Hair; Humans; Minoxidil | 2002 |
The potential role of minoxidil in the hair transplantation setting.
Topics: Administration, Oral; Administration, Topical; Alopecia; Combined Modality Therapy; Enzyme Inhibitor | 2002 |
Current and novel methods for assessing efficacy of hair growth promoters in pattern hair loss.
Topics: Alopecia; Female; Hair; Humans; Male; Minoxidil; Photography; Treatment Outcome | 2003 |
Androgenetic alopecia in adolescents.
Topics: Adolescent; Alopecia; Humans; Incidence; Minoxidil; Self Concept; Vasodilator Agents | 2003 |
Hypertrichosis in females applying minoxidil topical solution and in normal controls.
Topics: Administration, Cutaneous; Adult; Alopecia; Dose-Response Relationship, Drug; Facial Dermatoses; Fem | 2003 |
Common hair loss disorders.
Topics: Alopecia; Antifungal Agents; Diagnosis, Differential; Fluconazole; Humans; Hypotrichosis; Minoxidil; | 2003 |
Androgenetic alopecia in women.
Topics: Alopecia; Clinical Laboratory Techniques; Controlled Clinical Trials as Topic; Diagnosis, Differenti | 2003 |
[Androgenetic alopecia. Current aspects of a common phenotype].
Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Alopecia; Disease Progression; Enzyme Inhibitors; Female; | 2003 |
Androgenetic alopecia: pathogenesis and potential for therapy.
Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Alopecia; Dihydrotestosterone; Female; Finasteride; Genes | 2002 |
Minoxidil: mechanisms of action on hair growth.
Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair; | 2004 |
Minoxidil: mechanisms of action on hair growth.
Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair; | 2004 |
Minoxidil: mechanisms of action on hair growth.
Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair; | 2004 |
Minoxidil: mechanisms of action on hair growth.
Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair; | 2004 |
Minoxidil: mechanisms of action on hair growth.
Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair; | 2004 |
Minoxidil: mechanisms of action on hair growth.
Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair; | 2004 |
Minoxidil: mechanisms of action on hair growth.
Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair; | 2004 |
Minoxidil: mechanisms of action on hair growth.
Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair; | 2004 |
Minoxidil: mechanisms of action on hair growth.
Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair; | 2004 |
Minoxidil: mechanisms of action on hair growth.
Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair; | 2004 |
Minoxidil: mechanisms of action on hair growth.
Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair; | 2004 |
Minoxidil: mechanisms of action on hair growth.
Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair; | 2004 |
Minoxidil: mechanisms of action on hair growth.
Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair; | 2004 |
Minoxidil: mechanisms of action on hair growth.
Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair; | 2004 |
Minoxidil: mechanisms of action on hair growth.
Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair; | 2004 |
Minoxidil: mechanisms of action on hair growth.
Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair; | 2004 |
Hair loss remedies--separating fact from fiction.
Topics: Alopecia; Azasteroids; Dietary Supplements; Dutasteride; Enzyme Inhibitors; Female; Finasteride; Hum | 2004 |
Pharmacologic management of pattern hair loss.
Topics: Administration, Topical; Alopecia; Androgen Antagonists; Dose-Response Relationship, Drug; Drug Admi | 2004 |
[Pathomechanism of androgenetic alopecia and new treatment].
Topics: Alopecia; Androgens; Animals; Coculture Techniques; Finasteride; Hair Follicle; Humans; Insulin-Like | 2004 |
Androgenetic alopecia and current methods of treatment.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Enzyme Inhibitors; Female; Finasteride; Hair; Hair Follicle; | 2005 |
Psychological effect, pathophysiology, and management of androgenetic alopecia in men.
Topics: Alopecia; Finasteride; Hair; Humans; Male; Minoxidil | 2005 |
Rapqunzel no more. Hair loss in older women.
Topics: Age Factors; Aging; Alopecia; Diagnosis, Differential; Diet; Female; Hair; Hair Preparations; Humans | 2005 |
[The treatment of female pattern hair loss].
Topics: Administration, Oral; Administration, Topical; Adult; Age Distribution; Alopecia; Female; Finland; F | 2006 |
Androgenetic alopecia.
Topics: Alopecia; Androgens; Comorbidity; Finasteride; Humans; Male; Minoxidil; Models, Biological; Prevalen | 2007 |
Clinical practice. Hair loss in women.
Topics: Alopecia; Androgen Antagonists; Female; Hair; Humans; Middle Aged; Minoxidil; Practice Guidelines as | 2007 |
Female pattern hair loss: current treatment concepts.
Topics: Alopecia; Androgen Antagonists; Female; Hair Preparations; Humans; Minoxidil | 2007 |
[Hair follicle regeneration].
Topics: Alopecia; Animals; Cell- and Tissue-Based Therapy; Dermis; Finasteride; Hair; Hair Follicle; Humans; | 2008 |
Female androgenetic alopecia: an update.
Topics: Alopecia; Androgens; Cyproterone Acetate; Female; Humans; Minoxidil; Prognosis; Spironolactone | 1995 |
Status of medical treatment for androgenetic alopecia.
Topics: Alopecia; Female; Humans; Male; Minoxidil | 1993 |
Minoxidil. Update on its clinical role.
Topics: Alopecia; Alopecia Areata; Female; Humans; Male; Minoxidil | 1993 |
[The therapy of androgenetic alopecia with minoxidil].
Topics: Alopecia; Drug Evaluation; Female; Humans; Male; Minoxidil | 1993 |
[Current treatment of androgenetic male and female alopecia (with the exception of hormone treatment)].
Topics: Alopecia; Androgen Antagonists; Androgens; Female; Hair; Humans; Male; Minoxidil; Prognosis; Vitamin | 1997 |
[Male alopecia: etiopathogenic concepts and current therapies].
Topics: 5-alpha Reductase Inhibitors; Alopecia; Female; Finasteride; Humans; Inflammation; Male; Minoxidil; | 1997 |
Hair regrowth. Therapeutic agents.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Alopecia; Alopecia Areata; Androgen Antagon | 1998 |
[Androgenetic alopecia].
Topics: Alopecia; Enzyme Inhibitors; Finasteride; Humans; Male; Minoxidil; Treatment Outcome; Vasodilator Ag | 1997 |
Male pattern androgenetic alopecia.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Alopecia; Androgens; Antihypertens | 1998 |
Understanding and managing common baldness.
Topics: Alopecia; Androgen Antagonists; Cyproterone Acetate; Female; Finasteride; Hair; Humans; Incidence; M | 1999 |
Medical treatments for balding in men.
Topics: Alopecia; Finasteride; Hair; Humans; Male; Minoxidil; Patient Education as Topic; Severity of Illnes | 1999 |
Androgenetic alopecia.
Topics: Alopecia; Female; Finasteride; Humans; Male; Minoxidil | 1999 |
Management of androgenetic alopecia.
Topics: Alopecia; Androgen Antagonists; Female; Humans; Male; Minoxidil | 1999 |
Treatment of hair loss.
Topics: 5-alpha Reductase Inhibitors; Administration, Topical; Alopecia; Alopecia Areata; Anthralin; Anti-In | 1999 |
The psychosocial consequences of androgenetic alopecia: a review of the research literature.
Topics: Alopecia; Body Image; Culture; Enzyme Inhibitors; Female; Finasteride; Humans; Interpersonal Relatio | 1999 |
Current management of androgenetic alopecia in men.
Topics: Alopecia; Androgen Antagonists; Humans; Male; Minoxidil | 1999 |
Finasteride revisited: Proscar for the prostate and Propecia for the pate.
Topics: Adrenergic alpha-Antagonists; Alopecia; Enzyme Inhibitors; Finasteride; Humans; Male; Minoxidil; Pro | 2000 |
[Drug treatment of androgenetic alopecia in men].
Topics: Adult; Alopecia; Finasteride; Humans; Male; Minoxidil | 2000 |
Male pattern baldness.
Topics: 5-alpha Reductase Inhibitors; Administration, Cutaneous; Age of Onset; Alopecia; Coronary Disease; E | 2000 |
Medical management of male pattern hair loss.
Topics: Alopecia; Enzyme Inhibitors; Finasteride; Hair Follicle; Humans; Minoxidil | 2000 |
Treatments for androgenetic alopecia and alopecia areata: current options and future prospects.
Topics: Adrenal Cortex Hormones; Alopecia; Animals; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fi | 2001 |
Hair loss.
Topics: Adult; Alopecia; Child; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Finasteride; Hu | 2000 |
Management of male pattern hair loss.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Alopecia; Enzyme Inhibitors; Finasteride; H | 2001 |
Baldness. Medical solutions for men and women.
Topics: Alopecia; Enzyme Inhibitors; Female; Finasteride; Hair; Humans; Male; Minoxidil; Scalp; Sex Factors; | 2001 |
Androgenetic alopecia: overview.
Topics: Alopecia; Androgens; Enzyme Inhibitors; Female; Finasteride; Humans; Male; Minoxidil; Nonprescriptio | 1999 |
[Loss of hair].
Topics: Alopecia; Androgen Antagonists; Cyproterone Acetate; Enzyme Inhibitors; Female; Finasteride; Hair; H | 2000 |
Quantitative models for the study of hair growth in vivo.
Topics: Aging; Alopecia; Animals; Diazoxide; DNA Replication; Hair; Humans; Macaca; Minoxidil; Models, Biolo | 1991 |
Cosmetic modalities for aging skin: what to tell patients.
Topics: Aged; Alopecia; Collagen; Cryosurgery; Dermabrasion; Humans; Minoxidil; Skin Aging; Skin Diseases; T | 1990 |
Topical minoxidil does little for baldness.
Topics: Administration, Topical; Alopecia; Humans; Minoxidil | 1989 |
Topical minoxidil: review of efficacy and safety.
Topics: Administration, Topical; Alopecia; Antihypertensive Agents; Clinical Trials as Topic; Consumer Produ | 1989 |
Hair loss. What causes it and what can be done about it.
Topics: Adult; Age Factors; Alopecia; Contraceptives, Oral; Dihydrotestosterone; Female; Hair; Humans; Male; | 1989 |
[Minoxidil. Objectivity and criticism].
Topics: Alopecia; Cell Differentiation; Cells, Cultured; Hair; Humans; Keratinocytes; Minoxidil; Skin; Vasod | 1989 |
[New therapeutic aspects in non-cicatricial alopecias].
Topics: Alopecia; Alopecia Areata; Androgen Antagonists; Autoimmune Diseases; Humans; Minoxidil | 1988 |
[The tractiophototrichogram, an objective method for evaluating hair loss].
Topics: Alopecia; Hair; Humans; Male; Minoxidil; Photography | 1988 |
[Topical minoxidil in the treatment of alopecia].
Topics: Administration, Topical; Alopecia; Alopecia Areata; Humans; Minoxidil | 1988 |
Topical minoxidil therapy for hair regrowth.
Topics: Administration, Cutaneous; Alopecia; Animals; Clinical Trials as Topic; Humans; Male; Minoxidil; Ski | 1987 |
Hair follicle biology and topical minoxidil: possible mechanisms of action.
Topics: Administration, Cutaneous; Alopecia; Female; Hair; Humans; Male; Minoxidil | 1987 |
Topical minoxidil in the treatment of male pattern alopecia.
Topics: Administration, Topical; Alopecia; Humans; Male; Minoxidil | 1987 |
Topical minoxidil. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in alopecia areata and alopecia androgenetica.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Humans; Minoxidil | 1987 |
Topically applied minoxidil in baldness.
Topics: Administration, Topical; Alopecia; Animals; Biopsy; Double-Blind Method; Drug Evaluation; Drug Evalu | 1985 |
125 trials available for minoxidil and Alopecia
| Article | Year |
|---|---|
A randomized clinical trial on therapeutic effects of 0.25 mg oral minoxidil tablets on treatment of female pattern hair loss.
Topics: Administration, Topical; Alopecia; Double-Blind Method; Female; Hair; Humans; Minoxidil; Tablets | 2021 |
Clinical observation of basic fibroblast growth factor (bFGF) combined with minoxidil in the treatment of male androgenetic alopecia.
Topics: Alopecia; Fibroblast Growth Factor 2; Finasteride; Humans; Male; Minoxidil; Treatment Outcome | 2022 |
Randomized clinical trial of low-dose oral minoxidil for the treatment of female pattern hair loss: 0.25 mg versus 1 mg.
Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Treatment Outcome | 2022 |
Comparison between "5% minoxidil plus 2% flutamide" solution vs. "5% minoxidil" solution in the treatment of androgenetic alopecia.
Topics: Administration, Topical; Alopecia; Finasteride; Flutamide; Humans; Minoxidil; Treatment Outcome | 2022 |
Efficacy of a mixed preparation containing piperine, capsaicin and curcumin in the treatment of alopecia areata.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Capsaicin; Curcumin; Humans; Minoxidil | 2022 |
Microneedling plus topical dutasteride solution for androgenetic alopecia: a randomized placebo-controlled study.
Topics: Administration, Topical; Alopecia; Double-Blind Method; Dutasteride; Finasteride; Humans; Minoxidil; | 2022 |
A study of combination unilateral subcutaneous botulinum toxin a treatment for androgenetic alopecia.
Topics: Alopecia; Botulinum Toxins, Type A; Finasteride; Humans; Minoxidil; Treatment Outcome | 2022 |
Comparative study between topical methotrexate 1% gel and minoxidil 5% gel in the treatment of localized alopecia areata.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Gels; Humans; Methotrexate; Minoxidil; Treatment | 2022 |
Topical cetirizine for treating androgenetic alopecia: A systematic review.
Topics: Administration, Topical; Alopecia; Cetirizine; Hair; Humans; Minoxidil; Treatment Outcome | 2022 |
Randomized trial of microneedling combined with 2% minoxidil topical solution for the treatment of female pattern hair loss in a Chinese population.
Topics: Administration, Topical; Alopecia; East Asian People; Female; Hair; Humans; Minoxidil; Treatment Out | 2022 |
Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial.
Topics: Administration, Topical; Adult; Alopecia; Alopecia Areata; Betamethasone; Double-Blind Method; Femal | 2022 |
Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Topical; Alopecia; Cetirizine; Drug-Related Side Effects and Adverse Reactions; Fema | 2023 |
EVALUATION OF THE EFFECT OF TOPICALLY APPLIED METHYLSULFONYLMETHANE AND THEIR COMBINATION WITH MINOXIDIL SOLUTION FOR IMPROVEMENT OF HAIR GROWTH IN MALE MICE.
Topics: Alopecia; Animals; Male; Mice; Minoxidil; Vascular Endothelial Growth Factor A | 2022 |
Efficacy of autologous platelet-rich plasma therapy versus topical Minoxidil in men with moderate androgenetic alopecia: a randomized open-label trial.
Topics: Alopecia; Hair; Humans; Male; Minoxidil; Platelet-Rich Plasma; Treatment Outcome | 2023 |
Evaluation of platelet-rich plasma plus basic fibroblast growth factor combined with minoxidil in the treatment of androgenetic alopecia: A randomized controlled trial.
Topics: Alopecia; Fibroblast Growth Factor 2; Humans; Minoxidil; Platelet-Rich Plasma; Prospective Studies; | 2023 |
Injections of platelet-rich plasma prepared by automatic blood cell separator combined with topical 5% minoxidil in the treatment of male androgenetic alopecia.
Topics: Alopecia; Blood Cells; Hair; Humans; Male; Minoxidil; Platelet-Rich Plasma; Treatment Outcome | 2023 |
Topical 5% minoxidil versus combined erbium YAG laser and topical 5% minoxidil in androgenetic alopecia: A randomized controlled trial.
Topics: Administration, Cutaneous; Administration, Topical; Alopecia; Humans; Lasers, Solid-State; Male; Min | 2023 |
Combination of adipose-derived stem cell conditioned media and minoxidil for hair regrowth in male androgenetic alopecia: a randomized, double-blind clinical trial.
Topics: Adipocytes; Alopecia; Culture Media, Conditioned; Drug-Related Side Effects and Adverse Reactions; H | 2023 |
A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia.
Topics: Alopecia; Hair; Humans; Male; Minoxidil; Platelet-Rich Plasma | 2023 |
Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation.
Topics: Administration, Topical; Adult; Alopecia; Double-Blind Method; Hair; Humans; Male; Minoxidil; Patien | 2021 |
Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Alopecia; Dermatologic Age | 2020 |
A Randomized, Controlled Pilot Trial Comparing Platelet-Rich Plasma to Topical Minoxidil Foam for Treatment of Androgenic Alopecia in Women.
Topics: Administration, Topical; Adult; Aerosols; Alopecia; Cross-Over Studies; Double-Blind Method; Female; | 2020 |
Placebo-controlled dose-effect studies with topical minoxidil 2% or 5% in male-patterned hair loss treated with oral finasteride employing an analytical and exhaustive study protocol.
Topics: Administration, Topical; Alopecia; Finasteride; Hair; Humans; Male; Minoxidil; Scalp; Treatment Outc | 2020 |
Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway.
Topics: Administration, Topical; Alopecia; China; Hair; Humans; Male; Minoxidil; Treatment Outcome; Wnt Sign | 2022 |
Propylene glycol free 5% minoxidil lotion formulation: cosmetic acceptability, local tolerability, clinical efficacy and in-vitro skin absorption evaluations.
Topics: Administration, Topical; Alopecia; Female; Humans; Male; Middle Aged; Minoxidil; Propylene Glycol; P | 2020 |
Efficacy of intradermal minoxidil 5% injections for treatment of patchy non-severe alopecia areata.
Topics: Alopecia; Alopecia Areata; Humans; Injections, Intradermal; Minoxidil; Prospective Studies; Triamcin | 2022 |
Comparative Evaluation of the Clinical Efficacy of PRP-Therapy, Minoxidil, and Their Combination with Immunohistochemical Study of the Dynamics of Cell Proliferation in the Treatment of Men with Androgenetic Alopecia.
Topics: Adult; Alopecia; Biopsy; Cell Count; Cell Proliferation; Combined Modality Therapy; Hair; Hair Folli | 2020 |
Efficacy and safety of a novel herbal solution for the treatment of androgenetic alopecia and comparison with 5% minoxidil: A double-blind, randomized controlled trial study.
Topics: Administration, Topical; Adult; Alopecia; Double-Blind Method; Herbal Medicine; Humans; Iran; Male; | 2020 |
Combination therapy with topical minoxidil and nano-microneedle-assisted fibroblast growth factor for male androgenetic alopecia: a randomized controlled trial in Chinese patients.
Topics: Administration, Topical; Alopecia; China; Double-Blind Method; Fibroblast Growth Factors; Hair; Huma | 2020 |
Intradermal injections with 0.5% minoxidil for the treatment of female androgenetic alopecia: A randomized, placebo-controlled trial.
Topics: Administration, Topical; Alopecia; Double-Blind Method; Female; Hair; Humans; Injections, Intraderma | 2021 |
A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study.
Topics: Administration, Topical; Alopecia; Drug Therapy, Combination; Hair; Humans; Minoxidil; Scalp; Spiron | 2021 |
Pumpkin seed oil vs. minoxidil 5% topical foam for the treatment of female pattern hair loss: A randomized comparative trial.
Topics: Alopecia; Cucurbita; Female; Hair; Humans; Minoxidil; Plant Oils | 2021 |
Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study.
Topics: Administration, Topical; Adult; Alopecia; Cetirizine; Histamine Antagonists; Humans; Male; Minoxidil | 2021 |
Efficacy of Minoxidil Combined With Photobiomodulation for the Treatment of Male Androgenetic Alopecia. A Double-Blind Half-Head Controlled Trial.
Topics: Alopecia; Double-Blind Method; Hair; Humans; Male; Minoxidil; Scalp; Treatment Outcome | 2021 |
SULT1A1 (Minoxidil Sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth.
Topics: Administration, Topical; Alopecia; Arylsulfotransferase; Hair; Humans; Male; Minoxidil; Sulfotransfe | 2022 |
Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double-blind, placebo-controlled, phase 1B clinical trial.
Topics: Alopecia; Double-Blind Method; Female; Hair; Humans; Male; Minoxidil; Treatment Outcome | 2022 |
Low level light-minoxidil 5% combination versus either therapeutic modality alone in management of female patterned hair loss: A randomized controlled study.
Topics: Adult; Alopecia; Combined Modality Therapy; Female; Humans; Low-Level Light Therapy; Microscopy, Aco | 2017 |
Platelet-Rich Plasma in Combination With 5% Minoxidil Topical Solution and 1 mg Oral Finasteride for the Treatment of Androgenetic Alopecia: A Randomized Placebo-Controlled, Double-Blind, Half-Head Study.
Topics: Administration, Topical; Alopecia; Angiogenesis Inducing Agents; Double-Blind Method; Drug Therapy, | 2018 |
An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia.
Topics: Administration, Topical; Adult; Alopecia; Caffeine; Humans; Male; Middle Aged; Minoxidil; Treatment | 2017 |
The clinical effect of JetpPeel-assisted topical minoxidil in the treatment of androgenetic alopecia: A randomized pilot study.
Topics: Administration, Cutaneous; Adult; Alopecia; Drug Delivery Systems; Hair; Humans; Male; Middle Aged; | 2018 |
A Comparative Study between the Efficacy and Safety of 5% Minoxidil Solution and 5% Minoxidil Milky Lotion in the Treatment of Male Androgenic Alopecia.
Topics: Administration, Topical; Adult; Aged; Alopecia; Butylene Glycols; Emollients; Humans; Male; Middle A | 2017 |
A pilot split-scalp study of combined fractional radiofrequency microneedling and 5% topical minoxidil in treating male pattern hair loss.
Topics: Administration, Topical; Adult; Alopecia; Combined Modality Therapy; Cosmetic Techniques; Humans; Ma | 2018 |
A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.
Topics: 5-alpha Reductase Inhibitors; Administration, Cutaneous; Adult; Alopecia; Dihydrotestosterone; Doubl | 2018 |
Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study.
Topics: 5-alpha Reductase Inhibitors; Administration, Oral; Administration, Topical; Aged; Alopecia; Dihydro | 2019 |
A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia.
Topics: Administration, Cutaneous; Administration, Topical; Adult; Alopecia; Combined Modality Therapy; Glas | 2019 |
Comparing the Efficacy of Mesotherapy to Topical Minoxidil in the Treatment of Female Pattern Hair Loss Using Ultrasound Biomicroscopy: A Randomized Controlled Trial.
Topics: Administration, Topical; Adult; Alopecia; Female; Humans; Mesotherapy; Microscopy, Acoustic; Middle | 2019 |
Preparation and evaluation of a multimodal minoxidil microemulsion versus minoxidil alone in the treatment of androgenic alopecia of mixed etiology: a pilot study.
Topics: Adolescent; Adult; Alopecia; Antihypertensive Agents; Double-Blind Method; Drug Stability; Emulsions | 2013 |
Comparison of the efficacy of topical minoxidil 5% and adenosine 0.75% solutions on male androgenetic alopecia and measuring patient satisfaction rate.
Topics: Adenosine; Alopecia; Humans; Minoxidil; Patient Satisfaction; Prospective Studies; Vasodilator Agent | 2013 |
Similar response patterns to topical minoxidil foam 5% in frontal and vertex scalp of men with androgenetic alopecia: a microarray analysis.
Topics: Administration, Cutaneous; Adolescent; Adult; Alopecia; Controlled Before-After Studies; Dermatologi | 2015 |
A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men.
Topics: Administration, Cutaneous; Adult; Aged; Alopecia; Double-Blind Method; Hair; Humans; Male; Middle Ag | 2015 |
Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104-week open-label clinical trial.
Topics: Administration, Topical; Alopecia; Double-Blind Method; Humans; Male; Minoxidil; Placebos | 2016 |
Efficacy and safety of 5% minoxidil topical foam in male pattern hair loss treatment and patient satisfaction.
Topics: Administration, Topical; Adult; Alopecia; Humans; Male; Middle Aged; Minoxidil; Patient Satisfaction | 2016 |
Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men.
Topics: Adult; Alopecia; Asian People; Double-Blind Method; Hair; Humans; Japan; Male; Middle Aged; Minoxidi | 2009 |
A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women.
Topics: Adult; Aged; Alopecia; Drug Administration Schedule; Female; Humans; Middle Aged; Minoxidil; Pharmac | 2011 |
Curcuma aeruginosa, a novel botanically derived 5α-reductase inhibitor in the treatment of male-pattern baldness: a multicenter, randomized, double-blind, placebo-controlled study.
Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Curcuma; Double-Blind Method; Drug Therapy, Combinati | 2012 |
[Efficacy and tolerability of 5% minoxidil solution (Carexidil®) in male and female androgenetic alopecia: a 6-month open multicentric study].
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Alopecia; Dermatologic Agents; Dermoscopy; Drug | 2011 |
Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study.
Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Double-Blind Method; Drug Therapy, Combination; Finas | 2012 |
Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study.
Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Double-Blind Method; Drug Therapy, Combination; Finas | 2012 |
Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study.
Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Double-Blind Method; Drug Therapy, Combination; Finas | 2012 |
Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study.
Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Double-Blind Method; Drug Therapy, Combination; Finas | 2012 |
A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.
Topics: Administration, Topical; Adolescent; Adult; Alopecia; Double-Blind Method; Drug Tolerance; Humans; M | 2002 |
Comparative efficacy of various treatment regimens for androgenetic alopecia in men.
Topics: 5-alpha Reductase Inhibitors; Administration, Oral; Administration, Topical; Adolescent; Adult; Alop | 2002 |
[Effect of minoxidil on hair growth in androgenic alopecia in women].
Topics: Administration, Cutaneous; Adult; Alopecia; Female; Hair; Humans; Middle Aged; Minoxidil; Time Facto | 2002 |
The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial.
Topics: Adolescent; Adult; Alopecia; Analysis of Variance; Drug Therapy, Combination; Fiber Optic Technology | 2003 |
A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.
Topics: Administration, Topical; Adolescent; Adult; Alopecia; Double-Blind Method; Female; Hair; Humans; Mid | 2004 |
An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Alopecia; Analysis of Variance; Do | 2004 |
Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women.
Topics: Administration, Topical; Alopecia; Drug Eruptions; Estradiol; Female; Germany; Hair; Humans; Middle | 2007 |
[Effectiveness of the treatment plan for androgenetic alopecia].
Topics: Adolescent; Adult; Alopecia; Antifungal Agents; Chronic Disease; Enzyme Inhibitors; Female; Finaster | 2007 |
A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.
Topics: Administration, Topical; Adult; Alopecia; Double-Blind Method; Hair; Humans; Male; Middle Aged; Mino | 2007 |
Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial.
Topics: Administration, Topical; Adult; Alopecia; Dermatologic Agents; Double-Blind Method; Drug Therapy, Co | 2007 |
Is topical minoxidil solution effective on androgenetic alopecia in routine daily practice?
Topics: Administration, Topical; Adult; Alopecia; Dermatologic Agents; Humans; Male; Minoxidil; Patient Drop | 2007 |
Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies.
Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia; Estradiol; Estrogen Antagonists; Female; | 2008 |
Minoxidil stimulates cutaneous blood flow in human balding scalps: pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography.
Topics: Administration, Topical; Adult; Aged; Alopecia; Blood Flow Velocity; Clinical Trials as Topic; Doubl | 1984 |
Topical minoxidil for hair regrowth.
Topics: Administration, Topical; Adolescent; Adult; Alopecia; Alopecia Areata; Androgens; Clinical Trials as | 1984 |
Minoxidil (Mx) as a prophylaxis of doxorubicin--induced alopecia.
Topics: Adult; Aged; Alopecia; Double-Blind Method; Doxorubicin; Female; Humans; Middle Aged; Minoxidil; Neo | 1994 |
Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation.
Topics: Administration, Cutaneous; Adult; Aged; Alopecia; Antibodies, Monoclonal; Antigens, CD; CD4 Antigens | 1993 |
Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution.
Topics: Administration, Topical; Adolescent; Adult; Alopecia; Double-Blind Method; Female; Humans; Middle Ag | 1994 |
Use of topical minoxidil therapy for androgenetic alopecia in women.
Topics: Administration, Cutaneous; Adolescent; Adult; Age Factors; Alopecia; Dermatitis, Contact; Double-Bli | 1993 |
Topical minoxidil therapy for androgenic alopecia in the Middle East. The Middle-Eastern Topical Minoxidil Study Group.
Topics: Administration, Cutaneous; Adult; Age Factors; Alopecia; Hair; Humans; Male; Middle Aged; Middle Eas | 1993 |
A randomized trial of minoxidil in chemotherapy-induced alopecia.
Topics: Administration, Cutaneous; Adult; Alopecia; Antibiotics, Antineoplastic; Antimetabolites, Antineopla | 1996 |
Propecia and Rogaine Extra Strength for alopecia.
Topics: 5-alpha Reductase Inhibitors; Adolescent; Adult; Alopecia; Clinical Trials as Topic; Drug Costs; Enz | 1998 |
Ketoconazole shampoo: effect of long-term use in androgenic alopecia.
Topics: Adult; Alopecia; Analysis of Variance; Antifungal Agents; Drug Therapy, Combination; Hair; Hair Prep | 1998 |
Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment.
Topics: Administration, Topical; Adolescent; Adult; Alopecia; Double-Blind Method; Hair; Humans; Male; Minox | 1999 |
Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial.
Topics: Administration, Topical; Adult; Alopecia; Androgen Antagonists; Body Mass Index; Contraceptives, Ora | 2002 |
Treatment of female androgenetic alopecia with minoxidil 2%.
Topics: Administration, Topical; Adult; Alopecia; Double-Blind Method; Female; Humans; Minoxidil; Scalp | 1992 |
Contact dermatitis in reaction to 2% topical minoxidil solution.
Topics: Administration, Topical; Adult; Alopecia; Dermatitis, Contact; Double-Blind Method; Drug Eruptions; | 1991 |
Psychologic characteristics of men with alopecia androgenetica and their modification.
Topics: Adolescent; Adult; Alopecia; Attitude; Humans; Interpersonal Relations; Male; Middle Aged; Minoxidil | 1991 |
Australian trial of topical minoxidil and placebo in early male pattern baldness.
Topics: Administration, Cutaneous; Adolescent; Adult; Alopecia; Australia; Double-Blind Method; Humans; Male | 1990 |
[Efficacy and cardiovascular tolerability of minotricon in the treatment of seborrheic alopecia].
Topics: Adolescent; Adult; Alopecia; Dermatitis, Seborrheic; Drug Tolerance; Female; Humans; Male; Middle Ag | 1990 |
Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil.
Topics: Administration, Cutaneous; Adult; Alopecia; Drug Administration Schedule; Follow-Up Studies; Humans; | 1990 |
[A critical review of the results of clinical experimentation with topical minoxidil 2%].
Topics: Administration, Topical; Adult; Alopecia; Double-Blind Method; Humans; Male; Middle Aged; Minoxidil; | 1990 |
Quantitative estimation of hair growth. I. androgenetic alopecia in women: effect of minoxidil.
Topics: Adolescent; Adult; Alopecia; Double-Blind Method; Female; Hair; Humans; Middle Aged; Minoxidil | 1990 |
Relationship between contact time of applied dose and percutaneous absorption of minoxidil from a topical solution.
Topics: Administration, Topical; Adult; Alopecia; Chromatography, High Pressure Liquid; Humans; Male; Middle | 1990 |
[It is difficult to predict the effect of minoxidil liniment on hair loss in men].
Topics: Alopecia; Drug Evaluation; Humans; Liniments; Male; Minoxidil; Randomized Controlled Trials as Topic | 1990 |
Does topical minoxidil increase skin blood flow? A laser Doppler flowmetry study.
Topics: Administration, Cutaneous; Adult; Alopecia; Female; Humans; Lasers; Male; Middle Aged; Minoxidil; Re | 1988 |
Topical minoxidil: review of efficacy and safety.
Topics: Administration, Topical; Alopecia; Antihypertensive Agents; Clinical Trials as Topic; Consumer Produ | 1989 |
Why men with hair loss go to the doctor.
Topics: Alopecia; Clinical Trials as Topic; Humans; Male; Minoxidil; Referral and Consultation | 1989 |
[Minoxidil: no hope for bald people].
Topics: Alopecia; Double-Blind Method; Humans; Minoxidil; Multicenter Studies as Topic | 1989 |
Quantitative assessment of 2% topical minoxidil in the treatment of male pattern baldness.
Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Double-Blind Method; Humans; Mal | 1989 |
Topical minoxidil sensitization in androgenic alopecia.
Topics: Administration, Topical; Alopecia; Clinical Trials as Topic; Double-Blind Method; Drug Eruptions; Hu | 1987 |
[Minoxidil--a hope for patients with androgen alopecia?].
Topics: Adolescent; Adult; Alopecia; Androgens; Clinical Trials as Topic; Humans; Male; Middle Aged; Minoxid | 1988 |
Topical minoxidil: cardiac effects in bald man.
Topics: Administration, Topical; Adolescent; Adult; Alopecia; Blood Pressure; Double-Blind Method; Heart; He | 1988 |
Effect of ultraviolet light on topical minoxidil-induced hair growth in advanced male pattern baldness.
Topics: Adult; Alopecia; Chronic Disease; Clinical Trials as Topic; Combined Modality Therapy; Humans; Male; | 1987 |
Topical minoxidil in male pattern baldness: effects of discontinuation of treatment.
Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Dose-Response Relationship, Drug | 1987 |
Topical minoxidil for baldness.
Topics: Administration, Cutaneous; Alopecia; Alopecia Areata; Clinical Trials as Topic; Humans; Male; Minoxi | 1987 |
Topical minoxidil therapy for hair regrowth.
Topics: Administration, Cutaneous; Alopecia; Animals; Clinical Trials as Topic; Humans; Male; Minoxidil; Ski | 1987 |
Topical minoxidil therapy for androgenetic alopecia. A 30-month study.
Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Double-Blind Method; Hair; Human | 1987 |
2% topical minoxidil solution in male-pattern baldness: preliminary European results.
Topics: Administration, Cutaneous; Adult; Alopecia; Clinical Trials as Topic; Dermatitis, Contact; Double-Bl | 1987 |
Comparable efficacy of 2% minoxidil gel and solution formulations in the treatment of male pattern alopecia.
Topics: Adolescent; Adult; Alopecia; Double-Blind Method; Drug Administration Schedule; Gels; Humans; Male; | 1988 |
Topical minoxidil for male pattern baldness.
Topics: Adult; Alopecia; Clinical Trials as Topic; Double-Blind Method; Female; Hair; Humans; Male; Middle A | 1986 |
Androgenetic alopecia treated with topical minoxidil.
Topics: Administration, Topical; Alopecia; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mino | 1987 |
Dose-response study of topical minoxidil in male pattern alopecia.
Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Dose-Response Relationship, Drug | 1987 |
Safety and efficacy of topical minoxidil in the management of androgenetic alopecia.
Topics: Administration, Topical; Adult; Alopecia; Blood Pressure; Clinical Trials as Topic; Double-Blind Met | 1987 |
Long-term follow-up of men with male pattern baldness treated with topical minoxidil.
Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Drug Administration Schedule; Fo | 1987 |
Androgenetic alopecia: treatment results with topical minoxidil.
Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Double-Blind Method; Humans; Mal | 1987 |
Use of topical minoxidil in the treatment of male pattern baldness.
Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Double-Blind Method; Humans; Mal | 1987 |
Long-term efficacy of topical minoxidil in male pattern baldness.
Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Double-Blind Method; Humans; Mal | 1987 |
Topical minoxidil in early androgenetic alopecia.
Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Double-Blind Method; Humans; Mal | 1987 |
Deaths occurring during clinical studies of topical minoxidil.
Topics: Administration, Topical; Adult; Aged; Alopecia; Clinical Trials as Topic; Female; Humans; Male; Midd | 1987 |
Topical minoxidil therapy for hereditary male pattern alopecia.
Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia; Clinical Trials as Topic; Follow-Up Stud | 1987 |
Topical minoxidil for androgenetic alopecia: optimizing the chance for success by appropriate patient selection.
Topics: Administration, Cutaneous; Alopecia; Double-Blind Method; Humans; Male; Minoxidil | 1987 |
Topical minoxidil in the treatment of alopecia areata and male-pattern alopecia.
Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia; Alopecia Areata; Child; Female; Humans; | 1986 |
Dose-response study of topical minoxidil in male pattern baldness.
Topics: Adult; Alopecia; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Humans; | 1986 |
Topical tretinoin for hair growth promotion.
Topics: Administration, Topical; Adult; Alopecia; Drug Combinations; Female; Hair; Humans; Male; Middle Aged | 1986 |
Topical minoxidil therapy in hereditary androgenetic alopecia.
Topics: Administration, Topical; Alopecia; Clinical Trials as Topic; Double-Blind Method; Hair; Humans; Male | 1985 |
Topical minoxidil in early male pattern baldness.
Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Double-Blind Method; Humans; Mal | 1985 |
The effect of topical minoxidil on blood pressure.
Topics: Administration, Topical; Adult; Alopecia; Blood Pressure; Clinical Trials as Topic; Double-Blind Met | 1985 |
Topical minoxidil dose-response effect in alopecia areata.
Topics: Administration, Topical; Adolescent; Adult; Alopecia; Child; Dose-Response Relationship, Drug; Femal | 1986 |
357 other studies available for minoxidil and Alopecia
| Article | Year |
|---|---|
Thyroid receptor agonists for the treatment of androgenetic alopecia.
Topics: Administration, Topical; Alopecia; Animals; BALB 3T3 Cells; Hair; Humans; Macaca; Mice; Neutral Red; | 2010 |
Low-dose oral minoxidil increases hair density and thickness in androgenetic alopecia: a retrospective analysis of 60 patients.
Topics: Alopecia; Hair; Humans; Minoxidil; Retrospective Studies; Treatment Outcome | 2022 |
Minoxidil-induced hypertrichosis in a breastfed infant.
Topics: Alopecia; Breast Feeding; Female; Humans; Hypertension; Hypertrichosis; Infant; Minoxidil | 2022 |
Bicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss: A retrospective review of 35 patients.
Topics: Administration, Topical; Alopecia; Anilides; Female; Humans; Hypertrichosis; Minoxidil; Nitriles; Re | 2022 |
Systemic minoxidil as maintenance treatment in alopecia areata: a retrospective case series of 24 patients.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Hair; Humans; Immunotherapy; Minoxidil; Retrospe | 2022 |
Frontal edema due to mesotherapy for androgenetic alopecia: A case series.
Topics: Alopecia; Edema; Female; Finasteride; Humans; Male; Mesotherapy; Minoxidil; Retrospective Studies; T | 2022 |
Effect of minoxidil formulations on human scalp skin xenotransplants on SCID mice: A novel pre-clinical in vivo assay for androgenetic alopecia research.
Topics: Administration, Topical; Alopecia; Animals; Hair; Humans; Mice; Mice, SCID; Minoxidil; Scalp; Treatm | 2022 |
Treatment with oral vitamin D alone, topical minoxidil, or combination of both in patients with female pattern hair loss: A comparative clinical and dermoscopic study.
Topics: Alopecia; Female; Hair; Humans; Minoxidil; Treatment Outcome; Vitamin D | 2022 |
Comparative histological and immunohistochemical study on the effect of platelet rich plasma/minoxidil, alone or in combination, on hair growth in a rat model of androgenic alopecia.
Topics: Alopecia; Animals; Hair Follicle; Humans; Male; Minoxidil; Platelet-Rich Plasma; Rats; Treatment Out | 2022 |
Preparation of topical bimatoprost with enhanced skin infiltration and
Topics: Administration, Topical; Alopecia; Animals; Antioxidants; Bimatoprost; Cell Proliferation; Dose-Resp | 2022 |
Topical minoxidil-induced paresthesia.
Topics: Administration, Topical; Alopecia; Double-Blind Method; Hair; Humans; Minoxidil; Paresthesia | 2022 |
Hair Are the Rankings-5-α Reductase Inhibitors and Minoxidil in Male Androgenetic Alopecia.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Hair; Humans; Male; Minoxidil | 2022 |
Nanostructured lipid carriers loaded with an association of minoxidil and latanoprost for targeted topical therapy of alopecia.
Topics: Administration, Topical; Alopecia; Animals; Drug Delivery Systems; Hair Follicle; Humans; Latanopros | 2022 |
Minoxidil-loaded hyaluronic acid dissolving microneedles to alleviate hair loss in an alopecia animal model.
Topics: Alopecia; Animals; Antineoplastic Agents; Disease Models, Animal; Hyaluronic Acid; Mice; Minoxidil | 2022 |
Oral minoxidil use in androgenetic alopecia and telogen effluvium.
Topics: Adult; Aged; Alopecia; Alopecia Areata; Female; Humans; Male; Middle Aged; Minoxidil; Retrospective | 2023 |
Dutasteride intralesional microinjections in combination with oral minoxidil vs. oral minoxidil monotherapy in men with androgenetic alopecia: a retrospective analysis of 105 patients.
Topics: Alopecia; Dutasteride; Humans; Male; Microinjections; Minoxidil; Retrospective Studies; Treatment Ou | 2022 |
Reply to: "Comment on: Bicalutamide Improves Minoxidil-Induced Hypertrichosis in Female Pattern Hair Loss: A Retrospective Review of 35 Patients".
Topics: Administration, Topical; Alopecia; Anilides; Female; Humans; Hypertrichosis; Minoxidil; Nitriles; Re | 2022 |
Comment on "Bicalutamide Improves Minoxidil-Induced Hypertrichosis in Female Pattern Hair Loss: A Retrospective Review of 35 Patients".
Topics: Alopecia; Anilides; Female; Humans; Hypertrichosis; Minoxidil; Nitriles; Retrospective Studies; Tosy | 2022 |
Unusual clinical presentation of allergic contact dermatitis to topical minoxidil.
Topics: Administration, Topical; Alopecia; Dermatitis, Allergic Contact; Humans; Minoxidil; Patch Tests | 2022 |
Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study.
Topics: Alopecia; Alopecia Areata; Child; Humans; Minoxidil | 2022 |
Morning Periorbital Edema Related to Low-Dose Oral Minoxidil.
Topics: Alopecia; Angioedema; Edema; Humans; Minoxidil | 2023 |
Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia.
Topics: Administration, Topical; Alopecia; Blood Pressure Monitoring, Ambulatory; Humans; Male; Minoxidil; P | 2023 |
Comparing combination low-dose oral minoxidil and topical minoxidil with oral minoxidil alone for the treatment of non-scarring alopecia: A retrospective chart review.
Topics: Administration, Topical; Alopecia; Humans; Minoxidil; Retrospective Studies; Treatment Outcome; Vaso | 2022 |
Treatment of hereditary hypotrichosis simplex of the scalp with oral minoxidil and growth factors.
Topics: Alopecia; Humans; Hypotrichosis; Intercellular Signaling Peptides and Proteins; Minoxidil; Scalp | 2022 |
Safety and tolerability of low-dose oral minoxidil in adolescents: A retrospective review.
Topics: Administration, Oral; Adolescent; Alopecia; Humans; Minoxidil; Retrospective Studies | 2023 |
A Drug-Free, Hair Follicle Cycling Regulatable, Separable, Antibacterial Microneedle Patch for Hair Regeneration Therapy.
Topics: Alopecia; Animals; Anti-Bacterial Agents; Cells, Cultured; Chitosan; Hair; Hair Follicle; Hyaluronic | 2022 |
Effects of microneedling with 5% minoxidil topical solution combination therapy in treatment of androgenetic alopecia.
Topics: Administration, Topical; Alopecia; Combined Modality Therapy; Hair; Humans; Minoxidil; Retrospective | 2022 |
Conditioned media-integrated microneedles for hair regeneration through perifollicular angiogenesis.
Topics: Alopecia; Animals; Culture Media, Conditioned; Hair; Hair Follicle; Mice; Minoxidil; Neovascularizat | 2022 |
Systemic minoxidil for hair disorders in pediatric patients: a safety and tolerability review.
Topics: Administration, Topical; Adult; Alopecia; Child; Child, Preschool; Hair; Humans; Infant; Infant, New | 2023 |
Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil.
Topics: Administration, Topical; Alopecia; Blood Pressure Monitoring, Ambulatory; Controlled Before-After St | 2022 |
Low-dose oral minoxidil in female patients with lichen planopilaris: Real-life experience.
Topics: Alopecia; Female; Humans; Lichen Planus; Minoxidil | 2023 |
Active Antialopecia Chemical Identification of
Topics: Alopecia; Animals; Convolvulaceae; Humans; Minoxidil; Molecular Docking Simulation; Molecular Dynami | 2022 |
Dermoscopic evaluation of the efficacy of combination of topical spironolactone 5% and minoxidil 5% solutions in the treatment of androgenetic alopecia: A cross sectional-comparative study.
Topics: Administration, Topical; Alopecia; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Mal | 2022 |
Rare Concurrence of Alopecia Areata in the Setting of the Lipedematous Scalp.
Topics: Alopecia; Alopecia Areata; Glycyrrhizic Acid; Humans; Lipedema; Minoxidil; Scalp; Vitamin D | 2022 |
Evaluation of efficacy of derma roller sizes vs topical application for administration of QR678 Neo® hair regrowth formulation in the treatment of androgenetic alopecia.
Topics: Administration, Topical; Alopecia; Hair; Humans; Minoxidil; Treatment Outcome | 2022 |
What's New in Therapy for Male Androgenetic Alopecia?
Topics: Alopecia; Dutasteride; Finasteride; Humans; Male; Minoxidil; Retrospective Studies; Treatment Outcom | 2023 |
In Vitro and In Vivo Scalp Retention and Penetration of 99mTc-Minoxidil Solution.
Topics: Administration, Topical; Alopecia; Excipients; Humans; Minoxidil; Propylene Glycol; Scalp; Skin; Ski | 2023 |
A Survey of Patient Attitudes Towards Topical Minoxidil in the Treatment of Hair Loss.
Topics: Alopecia; Attitude; Dihydrotestosterone; Female; Humans; Male; Minoxidil; Scalp; Treatment Outcome | 2022 |
Digital health platforms expand access and improve care for male androgenetic alopecia.
Topics: Alopecia; Finasteride; Hair; Humans; Male; Minoxidil; Treatment Outcome | 2023 |
Machine Learning Guided Discovery of Superoxide Dismutase Nanozymes for Androgenetic Alopecia.
Topics: Alopecia; Hair; Humans; Machine Learning; Minoxidil; Superoxide Dismutase | 2022 |
Evaluating the Efficacy of Platelet Rich Plasma and 1550 nm Fractional Laser in Combination and Alone for the Management of Androgenetic Alopecia.
Topics: Alopecia; Female; Finasteride; Humans; Lasers, Solid-State; Male; Minoxidil; Platelet-Rich Plasma; T | 2022 |
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation | 2023 |
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation | 2023 |
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation | 2023 |
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation | 2023 |
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation | 2023 |
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation | 2023 |
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation | 2023 |
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation | 2023 |
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation | 2023 |
Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study.
Topics: Administration, Topical; Alopecia; Breast Neoplasms; Female; Humans; Minoxidil; Patients; Retrospect | 2023 |
Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study.
Topics: Administration, Topical; Alopecia; Breast Neoplasms; Female; Humans; Minoxidil; Patients; Retrospect | 2023 |
Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study.
Topics: Administration, Topical; Alopecia; Breast Neoplasms; Female; Humans; Minoxidil; Patients; Retrospect | 2023 |
Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study.
Topics: Administration, Topical; Alopecia; Breast Neoplasms; Female; Humans; Minoxidil; Patients; Retrospect | 2023 |
PROTAC Degraders of Androgen Receptor-Integrated Dissolving Microneedles for Androgenetic Alopecia and Recrudescence Treatment via Single Topical Administration.
Topics: Administration, Topical; Adolescent; Alopecia; Androgens; Humans; Minoxidil; Proteolysis Targeting C | 2023 |
In Brief: Oral minoxidil for hair loss.
Topics: Administration, Topical; Alopecia; Humans; Minoxidil; Treatment Outcome | 2022 |
Allergic Contact Dermatitis Due to Minoxidil in a Patient with Alopecia Areata.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Dermatitis, Allergic Contact; Humans; Minoxidil; | 2022 |
Regrowth of hair in congenital triangular alopecia induced by sublingual minoxidil.
Topics: Administration, Topical; Alopecia; Genetic Diseases, X-Linked; Hair; Humans; Minoxidil | 2023 |
Effects of oral minoxidil on nails: a cross-sectional analysis.
Topics: Alopecia; Cross-Sectional Studies; Humans; Minoxidil; Nails | 2023 |
Hair regrowth boosting via minoxidil cubosomes: Formulation development, in vivo hair regrowth evaluation, histopathological examination and confocal laser microscopy imaging.
Topics: Alopecia; Hair; Humans; Microscopy, Confocal; Minoxidil; Skin | 2023 |
Low-dose oral minoxidil improves hair density in traction alopecia.
Topics: Administration, Topical; Alopecia; Hair; Humans; Minoxidil; Traction; Treatment Outcome | 2023 |
Topical Minoxidil Adherence in Patients With Alopecia.
Topics: Alopecia; Humans; Minoxidil; Patient Compliance; Social Group | 2023 |
A case of aromatase inhibitor-induced alopecia successfully treated with low-dose oral minoxidil.
Topics: Administration, Topical; Alopecia; Aromatase Inhibitors; Humans; Minoxidil; Treatment Outcome | 2023 |
Dissolving Microneedle Patch Integrated with Microspheres for Long-Acting Hair Regrowth Therapy.
Topics: Administration, Topical; Alopecia; Animals; Female; Hair; Mice; Microspheres; Minoxidil; Treatment O | 2023 |
Could oral minoxidil be superior to its topical variant for treatment of female pattern hair loss?
Topics: Alopecia; Female; Humans; Minoxidil; Vasodilator Agents | 2023 |
Boosting hair growth through follicular delivery of Melatonin through lecithin-enhanced Pickering emulsion stabilized by chitosan-dextran nanoparticles in testosterone induced androgenic alopecia rat model.
Topics: Alopecia; Animals; Antioxidants; Chitosan; Dextrans; Emulsions; Hair; Lecithins; Melatonin; Minoxidi | 2023 |
Changes in Minoxidil Prescribing After Media Attention About Oral Use for Hair Loss.
Topics: Administration, Oral; Alopecia; Humans; Minoxidil | 2023 |
The medicinal activity of lyophilized aqueous seed extract of Lepidium sativum L. in an androgenic alopecia model.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Animals; Chromatography, Liquid; Hair; Lepidium sativum; Min | 2023 |
Minoxidil and vitamin E therapy for nail growth disorders: A retrospective study.
Topics: Alopecia; Distance Counseling; Humans; Minoxidil; Nail Diseases; Nails; Retrospective Studies; Vitam | 2023 |
Real-World, Open-Label Study of the Efficacy and Safety of a Novel Serum in Androgenetic Alopecia.
Topics: Alopecia; Drug Administration Schedule; Female; Finasteride; Humans; Male; Minoxidil; Treatment Outc | 2023 |
RF - Bicalutamide: An Emergent Treatment Option in Trichology.
Topics: Administration, Topical; Alopecia; Humans; Minoxidil; Treatment Outcome | 2023 |
Intradermal Delivery of Alopecia Therapeutics: Current State and Future Prospects.
Topics: Alopecia; Drug-Related Side Effects and Adverse Reactions; Dutasteride; Humans; Mesotherapy; Minoxid | 2023 |
Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic alopecia.
Topics: Alopecia; Alopecia Areata; Hair; Humans; Minoxidil; Quality of Life | 2023 |
Retrospective review of oral and topical minoxidil for cancer treatment-induced hair loss.
Topics: Administration, Topical; Alopecia; Hair; Humans; Minoxidil; Neoplasms; Retrospective Studies; Treatm | 2023 |
Sensitive Quantitative In Vivo Assay for Evaluating the Effects of Biomolecules on Hair Growth and Coloring Using Direct Microinjections into Mouse Whisker Follicles.
Topics: Alopecia; Animals; Hair; Mice; Microinjections; Minoxidil; Vibrissae | 2023 |
Fabrication of carboxymethyl cellulose/hyaluronic acid/polyvinylpyrrolidone composite pastes incorporation of minoxidil-loaded ferulic acid-derived lignin nanoparticles and valproic acid for treatment of androgenetic alopecia.
Topics: Alopecia; Animals; Carboxymethylcellulose Sodium; Hyaluronic Acid; Lignin; Mice; Minoxidil; Nanopart | 2023 |
Investigation of oral finasteride enhanced occipital hair diameter index in different types of male androgenetic alopecia.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Finasteride; Hair; Humans; Male; Minoxidil | 2023 |
New Target for Minoxidil in the Treatment of Androgenetic Alopecia.
Topics: Alopecia; Dietary Supplements; Estradiol; Humans; Minoxidil; Molecular Docking Simulation | 2023 |
Co-delivery of minoxidil and tocopherol acetate ethosomes to reshape the hair Follicular Microenvironment and promote hair regeneration in androgenetic alopecia.
Topics: Alopecia; alpha-Tocopherol; Animals; Hair; Mice; Minoxidil; Regeneration; Treatment Outcome | 2023 |
Vellus-to-terminal Hair Follicle Reconversion Occurs in Male Pattern Balding and is Promoted by Minoxidil and Platelet-rich Plasma: In Vivo Evidence from a New Humanized Mouse Model of Androgenetic Alopecia.
Topics: Alopecia; Animals; Hair; Hair Follicle; Male; Mice; Minoxidil; Platelet-Rich Plasma; Treatment Outco | 2023 |
Inverse androgenic alopecia.
Topics: Alopecia; Androgen Antagonists; Finasteride; Humans; Male; Minoxidil; Treatment Outcome | 2023 |
Low dose oral minoxidil and the conundrum of cardiovascular complications.
Topics: Administration, Topical; Alopecia; Antihypertensive Agents; Hair; Humans; Hypertrichosis; Minoxidil | 2023 |
Increased prescriptions of oral minoxidil after a high-profile newspaper article about its benefits for hair loss.
Topics: Administration, Topical; Alopecia; Hair; Humans; Minoxidil; Treatment Outcome | 2023 |
Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients.
Topics: Administration, Cutaneous; Alopecia; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Humans; Mi | 2023 |
Successful use of topical minoxidil in the treatment of hypotrichosis associated with desmoplakin mutations.
Topics: Administration, Topical; Alopecia; Child; Dermatologic Agents; Desmoplakins; Genetic Diseases, X-Lin | 2019 |
Oral minoxidil bio-activation by hair follicle outer root sheath cell sulfotransferase enzymes predicts clinical efficacy in female pattern hair loss.
Topics: Administration, Oral; Alopecia; Female; Hair Follicle; Humans; Minoxidil; Sulfotransferases | 2020 |
Combination tofacitinib and oral minoxidil treatment for severe alopecia areata.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Humans; Minoxidil; Piperidines; Pyrimidines | 2021 |
Reply to: "Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation".
Topics: Alopecia; Documentation; Finasteride; Humans; Male; Minoxidil | 2020 |
Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation.
Topics: Alopecia; Documentation; Finasteride; Humans; Male; Minoxidil | 2020 |
Alopecia universalis treated with simvastatin/ezetimibe, minoxidil, and prednisolone in a 6-year-old girl.
Topics: Alopecia; Child; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Female; Humans; | 2020 |
Exploring the potential of minoxidil tretinoin liposomal based hydrogel for topical delivery in the treatment of androgenic alopecia.
Topics: Administration, Topical; Alopecia; Animals; Biological Transport; Drug Therapy, Combination; Hydroge | 2020 |
Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil treatment in Brazilian female pattern hair loss patients.
Topics: Administration, Topical; Adult; Aged; Alopecia; Brazil; Female; Hair Follicle; Humans; Middle Aged; | 2020 |
Efficacy and Influence Factors of 308-nm Excimer Lamp with Minoxidil in the Treatment of Alopecia Areata.
Topics: Alopecia; Alopecia Areata; Female; Hair; Humans; Lasers, Excimer; Male; Minoxidil; Prospective Studi | 2020 |
[XANTHOTRICHIA (YELLOWING OF THE HAIR) DUE TO MINOXIDIL TREATMENT].
Topics: Administration, Topical; Alopecia; Color; Hair; Humans; Minoxidil | 2020 |
Severity of androgenetic alopecia associated with poor sleeping habits and carnivorous eating and junk food consumption-A web-based investigation of male pattern hair loss in China.
Topics: Alopecia; China; Humans; Internet; Male; Minoxidil; Sleep | 2020 |
Colored Polymeric Nanofiber Loaded with Minoxidil Sulphate as Beauty Coverage and Restoring Hair Loss.
Topics: Alopecia; Drug Carriers; Drug Liberation; Humans; Minoxidil; Nanofibers; Polymers | 2020 |
Effective combination therapy with high concentration of Minoxidil and Carboxygas in resistant Androgenetic alopecia: Report of nine cases.
Topics: Adult; Alopecia; Female; Hair; Hair Follicle; Humans; Male; Middle Aged; Minoxidil | 2020 |
Rapid response of topical minoxidil in congenital triangular alopecia.
Topics: Administration, Topical; Alopecia; Ectodermal Dysplasia; Genetic Diseases, X-Linked; Humans; Minoxid | 2020 |
How safe is prescribing oral minoxidil in patients allergic to topical minoxidil?
Topics: Administration, Topical; Alopecia; Humans; Hypersensitivity; Minoxidil | 2022 |
Oral minoxidil improves background hair thickness in lichen planopilaris.
Topics: Administration, Oral; Adult; Aged; Alopecia; Female; Hair; Humans; Hypertrichosis; Hypotension, Orth | 2021 |
The hydroxypropyl-β-cyclodextrin-minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Topical; Alopecia; Animals; Blood Pressure; Elect | 2020 |
Treatment of male and female pattern hair loss with sublingual minoxidil: a retrospective case-series of 64 patients.
Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Male; Minoxidil; Research; Retrospective St | 2020 |
Novel topical booster enhances follicular sulfotransferase activity in patients with androgenetic alopecia: a new strategy to improve minoxidil response.
Topics: Administration, Topical; Alopecia; Hair Follicle; Humans; Minoxidil; Sulfotransferases | 2020 |
Direct acting oral anticoagulants and alopecia: to go further with data mining in pharmacovigilance databases.
Topics: Administration, Oral; Alopecia; Anticoagulants; Dabigatran; Data Mining; Databases, Factual; Humans; | 2020 |
Efficacy and safety of very-low-dose oral minoxidil 1.25 mg in male androgenetic alopecia.
Topics: Administration, Oral; Adolescent; Adult; Alopecia; Humans; Male; Middle Aged; Minoxidil; Treatment O | 2020 |
The Utilization of YouTube as a Resource on Hair Loss Treatments.
Topics: Alopecia; Female; Humans; Male; Minoxidil; Pharmaceutical Preparations; Social Media; Video Recordin | 2020 |
Favorable effects of microneedling on long-standing androgenetic alopecia in an elderly man: A case report.
Topics: Aged; Alopecia; Erythema; Hair; Humans; Male; Minoxidil; Scalp; Treatment Outcome | 2021 |
Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report.
Topics: Administration, Oral; Adult; Alopecia; Central Serous Chorioretinopathy; Coloring Agents; Eplerenone | 2020 |
Usefulness of home-use microneedle devices in the treatment of pattern hair loss.
Topics: Administration, Topical; Alopecia; Analysis of Variance; Hair; Humans; Minoxidil; Needles | 2021 |
Minoxidil Sulfotransferase Enzyme (SULT1A1) genetic variants predicts response to oral minoxidil treatment for female pattern hair loss.
Topics: Administration, Oral; Alopecia; Arylsulfotransferase; Female; Humans; Minoxidil; Sulfotransferases; | 2021 |
Contact dermatitis to minoxidil.
Topics: Adult; Alopecia; Dermatitis, Allergic Contact; Dermatologic Agents; Humans; Male; Minoxidil; Patch T | 2021 |
Frontal Fibrosing Alopecia Presenting as Androgenetic Alopecia in an African American Woman.
Topics: Administration, Cutaneous; Alopecia; Diagnosis, Differential; Female; Forehead; Humans; Lichen Planu | 2020 |
Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer.
Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia; Central Nervous System Neoplasms; Child; | 2020 |
Microneedling and Platelet-Rich Plasma versus Microneedling and 5% Topical Minoxidil Therapy in Male Pattern Hair Loss.
Topics: Administration, Topical; Adult; Alopecia; Combined Modality Therapy; Cosmetic Techniques; Humans; Ma | 2020 |
Severe hypertrichosis in infants due to transdermic exposure to 5% and 7% topical minoxidil.
Topics: Administration, Cutaneous; Administration, Topical; Alopecia; Humans; Hypertrichosis; Infant; Minoxi | 2020 |
Novel "After Minoxidil" spray improves topical minoxidil compliance and hair style manageability.
Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Patient Compliance | 2020 |
Efficacy and safety of oral minoxidil in female androgenetic alopecia.
Topics: Adolescent; Adult; Aged; Alopecia; Double-Blind Method; Female; Hair; Humans; Middle Aged; Minoxidil | 2020 |
Microneedling in androgenetic alopecia; comparing two different depths of microneedles.
Topics: Adolescent; Adult; Alopecia; Hair; Humans; Middle Aged; Minoxidil; Young Adult | 2021 |
Characterization and management of hypertrichosis induced by low-dose oral minoxidil in the treatment of hair loss.
Topics: Adolescent; Adult; Aged; Alopecia; Antihypertensive Agents; Female; Hair Removal; Humans; Hypertrich | 2021 |
Evaluation of the effect of autologous platelet-rich plasma on androgenic alopecia.
Topics: Adolescent; Adult; Alopecia; Finasteride; Hair; Humans; Minoxidil; Platelet-Rich Plasma; Treatment O | 2020 |
Comparison of low-level light therapy and combination therapy of 5% minoxidil in the treatment of female pattern hair loss.
Topics: Adult; Alopecia; Combined Modality Therapy; Female; Humans; Low-Level Light Therapy; Male; Middle Ag | 2021 |
[Central serous chorioretinopathy associated with minoxidil 2].
Topics: Adult; Alopecia; Central Serous Chorioretinopathy; Humans; Male; Minoxidil; Retinal Detachment; With | 2020 |
Efficacy of systemic minoxidil and tofacitinib combination in treatment-resistant alopecia universalis.
Topics: Alopecia; Alopecia Areata; Humans; Minoxidil; Piperidines; Pyrimidines; Pyrroles | 2021 |
Low-dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series.
Topics: Administration, Oral; Adult; Alopecia; Canada; Dose-Response Relationship, Drug; Female; Follow-Up S | 2021 |
Low-Level Laser Therapy for Androgenetic Alopecia.
Topics: Alopecia; Humans; Low-Level Light Therapy; Minoxidil | 2021 |
Adverse effects of low-dose oral minoxidil for androgenetic alopecia in 435 patients.
Topics: Adult; Alopecia; Body Weight; Dermatologic Agents; Headache; Humans; Hypertrichosis; Male; Minoxidil | 2021 |
HIF-1α Stimulators Function Equally to Leading Hair Loss Agents in Enhancing Dermal Papilla Growth.
Topics: Alopecia; Cells, Cultured; Deferiprone; Deferoxamine; Dermis; Hair Follicle; Humans; Hypoxia-Inducib | 2020 |
Combination oral minoxidil and spironolactone for the treatment of androgenetic alopecia in adolescent girls.
Topics: Administration, Oral; Adolescent; Alopecia; Dermoscopy; Drug Therapy, Combination; Female; Hair Foll | 2021 |
Side effects of low-dose oral minoxidil for treating alopecia.
Topics: Administration, Oral; Alopecia; Drug-Related Side Effects and Adverse Reactions; Humans; Minoxidil | 2021 |
Comment on "Low dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series": Adding further evidence about side effects.
Topics: Alopecia; Humans; Minoxidil; North America; Retrospective Studies; Treatment Outcome | 2021 |
Therapeutic implications of topical cetirizine 1% in treatment of male androgenetic alopecia: A case-controlled study.
Topics: Administration, Topical; Adult; Alopecia; Cetirizine; Hair; Humans; Male; Middle Aged; Minoxidil; Yo | 2021 |
Coming full circle (almost): Low dose oral minoxidil for alopecia.
Topics: Alopecia; Humans; Minoxidil | 2021 |
[A new treatment for androgenetic alopecia : platelet-rich plasma injections].
Topics: Alopecia; Female; Humans; Male; Minoxidil; Platelet-Rich Plasma; Scalp; Treatment Outcome | 2021 |
Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Child; Dizziness; Edema; | 2021 |
Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Child; Dizziness; Edema; | 2021 |
Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Child; Dizziness; Edema; | 2021 |
Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Child; Dizziness; Edema; | 2021 |
The effect of hyperbaric oxygen therapy combined with hair transplantation surgery for the treatment of alopecia.
Topics: Alopecia; Humans; Hyperbaric Oxygenation; Minoxidil | 2022 |
"Comparison of QR 678
Topics: Alopecia; Combined Modality Therapy; Finasteride; Hair; Humans; Male; Minoxidil | 2021 |
Low-Level Light Therapy Downregulates Scalp Inflammatory Biomarkers in Men With Androgenetic Alopecia and Boosts Minoxidil 2% to Bring a Sustainable Hair Regrowth Activity.
Topics: Alopecia; Biomarkers; Humans; Low-Level Light Therapy; Male; MicroRNAs; Minoxidil; Scalp; Treatment | 2021 |
Significant hair regrowth in a Middle Eastern woman with central centrifugal cicatricial alopecia.
Topics: Adult; Alopecia; Anilides; Female; Hair; Humans; Minoxidil; Nitriles; Remission Induction; Tosyl Com | 2022 |
Ceria Nanozyme-Integrated Microneedles Reshape the Perifollicular Microenvironment for Androgenetic Alopecia Treatment.
Topics: Alopecia; Animals; Hair; Hair Follicle; Mice; Minoxidil; Reactive Oxygen Species | 2021 |
Bitemporal hair loss related to traction alopecia.
Topics: Alopecia; Female; Humans; Minoxidil; Traction; Vasodilator Agents; Young Adult | 2016 |
Reversible Alopecia with Localized Scalp Necrosis After Accidental Embolization of the Parietal Artery with Hyaluronic Acid.
Topics: Adult; Alopecia; Arterial Occlusive Diseases; Arteries; Biopsy, Needle; Cosmetic Techniques; Dermal | 2017 |
Minoxidil is a potential neuroprotective drug for paclitaxel-induced peripheral neuropathy.
Topics: Alopecia; Animals; Antineoplastic Agents, Phytogenic; Calcium; Cell Line, Tumor; Disease Models, Ani | 2017 |
A Retrospective Review of Treatment Results for Patients With Central Centrifugal Cicatrical Alopecia.
Topics: Administration, Topical; Adult; Alopecia; Biopsy; Black or African American; Black People; Cicatrix; | 2017 |
Association Between Gender and Drug Cost for Over-the-Counter Minoxidil.
Topics: Alopecia; Drug Costs; Female; Humans; Male; Minoxidil; Nonprescription Drugs; Retrospective Studies; | 2017 |
An analysis of gene expression data involving examination of signaling pathways activation reveals new insights into the mechanism of action of minoxidil topical foam in men with androgenetic alopecia.
Topics: Administration, Topical; Adolescent; Adult; Alopecia; Gene Expression Profiling; Gene Expression Reg | 2017 |
Androgenic alopecia: an entity to consider in adolescence.
Topics: Adolescent; Alopecia; Contraceptives, Oral, Hormonal; Female; Humans; Mineralocorticoid Receptor Ant | 2017 |
Preparation and in vivo evaluation of lecithin-based microparticles for topical delivery of minoxidil.
Topics: Administration, Cutaneous; Alopecia; Animals; Drug Carriers; Drug Delivery Systems; Female; Hair; Hu | 2017 |
Topical cetirizine 1% for treatment of androgenetic alopecia.
Topics: Administration, Topical; Alopecia; Cetirizine; Hair; Humans; Minoxidil | 2017 |
Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction.
Topics: Administration, Topical; Alopecia; Animals; Hair; Janus Kinase 3; Male; Mice; Mice, Inbred C57BL; Mi | 2017 |
Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Drug Therapy, Combination; Dutasteride; Evidence-Based Medic | 2018 |
Alginate-Based Hydrogel Containing Minoxidil/Hydroxypropyl-β-Cyclodextrin Inclusion Complex for Topical Alopecia Treatment.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Cutaneous; Administration, Topical; Alginates; Al | 2018 |
Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Diuretics; Drug Combinat | 2018 |
Minoxidil-encapsulated poly(L-lactide-co-glycolide) nanoparticles with hair follicle delivery properties prepared using W/O/W solvent evaporation and sonication.
Topics: Administration, Cutaneous; Alopecia; Animals; Drug Carriers; Drug Delivery Systems; Drug Liberation; | 2018 |
Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bre | 2018 |
Minoxidil for Endocrine Therapy-Induced Alopecia in Women With Breast Cancer-Saint Agatha's Blessing?
Topics: Alopecia; Breast; Breast Neoplasms; Female; Humans; Minoxidil | 2018 |
Bibbidi bobbidi bald: Two "hairowing" tales of Princess Package hairstyles.
Topics: Alopecia; Child, Preschool; Cicatrix; Female; Glucaric Acid; Hair; Humans; Minoxidil; Scalp; United | 2018 |
Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version.
Topics: Adenosine; Administration, Oral; Administration, Topical; Alopecia; Dutasteride; Female; Finasteride | 2018 |
Folliculitis decalvans: Effectiveness of therapies and prognostic factors in a multicenter series of 60 patients with long-term follow-up.
Topics: Adrenal Cortex Hormones; Alopecia; Anti-Bacterial Agents; Cicatrix; Cohort Studies; Combined Modalit | 2018 |
Platelet rich plasma for the management of hair loss: Better alone or in combination?
Topics: Alopecia; Cell- and Tissue-Based Therapy; Combined Modality Therapy; Finasteride; Hair Follicle; Hum | 2019 |
Female pattern hair loss.
Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Androgen Receptor Antagonists; Female; Humans; Minoxi | 2018 |
Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients.
Topics: Administration, Cutaneous; Adult; Alopecia; Aspirin; Drug Interactions; Enzyme Inhibitors; Hair Foll | 2018 |
Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C's of oral therapy.
Topics: Administration, Oral; Adult; Aged; Alopecia; Cost Savings; Drug Costs; Drug Therapy, Combination; Fe | 2018 |
Controversies in the treatment of androgenetic alopecia: The history of finasteride.
Topics: 5-alpha Reductase Inhibitors; Administration, Oral; Administration, Topical; Alopecia; Finasteride; | 2019 |
Anterior, frontal congenital triangular alopecia, redundancy in therapy without improvement.
Topics: Administration, Cutaneous; Alopecia; Biopsy; Drug Administration Schedule; Female; Genetic Diseases, | 2018 |
Characterization of follicular minoxidil sulfotransferase activity in a cohort of pattern hair loss patients from the Indian Subcontinent.
Topics: Adolescent; Adult; Alopecia; Biomarkers; Cross-Sectional Studies; Female; Hair; Humans; India; Male; | 2018 |
Over-the-Counter Hair Loss Treatments: Help or Hype?
Topics: Alopecia; Consumer Behavior; Humans; Minoxidil; Nonprescription Drugs; Phytotherapy; United States; | 2018 |
Immune checkpoint inhibitor-related alopecia: Insight into the pathophysiology utilizing non-invasive diagnostic techniques.
Topics: Administration, Topical; Aged; Alopecia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2019 |
Severe Bitemporal Alopecia As a Complication of the Thread Lift Procedure.
Topics: Alopecia; Female; Humans; Middle Aged; Minoxidil; Postoperative Complications; Rhytidoplasty; Vasodi | 2019 |
Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow.
Topics: Administration, Topical; Adult; Alopecia; Female; Humans; Male; Middle Aged; Minoxidil; Vasodilator | 2019 |
Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents | 2019 |
Laser-assisted drug delivery for the treatment of androgenetic alopecia: ablative laser fractional photothermolysis to enhance cutaneous topical delivery of platelet-rich plasma - with or without concurrent bimatoprost and/or minoxidil.
Topics: Administration, Cutaneous; Alopecia; Bimatoprost; Combined Modality Therapy; Drug Delivery Systems; | 2019 |
Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes.
Topics: Administration, Topical; Adult; Alopecia; Female; Gene Expression Regulation, Enzymologic; Humans; M | 2019 |
Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia.
Topics: Administration, Oral; Adult; Alopecia; Humans; Male; Middle Aged; Minoxidil; Retrospective Studies; | 2019 |
Excellent response to mesotherapy as adjunctive treatment in male androgenetic alopecia.
Topics: Administration, Oral; Administration, Topical; Alopecia; Combined Modality Therapy; Finasteride; Hum | 2020 |
RF - Oral Minoxidil for Female Pattern Hair Loss and Other Alopecias.
Topics: Administration, Oral; Alopecia; Humans; Minoxidil | 2019 |
Filler-induced alopecia.
Topics: Administration, Topical; Alopecia; Cosmetic Techniques; Dermal Fillers; Drug Therapy, Combination; F | 2019 |
Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil.
Topics: Administration, Topical; Adult; Alopecia; Alopecia Areata; Child; Combined Modality Therapy; Female; | 2019 |
Iontophoresis-targeted, follicular delivery of minoxidil sulfate for the treatment of alopecia.
Topics: Administration, Cutaneous; Alopecia; Animals; Drug Delivery Systems; Hair Follicle; Iontophoresis; M | 2013 |
Topical minoxidil treatment for congenital alopecia in hypohidrotic ectodermal dysplasia.
Topics: Administration, Topical; Alopecia; Child, Preschool; Ectodermal Dysplasia 1, Anhidrotic; Genetic Dis | 2013 |
Hair loss: it's not just for men. With most hair-loss therapies targeted to men, where can women turn for help?
Topics: Alopecia; Depression; Female; Hair; Health Knowledge, Attitudes, Practice; Humans; Male; Minoxidil; | 2013 |
The efficacy of 3% minoxidil vs. combined 3% minoxidil and Korean red ginseng in treating female pattern alopecia.
Topics: Administration, Oral; Administration, Topical; Alopecia; Cohort Studies; Drug Therapy, Combination; | 2014 |
Lipid nanoparticles for topical and transdermal application for alopecia treatment: development, physicochemical characterization, and in vitro release and penetration studies.
Topics: Administration, Topical; Alopecia; Animals; Delayed-Action Preparations; Dermatologic Agents; Drug D | 2014 |
New ethanol and propylene glycol free gel formulations containing a minoxidil-methyl-β-cyclodextrin complex as promising tools for alopecia treatment.
Topics: Alopecia; Animals; beta-Cyclodextrins; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical | 2015 |
Male frontal fibrosing alopecia with generalised hair loss.
Topics: Aged; Alopecia; Anti-Inflammatory Agents; Axilla; Dermatologic Agents; Extremities; Eyebrows; Fibros | 2014 |
Medicolegal aspects of prescribing dermatological medications in pregnancy.
Topics: Acne Vulgaris; Alopecia; Dermatitis, Atopic; Dermatologic Agents; Dermatology; Female; Fetal Disease | 2013 |
Minoxidil induced hypertrichosis in children.
Topics: Administration, Topical; Alopecia; Child, Preschool; Female; Humans; Hypertrichosis; Minoxidil | 2014 |
In vivo hair growth promotion effects of ultra-high molecular weight poly-γ-glutamic acid from Bacillus subtilis (Chungkookjang).
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Alopecia; Animals; Bacillus sub | 2015 |
Generalized Hypertrichosis Due to Topical Minoxidil.
Topics: Administration, Cutaneous; Adult; Alopecia; Clobetasol; Drug Combinations; Female; Humans; Hypertric | 2015 |
Potential synergistic effects of human placental extract and minoxidil on hair growth-promoting activity in C57BL/6J mice.
Topics: Alopecia; Analysis of Variance; Animals; beta Catenin; Cell Proliferation; Dermis; Drug Synergism; F | 2015 |
Anti-PDGF receptor β antibody-conjugated squarticles loaded with minoxidil for alopecia treatment by targeting hair follicles and dermal papilla cells.
Topics: Alopecia; Animals; Antibodies; Calorimetry, Differential Scanning; Hair Follicle; Mice; Mice, Nude; | 2015 |
Increasing utility of finasteride for frontal fibrosing alopecia.
Topics: Administration, Topical; Adrenal Cortex Hormones; Alopecia; Dose-Response Relationship, Drug; Drug A | 2015 |
A hairy fall: syncope resulting from topical application of minoxidil.
Topics: Administration, Topical; Adult; Alopecia; Antihypertensive Agents; Hair; Humans; Male; Minoxidil; Sy | 2015 |
[Drug treatment of alopecia].
Topics: Administration, Topical; Adrenal Cortex Hormones; Alopecia; Anti-Bacterial Agents; Cyclopropanes; Ev | 2015 |
Hair regrowth in male and female pattern hair loss does not involve the conversion of vellus hair to terminal hair.
Topics: Adult; Alopecia; Female; Finasteride; Hair Follicle; Humans; Male; Minoxidil; Retrospective Studies | 2016 |
Efficacy and Safety of Minoxidil 2% Solution in Combination With a Botanical Hair Solution in Women With Female Pattern Hair Loss/Androgenic Alopecia.
Topics: Adult; Alopecia; Drug Compounding; Drug Therapy, Combination; Female; Hair Preparations; Humans; Mid | 2016 |
Efficacy and Safety of Minoxidil 5% Foam in Combination With a Botanical Hair Solution in Men With Androgenic Alopecia.
Topics: Administration, Topical; Adult; Alopecia; Drug Compounding; Drug Therapy, Combination; Hair Preparat | 2016 |
I'm a 62-year-old woman, and the part in my hair seems to be widening. Am I going bald?
Topics: Alopecia; Female; Hair; Hair Follicle; Humans; Middle Aged; Minoxidil; Women's Health | 2016 |
Effectiveness of a Layer-by-Layer Microbubbles-Based Delivery System for Applying Minoxidil to Enhance Hair Growth.
Topics: Albumins; Alopecia; Animals; Chitosan; Disease Models, Animal; Drug Delivery Systems; Hair; Mice, In | 2016 |
Familial frontal fibrosing alopecia treated with dutasteride, minoxidil and artificial hair transplantation.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Dutasteride; Female; Fibrosis; Folliculitis; Forehead; Human | 2017 |
[Minoxidil : From side effects to therapy].
Topics: Alopecia; Dermatology; Evidence-Based Medicine; Humans; Hypertrichosis; Minoxidil; Treatment Outcome | 2016 |
Clinical and trichoscopic characteristics of temporal triangular alopecia: A multicenter study.
Topics: Administration, Topical; Adolescent; Age Factors; Alopecia; Child; Child, Preschool; Cohort Studies; | 2016 |
Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases.
Topics: 5-alpha Reductase Inhibitors; Adverse Drug Reaction Reporting Systems; Alopecia; Drug-Related Side E | 2016 |
Interventions for Female Pattern Hair Loss.
Topics: Alopecia; Female; Finasteride; Hair; Humans; Minoxidil | 2017 |
Alopecia in congenital hidrotic ectodermal dysplasia responding to treatment with a combination of topical minoxidil and tretinoin.
Topics: Administration, Topical; Alopecia; Child; Dermatologic Agents; Drug Therapy, Combination; Ectodermal | 2009 |
Treating female pattern hair loss. Noticeable hair loss can be deeply distressing. Here are some medical treatments that may help.
Topics: Administration, Cutaneous; Administration, Oral; Alopecia; Androgen Antagonists; Female; Hair; Healt | 2009 |
Androgenetic alopecia in the paediatric population: a retrospective review of 57 patients.
Topics: Adolescent; Adult; Age of Onset; Alopecia; Biopsy; Diagnosis, Differential; Enzyme Inhibitors; Femal | 2010 |
Alopecia and ocular alterations: a role for Minoxidil?
Topics: Adult; Alopecia; Antihypertensive Agents; Aquaporin 4; Cell Line, Tumor; Eye; Eye Diseases; Female; | 2010 |
Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss.
Topics: Adolescent; Adult; Alopecia; Androgen Antagonists; Female; Humans; Male; Middle Aged; Minoxidil; Off | 2010 |
Mayo Clinic office visit. Female-pattern hair loss. An interview with Rochelle Torgerson, M.D., Ph.D.
Topics: Alopecia; Androgen Antagonists; Female; Hair; Health Education; Health Knowledge, Attitudes, Practic | 2010 |
Minoxidil activates β-catenin pathway in human dermal papilla cells: a possible explanation for its anagen prolongation effect.
Topics: Alopecia; Animals; beta Catenin; Biopsy; Cyclic AMP-Dependent Protein Kinases; Female; Hair Follicle | 2011 |
Treatment of female pattern hair loss with the androgen receptor antagonist flutamide.
Topics: Adult; Alopecia; Androgen Receptor Antagonists; Drug Therapy, Combination; Female; Flutamide; Hair; | 2011 |
Aromatic C-nitrosation of a bioactive molecule. Nitrosation of minoxidil.
Topics: Alopecia; Animals; Antihypertensive Agents; Chromatography, Liquid; Dimethylnitrosamine; Drug-Relate | 2011 |
[Frontal fibrosing alopecia: dermoscopic features].
Topics: Adrenal Cortex Hormones; Alopecia; Dermoscopy; Drug Resistance; Eyebrows; Female; Fibrosis; Forehead | 2012 |
Central chorioretinopathy associated with topical use of minoxidil 2% for treatment of baldness.
Topics: Administration, Topical; Adult; Alopecia; Choroid Diseases; Fluorescein Angiography; Humans; Male; M | 2012 |
Erosive pustular dermatosis of the scalp from topical minoxidil 5% solution.
Topics: Aged; Alopecia; Dermatologic Agents; Drug Eruptions; Female; Humans; Minoxidil; Scalp; Scalp Dermato | 2013 |
Adolescent androgenic alopecia.
Topics: 5-alpha Reductase Inhibitors; Adolescent; Alopecia; Diagnosis, Differential; Female; Finasteride; Hu | 2011 |
Guidelines for the management of androgenetic alopecia (2010).
Topics: 5-alpha Reductase Inhibitors; Alopecia; Female; Finasteride; Hair; Humans; Male; Minoxidil; Randomiz | 2012 |
Relation between treatment efficacy and cumulative dose of 3% topical minoxidil in male pattern baldness.
Topics: Administration, Topical; Adolescent; Adult; Alopecia; Hair; Humans; Male; Medication Adherence; Midd | 2012 |
A case of alopecia universalis with agminated lentiginosis and multiple café-au-lait macules: a synchronous coincidence?
Topics: Alopecia; Cafe-au-Lait Spots; Child; Drug Therapy, Combination; Female; Humans; Lentigo; Minoxidil; | 2012 |
What's new in androgenetic alopecia: approvals, long-term safety data, cancer risk and treatment options for women.
Topics: Alopecia; Azasteroids; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Dutasteride; | 2011 |
Valproic acid induces hair regeneration in murine model and activates alkaline phosphatase activity in human dermal papilla cells.
Topics: Alkaline Phosphatase; Alopecia; Animals; beta Catenin; Cell Differentiation; Cells, Cultured; Dermis | 2012 |
Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast | 2012 |
Diffuse pattern essential syphilitic alopecia: an unusual form of secondary syphilis.
Topics: Adrenal Cortex Hormones; Adult; Alopecia; Anti-Bacterial Agents; Humans; Male; Minoxidil; Penicillin | 2012 |
Hair regrowth in a male patient with extensive androgenetic alopecia on estrogen therapy.
Topics: Administration, Cutaneous; Adult; Alopecia; Drug Therapy, Combination; Estradiol; Estrogens; Humans; | 2012 |
Visible-to-near IR quantum dot-based hypermulticolor high-content screening of herbal medicines for the efficacy monitoring of hair growth promotion and hair loss inhibition.
Topics: Alopecia; Blotting, Western; Down-Regulation; Flow Cytometry; Hair; Hair Follicle; High-Throughput S | 2013 |
The hydraulic influence in androgen-related hair growth: implications in autoimmune disease.
Topics: Alopecia; Animals; Autoimmune Diseases; Dihydrotestosterone; Disease Susceptibility; Female; Hair; H | 2002 |
Sensitization to saw palmetto and minoxidil in separate topical extemporaneous treatments for androgenetic alopecia.
Topics: Administration, Topical; Adult; Alopecia; Dermatitis, Allergic Contact; Female; Humans; Minoxidil; P | 2002 |
[TrichoScan. A new instrument for digital hair analysis].
Topics: Adult; Alopecia; Female; Finasteride; Follow-Up Studies; Hair; Hair Diseases; Humans; Image Processi | 2002 |
Information from your family doctor. What should I know about hair loss?
Topics: Alopecia; Hair; Humans; Minoxidil; Vasodilator Agents | 2003 |
By the way, doctor. I don't hear nearly as much about hair loss in women as in men. But I'm 65 and have watched my hair thin considerably over the past five or six years. Is there anything I can do about it? What about Rogaine?
Topics: Alopecia; Dermatologic Agents; Female; Hair; Humans; Minoxidil; Sex Factors | 2003 |
Minoxidil vs finasteride in the treatment of men with androgenetic alopecia.
Topics: Adolescent; Adult; Alopecia; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Minoxidil; R | 2003 |
Finasteride treatment may not prevent telogen effluvium after minoxidil withdrawal.
Topics: Administration, Oral; Administration, Topical; Adult; Alopecia; Drug Therapy, Combination; Enzyme In | 2003 |
[Hair loss].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alopecia; Alopecia Areata; Biopsy; Child; Clinical Tria | 2003 |
Androgenetic alopecia: combining medical and surgical treatments.
Topics: Alopecia; Combined Modality Therapy; Enzyme Inhibitors; Female; Finasteride; Hair Follicle; Humans; | 2003 |
Topical minoxidil counteracts stress-induced hair growth inhibition in mice.
Topics: Alopecia; Animals; Apoptosis; Cell Degranulation; Cell Division; Female; Hair Follicle; Mast Cells; | 2003 |
Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle.
Topics: Adult; Alopecia; Apoptosis; bcl-2-Associated X Protein; Cell Culture Techniques; Cell Division; Gene | 2004 |
[Hair loss-what can one do?].
Topics: Adult; Alopecia; Female; Hair; Humans; Male; Minoxidil | 2004 |
Evaluation and treatment of male and female pattern hair loss.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Administration, Topical; Adoles | 2005 |
Positive lymphocyte transformation test in a patient with allergic contact dermatitis of the scalp after short-term use of topical minoxidil solution.
Topics: Administration, Topical; Aged; Alopecia; Dermatitis, Allergic Contact; Drug Eruptions; Female; Human | 2005 |
Telling the bald truth.
Topics: Alopecia; Finasteride; Hair; Humans; Male; Minoxidil; United States | 2003 |
Simultaneous effects of tocopheryl polyethylene glycol succinate (TPGS) on local hair growth promotion and systemic absorption of topically applied minoxidil in a mouse model.
Topics: Administration, Topical; Alopecia; Animals; Disease Models, Animal; Drug Carriers; Hair; Male; Mice; | 2005 |
Frontal fibrosing alopecia: a survey in 16 patients.
Topics: Aged; Alopecia; Diagnosis, Differential; Disease Progression; Enzyme Inhibitors; Eyebrows; Female; F | 2005 |
Finasteride and minoxidil for alopecia revisited.
Topics: Adult; Alopecia; Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Enzyme Inhi | 2005 |
Recent findings with computerized methods for scalp hair growth measurements.
Topics: Adult; Alopecia; Computing Methodologies; Dermoscopy; Female; Hair; Hair Follicle; Humans; Male; Mid | 2005 |
Alopecia areata masquerading as frontal fibrosing alopecia.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Biopsy, Needle; Dermatologic Agents; Diagnosis, | 2006 |
Managing hair loss. Treatments may help.
Topics: Alopecia; Dermatologic Agents; Female; Finasteride; Humans; Male; Minoxidil | 2006 |
The additive effects of minoxidil and retinol on human hair growth in vitro.
Topics: Adult; Alopecia; Apoptosis; bcl-2-Associated X Protein; Cell Line; Cell Proliferation; Dose-Response | 2007 |
Treatment of female pattern hair loss with a combination of spironolactone and minoxidil.
Topics: Administration, Cutaneous; Administration, Oral; Alopecia; Drug Therapy, Combination; Female; Humans | 2007 |
Evolution of techniques in hair transplantation: a 12-year perspective.
Topics: Adult; Alopecia; Cosmetic Techniques; Disease Progression; Enzyme Inhibitors; Female; Finasteride; F | 2007 |
Reversal of androgenic alopecia by minoxidil: lack of effect of simultaneously administered intermediate doses of cyproterone acetate.
Topics: Adult; Alopecia; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; | 1983 |
Topical minoxidil in the treatment of alopecia areata.
Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia; Alopecia Areata; Child; Child, Preschool | 1983 |
Unusual hair changes with minoxidil therapy.
Topics: Adult; Alopecia; Hair; Hair Color; Humans; Male; Minoxidil; Pyrimidines | 1983 |
Reversal of male pattern baldness by minoxidil. A case report.
Topics: Adult; Alopecia; Humans; Hypertension; Male; Minoxidil; Pyrimidines | 1981 |
Reversal of baldness in patient receiving minoxidil for hypertension.
Topics: Adult; Alopecia; Humans; Hypertension; Male; Minoxidil; Pyrimidines | 1980 |
Improvement in androgenetic alopecia (stage V) using topical minoxidil in a retinoid vehicle and oral finasteride.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Alopecia; Cholestenone 5 alpha-Reductase; En | 1995 |
Minoxidil induced hair growth after leukaemia treatment?
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Humans; Male; Minoxidil; | 1995 |
Protection against cytosine arabinoside-induced alopecia by minoxidil in a rat animal model.
Topics: Alopecia; Animals; Animals, Newborn; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Disease Mo | 1995 |
Allergic contact dermatitis from minoxidil.
Topics: Administration, Topical; Adult; Alopecia; Dermatitis, Allergic Contact; Drug Eruptions; Humans; Male | 1995 |
Minoxidil over the counter.
Topics: Alopecia; Drug Costs; Humans; Minoxidil; Nonprescription Drugs | 1995 |
Alopecia: diagnosis and management.
Topics: Alopecia; Dermatomycoses; Female; Humans; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemi | 1995 |
[Increase of aminotransferase levels during percutaneous minoxidil therapy].
Topics: Administration, Cutaneous; Alanine Transaminase; Alopecia; Aspartate Aminotransferases; gamma-Glutam | 1994 |
Concerns about medical treatment for androgenetic alopecia.
Topics: Alopecia; Drug Monitoring; Humans; Male; Middle Aged; Minoxidil | 1994 |
Male pattern baldness.
Topics: Alopecia; Hair; Humans; Male; Minoxidil; Scalp; Surgical Flaps | 1994 |
Chemotherapy-induced alopecia.
Topics: Administration, Topical; Alopecia; Animals; Antineoplastic Agents; Antineoplastic Combined Chemother | 1993 |
Topical minoxidil for baldness: a reappraisal.
Topics: Administration, Cutaneous; Alopecia; Female; Humans; Male; Minoxidil; Multicenter Studies as Topic | 1994 |
[Treatment of androgenic alopecia with minoxidil].
Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Male; Minoxidil | 1993 |
Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Alopecia; Biopsy; Collagen; Female; Fibrosis; Fo | 1993 |
The penetration enhancer SEPA augments stimulation of scalp hair growth by topical minoxidil in the balding stumptail macaque.
Topics: Administration, Topical; Alopecia; Animals; Drug Delivery Systems; Female; Hair; Macaca mulatta; Min | 1995 |
Hair growth therapy(ies) for androgenetic alopecia.
Topics: Alopecia; Finasteride; Hair; Humans; Minoxidil; Tretinoin | 1996 |
Diffuse hypertrichosis during treatment with 5% topical minoxidil.
Topics: Administration, Cutaneous; Adolescent; Adult; Alopecia; Female; Humans; Hypertrichosis; Middle Aged; | 1997 |
Chronic telogen effluvium: potential complication for clinical trials in female androgenetic alopecia?
Topics: Adult; Alopecia; Clinical Trials as Topic; Dermatologic Agents; Diagnosis, Differential; Female; Hai | 1997 |
Human genetics. Hair apparent.
Topics: Alopecia; Animals; Enzyme Inhibitors; Female; Finasteride; Humans; Male; Mice; Minoxidil; Mutation; | 1998 |
Application of solid-phase extraction in the method development for determination of SEPA, an acronym for soft enhancement of percutaneous absorption, in human, rat, and rabbit serum using GC-FID method.
Topics: Absorption; Adjuvants, Pharmaceutic; Administration, Topical; Alopecia; Animals; Chromatography, Gas | 1998 |
Pustular allergic contact dermatitis from minoxidil.
Topics: Adult; Alopecia; Dermatitis, Allergic Contact; Facial Dermatoses; Female; Humans; Minoxidil; Skin | 1998 |
Retinoids and hair growth.
Topics: Alopecia; Animals; Drug Therapy, Combination; Enzyme Inhibitors; Female; Finasteride; Hair; Humans; | 1998 |
[Maxilène and alopecia].
Topics: Alopecia; Hair; Hair Preparations; Humans; Minoxidil; Organic Chemicals; Treatment Outcome | 1998 |
A 45-year-old man with dizziness.
Topics: Alopecia; Dizziness; Emergency Nursing; Humans; Male; Middle Aged; Minoxidil; Nursing Assessment; Tr | 1999 |
Minoxidil increases 17 beta-hydroxysteroid dehydrogenase and 5 alpha-reductase activity of cultured human dermal papilla cells from balding scalp.
Topics: 17-Hydroxysteroid Dehydrogenases; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adolescent; Adult; Aged; Al | 1999 |
Hair loss: does anything really help?
Topics: Alopecia; Female; Hair Follicle; Hair Preparations; Humans; Male; Minoxidil; Scalp; Surgical Flaps | 1996 |
Authors' conflicts of interest: a disclosure and editors' reply.
Topics: Alopecia; Conflict of Interest; Drug Industry; Financial Support; Finasteride; Humans; Minoxidil; Pu | 1999 |
Where's the hair?
Topics: Alopecia; Female; Finasteride; Hair; Humans; Male; Minoxidil | 1999 |
Minoxidil and male-pattern alopecia: a potential role for a local regulator of sebum secretion with vasoconstrictive effects?
Topics: Alopecia; Endothelin-1; Estrogens; Humans; Male; Minoxidil; Models, Theoretical; Sebum; Testosterone | 1999 |
[21-year old patient with a pituitary microadenoma and gynecomastia of recent onset].
Topics: Adenoma; Adrenal Gland Neoplasms; Adult; Alopecia; Diagnosis, Differential; Estradiol Congeners; Eth | 1999 |
Should men still go bald gracefully?
Topics: Alopecia; Enzyme Inhibitors; Finasteride; Hair Follicle; Humans; Male; Minoxidil | 2000 |
Short and curly.
Topics: Administration, Cutaneous; Alopecia; Diagnosis, Differential; Drug Hypersensitivity; Edema; Humans; | 2000 |
Alternative formulation for patients with contact reactions to topical 2% and 5% minoxidil vehicle ingredients.
Topics: Administration, Topical; Alopecia; Chemistry, Pharmaceutical; Dermatitis, Allergic Contact; Dose-Res | 2000 |
Permanent alopecia following chemotherapy and bone marrow transplantation.
Topics: Adult; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; | 2000 |
[Treatment for hair loss].
Topics: Alopecia; Alopecia Areata; Female; Finasteride; Humans; Male; Minoxidil | 2000 |
[Toward an effective treatment of androgenetic alopecia?].
Topics: Alopecia; Androgens; Female; Finasteride; Humans; Male; Minoxidil; Treatment Outcome | 2000 |
[Androgenetic alopecia: drug treatment].
Topics: Administration, Oral; Alopecia; Androgens; Animals; Clinical Trials as Topic; Female; Finasteride; H | 2000 |
A case of acute myocardial infarction associated with topical use of minoxidil (RiUP) for treatment of baldness.
Topics: Administration, Topical; Alopecia; Atrial Fibrillation; Electrocardiography; Humans; Male; Middle Ag | 2000 |
[Minoxidil: more than an antihypertensive].
Topics: Adult; Alopecia; Antihypertensive Agents; Female; Humans; Male; Minoxidil; Sex Factors; Solutions; V | 2001 |
KF19418, a new compound for hair growth promotion in vitro and in vivo mouse models.
Topics: Alopecia; Animals; Cells, Cultured; Culture Techniques; Dermatologic Agents; Disease Models, Animal; | 2001 |
[Status of scalp hair and therapy of alopecia in men in Switzerland].
Topics: Adolescent; Adult; Aged; Alopecia; Cross-Sectional Studies; Cyclic N-Oxides; Finasteride; Humans; In | 2001 |
[Hereditary hair loss. A tincture against expanding alopecia].
Topics: Administration, Topical; Alopecia; Dose-Response Relationship, Drug; Female; Humans; Male; Minoxidil | 2001 |
Topical application of cyclosporin A induces rapid-remodeling of damaged anagen hair follicles produced in cyclophosphamide administered mice.
Topics: Administration, Topical; Alopecia; Animals; Antineoplastic Agents, Alkylating; Cyclophosphamide; Cyc | 2001 |
[When hair is thinning. Preventing baldness].
Topics: Adult; Alopecia; Child; Estrogens; Family Practice; Female; Hair; Humans; Male; Minoxidil; Oxidoredu | 2001 |
Allergic contact dermatitis to topical minoxidil solution: etiology and treatment.
Topics: Administration, Topical; Aged; Alopecia; Dermatitis, Allergic Contact; Drug Eruptions; Female; Follo | 2002 |
My hair is thinning on the top of my head. What treatments are available for hair loss in women?
Topics: Alopecia; Diuretics; Enzyme Inhibitors; Female; Finasteride; Humans; Minoxidil; Spironolactone; Unit | 2002 |
Prevention of temporal alopecia following rhytidectomy: the prophylactic use of minoxidil. A study of 60 patients.
Topics: Administration, Topical; Aged; Aged, 80 and over; Alopecia; Female; Humans; Middle Aged; Minoxidil; | 2002 |
Pigmented contact dermatitis from topical minoxidil 5%.
Topics: Administration, Topical; Alopecia; Dermatitis, Allergic Contact; Humans; Hyperpigmentation; Male; Mi | 2002 |
[Androgenetic alopecia in the man].
Topics: Adult; Age Factors; Aged; Alopecia; Androgens; Finasteride; Hair; Hair Follicle; Humans; Male; Middl | 2002 |
[Diffuse hair loss in women].
Topics: Adult; Aged; Alopecia; Androgen Antagonists; Diagnosis, Differential; Estradiol Congeners; Female; H | 2002 |
Hair loss with minoxidil withdrawal.
Topics: Alopecia; Female; Hirsutism; Humans; Male; Middle Aged; Minoxidil; Substance Withdrawal Syndrome | 1992 |
Topical treatment with minoxidil 2% and smoking intolerance.
Topics: Administration, Topical; Adult; Alopecia; Humans; Male; Minoxidil; Smoking | 1992 |
Advertising baldly to the public.
Topics: Advertising; Alopecia; Drug Industry; Humans; Minoxidil; United States | 1992 |
[Treatment of androgenic alopecia with topical minoxidil].
Topics: Administration, Topical; Adult; Alopecia; Follow-Up Studies; Humans; Male; Minoxidil | 1991 |
The hair growing effect of minoxidil.
Topics: Alopecia; Animals; Hair; Hair Color; Male; Mice; Mice, Inbred C3H; Minoxidil; Skin; Time Factors | 1991 |
Minoxidil stimulates mouse vibrissae follicles in organ culture.
Topics: Alopecia; Animals; DNA; Flow Cytometry; Hair; Humans; Male; Mice; Minoxidil; Organ Culture Technique | 1991 |
Cosmetics and drugs. Is there a need for a third group: cosmeceutics?
Topics: Alopecia; Cosmetics; Dermatologic Agents; Humans; Minoxidil; Nonprescription Drugs; Photosensitivity | 1991 |
Topical minoxidil for male pattern baldness.
Topics: Administration, Topical; Alopecia; Humans; Male; Minoxidil | 1991 |
The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies.
Topics: Administration, Topical; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug | 1991 |
Hair replacement surgery.
Topics: Alopecia; Hair; Humans; Minoxidil | 1990 |
Safety and efficacy of 2% topical minoxidil in the management of male pattern baldness in Chinese.
Topics: Administration, Topical; Adolescent; Adult; Alopecia; Humans; Middle Aged; Minoxidil | 1990 |
Minoxidil with tretinoin in baldness.
Topics: Alopecia; Humans; Male; Minoxidil; Tretinoin | 1990 |
Dermatology days.
Topics: Aging; Alopecia; Androgens; Dermatitis, Contact; Dermatology; Fibrosis; Graft vs Host Disease; Human | 1990 |
Baldness and minoxidil advertising.
Topics: Advertising; Alopecia; Attitude; Humans; Male; Minoxidil | 1989 |
Baldness and minoxidil.
Topics: Advertising; Alopecia; Anxiety; Humans; Male; Minoxidil | 1989 |
Telogen effluvium and minoxidil.
Topics: Adult; Alopecia; Humans; Male; Middle Aged; Minoxidil | 1989 |
[The peculiar magic of minoxidil].
Topics: Adult; Alopecia; Humans; Male; Minoxidil; Physician-Patient Relations | 1989 |
Dermatology.
Topics: Alopecia; Dermatology; Female; Humans; Male; Minoxidil; Skin; Syphilis; Tretinoin | 1989 |
[Minoxidil: no hope for bald people].
Topics: Alopecia; Evaluation Studies as Topic; Male; Minoxidil | 1989 |
Approach to hair loss reduction.
Topics: Adult; Alopecia; Ethinyl Estradiol; Hair; Humans; Minoxidil; Progesterone | 1989 |
Animal models of androgen-dependent disorders of the pilosebaceous apparatus. 1. The androchronogenetic alopecia (AGA) mouse as a model for male-pattern baldness.
Topics: Alopecia; Androgens; Animals; Antihypertensive Agents; Disease Models, Animal; Female; Male; Mice; M | 1989 |
Explosive eruption of pyogenic granuloma on the scalp due to topical combination therapy of minoxidil and retinoic acid.
Topics: Alopecia; Drug Combinations; Hemangioma; Humans; Male; Middle Aged; Minoxidil; Scalp; Skin Neoplasms | 1989 |
[Stop giving discounts for Regaine].
Topics: Alopecia; Costs and Cost Analysis; Drug Therapy; Humans; Male; Minoxidil | 1989 |
Cosmetics by prescription.
Topics: Alopecia; Cosmetics; Drug Prescriptions; Humans; Minoxidil; Physicians, Family; Self Concept; Tretin | 1989 |
Minoxidil: hope for the bald?
Topics: Administration, Topical; Adult; Alopecia; Drug Evaluation; Humans; Male; Minoxidil; Skin Absorption | 1987 |
Topical minoxidil, scalp hair, and vasodilatation.
Topics: Administration, Topical; Alopecia; Ethics, Medical; Humans; Male; Minoxidil; Rheology; Scalp; Vasodi | 1987 |
Minoxidil for male-pattern baldness.
Topics: Alopecia; Humans; Male; Minoxidil | 1987 |
Minoxidil for male-pattern baldness.
Topics: Alopecia; Esthetics; Humans; Male; Minoxidil; Sex Factors | 1987 |
Topical minoxidil used before and after hair transplantation.
Topics: Administration, Topical; Adult; Alopecia; Hair; Humans; Male; Middle Aged; Minoxidil; Postoperative | 1989 |
Bald scalps and wrinkles.
Topics: Aging; Alopecia; Humans; Minoxidil; Skin; Tretinoin | 1989 |
Is minoxidil (Rogaine) clinically effective?
Topics: Advertising; Alopecia; Humans; Male; Minoxidil | 1989 |
Allergic contact dermatitis to minoxidil.
Topics: Adult; Alopecia; Drug Eruptions; Female; Humans; Minoxidil; Patch Tests; Scalp Dermatoses | 1985 |
Scalp comedones after topical minoxidil.
Topics: Acne Vulgaris; Alopecia; Humans; Male; Minoxidil; Scalp Dermatoses | 1985 |
Allergic contact dermatitis from minoxidil.
Topics: Adult; Alopecia; Drug Eruptions; Facial Dermatoses; Humans; Male; Minoxidil; Patch Tests; Scalp Derm | 1987 |
Alopecia: common and uncommon.
Topics: Administration, Topical; Adult; Alopecia; Alopecia Areata; Cicatrix; Female; Hair; Humans; Male; Min | 1986 |
Topical minoxidil for common baldness.
Topics: Administration, Topical; Alopecia; Female; Humans; Minoxidil; Substance-Related Disorders | 1986 |
Minoxidil. A few of the questions you're likely to hear.
Topics: Administration, Topical; Alopecia; Humans; Male; Minoxidil | 1988 |
[Toxic effects of 2% minoxidil].
Topics: Administration, Topical; Adolescent; Adult; Alopecia; Heart Rate; Humans; Male; Middle Aged; Minoxid | 1988 |
Topical minoxidil therapy for androgenetic alopecia.
Topics: Administration, Topical; Alopecia; Humans; Male; Minoxidil | 1988 |
Allergic contact dermatitis from minoxidil.
Topics: Alopecia; Dermatitis, Contact; Humans; Male; Minoxidil | 1988 |
[Sensitization for external treatment with minoxidil].
Topics: Administration, Topical; Alopecia; Dermatitis, Contact; Humans; Minoxidil | 1988 |
Duration of minoxidil therapy to yield maximum benefit.
Topics: Alopecia; Drug Evaluation; Female; Humans; Male; Minoxidil; Time Factors | 1988 |
Rogaine (topical minoxidil, 2%) in the management of male pattern baldness and alopecia areata. Proceedings of a symposium. Palm Beach, FL, May 17, 1986.
Topics: Alopecia; Alopecia Areata; Humans; Male; Minoxidil | 1987 |
Action of topical minoxidil in the bald stump-tailed macaque.
Topics: Administration, Topical; Alopecia; Animals; Female; Hair; Macaca; Male; Minoxidil; Scalp | 1987 |
Use of topical minoxidil as a possible adjunct to hair transplant surgery. A pilot study.
Topics: Administration, Topical; Adult; Alopecia; Hair; Humans; Male; Middle Aged; Minoxidil; Pilot Projects | 1987 |
[Minoxidil in the local treatment of alopecia areata and of androgenous alopecia].
Topics: Administration, Topical; Adult; Alopecia; Alopecia Areata; Drug Evaluation; Humans; Male; Minoxidil | 1986 |
Topical minoxidil for male pattern alopecia in two sets of twins.
Topics: Administration, Topical; Adult; Alopecia; Diseases in Twins; Humans; Male; Minoxidil | 1987 |
[Minoxidil: hope for bald people?].
Topics: Alopecia; Humans; Minoxidil; Solutions | 1987 |
[Minoxidil: hope for bald people?].
Topics: Alopecia; Female; Humans; Male; Minoxidil | 1987 |
[Minoxidil: hope for bald people?].
Topics: Adult; Alopecia; Humans; Male; Minoxidil; Statistics as Topic | 1987 |
Topical minoxidil for hair loss.
Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Male; Minoxidil | 1987 |
Alterations in scalp blood flow after the epicutaneous application of 3% minoxidil and 0.1% hexyl nicotinate in alopecia.
Topics: Adult; Alopecia; Humans; Male; Minoxidil; Nicotinic Acids; Regional Blood Flow; Scalp | 1987 |
Topical minoxidil: experimental and clinical results. Proceedings of a session of the 17th World Congress of Dermatology. Berlin, May 27, 1987.
Topics: Alopecia; Humans; Minoxidil | 1987 |
Topical minoxidil, experimental and clinical results.
Topics: Administration, Cutaneous; Alopecia; Humans; Minoxidil | 1987 |
Evaluation technics for male pattern baldness.
Topics: Alopecia; Humans; Male; Minoxidil | 1986 |
Topical minoxidil useful in 18% of patients with androgenetic alopecia: a study of 430 cases.
Topics: Administration, Topical; Adolescent; Adult; Alopecia; Androgens; Blood Pressure; Humans; Male; Middl | 1986 |
Promotion of hair growth.
Topics: Alopecia; Hair; Hair Preparations; Humans; Minoxidil | 1986 |
Topical minoxidil. A survey of use and complications.
Topics: Administration, Topical; Alopecia; Blood Pressure; Costs and Cost Analysis; Drug Utilization; Humans | 1987 |
A falling out following minoxidil: telogen effluvium.
Topics: Alopecia; Humans; Male; Middle Aged; Minoxidil; Substance Withdrawal Syndrome | 1987 |
Effect of time on male pattern baldness.
Topics: Alopecia; Humans; Male; Methods; Minoxidil; Time Factors | 1987 |
Topical minoxidil therapy and hair regrowth.
Topics: Adult; Alopecia; Animals; Hair; Humans; Macaca; Mice; Middle Aged; Minoxidil; Pyrimidines | 1985 |
Unravelling the pathophysiology of male pattern baldness.
Topics: Aged; Alopecia; Humans; Male; Minoxidil; Regional Blood Flow; Scalp; Vascular Resistance | 1985 |
Cyclic dynamics of hair follicles and the effect of minoxidil on the bald scalps of stumptailed macaques.
Topics: Administration, Topical; Age Factors; Alopecia; Animals; Female; Hair; Humans; Macaca; Male; Minoxid | 1985 |
Contact dermatitis to minoxidil.
Topics: Adult; Alopecia; Dermatitis, Contact; Facial Dermatoses; Humans; Male; Minoxidil; Scalp Dermatoses | 1985 |
Unapproved use of minoxidil.
Topics: Alopecia; Humans; Minoxidil; United States; United States Food and Drug Administration | 1985 |